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AT A GLANCE COMMENTARY  
Scientific Knowledge on the Subject 
Omega-3 poly-unsaturated fatty acids (n-3 PUFAs) have anti-inflammatory properties 
that may combat chronic inflammation and beneficially affect pulmonary function. However, 
few population-based studies have investigated the associations between n-3 PUFAs and 
pulmonary function, and although smokers have higher inflammation burden on average, no 
studies have examined whether smoking modifies these associations. Moreover, pulmonary 
function measures are heritable, with over 150 genetic loci identified through genome-wide 
association studies, yet no studies have assessed evidence for interactions between genetic 
variants and n-3 PUFAs or any other biomarker.  
 
What This Study Adds to the Field 
We investigated n-3 PUFA biomarker associations with pulmonary function tests (PFTs) 
in seven cohorts. After establishing the n-3 PUFA biomarker-PFT associations, we tested 
genome-wide interactions between genetic variants and the n-3 PUFA biomarkers on PFT 
measures and applied the joint 2 degree-of-freedom meta-analysis approach. In the model that 
included both docosahexaenoic acid and its interaction with genetic variants, we identified a 
novel DPP10 association with forced vital capacity at genome-wide significance. This DPP10 
association was not found in standard genome-wide analyses, and was only discovered after 
incorporating the interaction into a model with the environmental variable, namely n-3 PUFA 
biomarker levels. 
Note: This article has an online data supplement, which is accessible from this issue's table of 
content online at www.atsjournals.org
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ABSTRACT  
Rationale: Omega-3 poly-unsaturated fatty acids (n-3 PUFAs) have anti-inflammatory 
properties that could benefit adults with comprised pulmonary health. 
Objective: To investigate n-3 PUFA associations with spirometric measures of pulmonary 
function tests (PFTs) and determine underlying genetic susceptibility. 
Methods: Associations of n-3 PUFA biomarkers (alpha-linolenic acid, eicosapentaenoic acid, 
docosapentaenoic acid [DPA], and docosahexaenoic acid [DHA]) were evaluated with PFTs 
(forced expiratory volume in the first second [FEV1], forced vital capacity [FVC], and 
[FEV1/FVC]) in meta-analyses across seven cohorts from the Cohorts for Heart and Aging 
Research in Genomic Epidemiology Consortium (N=16,134 of European or African ancestry). 
PFT-associated n-3 PUFAs were carried forward to genome-wide interaction analyses in the four 
largest cohorts (N=11,962) and replicated in one cohort (N=1,687). Cohort-specific results were 
combined using joint 2 degree-of-freedom (2df) meta-analyses of single nucleotide 
polymorphism (SNP) associations and their interactions with n-3 PUFAs.  
Results: DPA and DHA were positively associated with FEV1 and FVC (P<0.025), with 
evidence for effect modification by smoking and by sex. Genome-wide analyses identified a 
novel association of rs11693320—an intronic DPP10 SNP—with FVC when incorporating an 
interaction with DHA, and the finding was replicated (P2df=9.4×10
-9 
across discovery and 
replication cohorts). The rs11693320-A allele (frequency~80%) was associated with lower FVC 
(PSNP=2.1×10
-9
; βSNP= -161.0mL), and the association was attenuated by higher DHA levels 
(PSNP×DHA interaction=2.1×10
-7
; βSNP×DHA interaction=36.2mL).  
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Conclusions: We corroborated beneficial effects of n-3 PUFAs on pulmonary function. By 
modeling genome-wide n-3 PUFA interactions, we identified a novel DPP10 SNP association 
with FVC that was not detectable in much larger studies ignoring this interaction.  
Keywords: forced expiratory volume; forced vital capacity; smoking; genome-wide association 
study; adult; n-3 PUFA; omega-3 fatty acids; docosahexaenoic acid; eicosapentaenoic acid; 
docosapentaenoic acid; alpha-linolenic acid 
Total word count for the abstract: 254 words  
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INTRODUCTION 
Pulmonary function tests (PFTs) provide indicators of lung health and mortality risk in 
the general population (1). Impaired pulmonary function increases the risk of chronic obstructive 
pulmonary disease (COPD) (2), which is one of the leading causes of death worldwide (3, 4). 
PFTs include measurement of forced expiratory volume in the first second (FEV1), forced vital 
capacity (FVC), and FEV1/FVC to diagnose COPD and follow its progression.  
PFTs are heritable traits (~35%) (5), and genome-wide association studies (GWASs) 
have identified >150 PFT-associated loci (6-13). Environmental factors, including cigarette 
smoking that contributes to chronic inflammation (14), also influence PFTs. Omega-3 poly-
unsaturated fatty acids (n-3 PUFAs) may mitigate the inflammatory response. N-3 PUFAs 
include alpha-linolenic acid (ALA), and its long-chain derivatives, eicosapentaenoic acid (EPA), 
docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA). ALA, the predominant n-3 
PUFA in the western diet, is present in vegetable oils; EPA, DPA, and DHA are found mainly in 
fish. After absorption, some dietary ALA is converted through endogenous elongation and 
desaturation reactions (15) to the long-chain derivatives. However, dietary ALA may not 
adequately replace dietary EPA, DPA, and DHA given the limited conversion rate (16). We 
focused on these n-3 PUFAs based on prior evidence that they help combat inflammation in the 
lung by generating lipid-derived mediators, such as resolvins (17, 18). 
Diets rich in n-3 PUFAs have been implicated in preventing chronic inflammatory 
diseases, including cardiovascular disease, rheumatoid arthritis, and dementia (19). Few studies 
have investigated the role of n-3 PUFAs in lung health. Two studies investigated dietary-reported 
n-3 PUFAs with PFTs; one found that higher n-3 PUFAs were associated with higher PFTs (20), 
while the other reported null associations (21). One study investigating serum n-3 PUFAs with 
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PFTs found positive associations of DHA with FEV1 and FVC (22). Another study, conducted 
only in ever smokers, found that higher plasma DHA was associated with lower odds of COPD 
(23).  
Tests that jointly model environmental factors and gene-by-environment interactions can 
identify novel genetic associations (24-26). No prior GWAS of PFTs have investigated 
interactions with n-3 PUFAs or other nutrient biomarkers. Here, we tested the association of n-3 
PUFA biomarkers with cross-sectional PFTs and then studied genome-wide interactions of 
single nucleotide polymorphisms (SNPs) and insertions/deletions (indels) with n-3 PUFAs on 
PFTs in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 
consortium. We combined cohort-specific results to estimate the n-3 PUFA-PFT associations and 
to identify genetic associations with PFTs when accounting for n-3 PUFA interactions. 
Preliminary results of our study, reporting n-3 PUFA biomarker associations with PFTs, were 
previously published in the form of an abstract (27). 
 
MATERIALS AND METHODS 
Cohorts and Participants  
Seven cohorts—AGES, ARIC, CARDIA, CHS, FHS, MESA, and RS—contributed to 
meta-analyses of n-3 PUFA-PFT associations. All cohorts included European ancestry (EA) 
participants; three cohorts also included African ancestry (AA) participants (Table 1). Our 
genome-wide interaction analyses focused on the five largest cohorts (N>500). Additional cohort 
details are provided in the Supplement and Tables E1–E3. Institutional Review Boards at the 
respective institutions approved all data collection.  
PFTs and N-3 PUFA Measurements 
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PFTs, specifically FEV1 (unit: mL), FVC (unit: mL), and FEV1/FVC (unit: %), were 
measured by spirometry. N-3 PUFAs were measured in plasma phospholipids in all cohorts 
except FHS (Supplement, Table E4 for measurement details and Table E5 for measurement 
times). N-3 PUFAs were measured in red blood cells in FHS, which are strongly correlated with 
plasma measures (16, 28). In each cohort, n-3 PUFAs were measured as a relative percent of 
total fatty acids. Both PFTs and n-3 PUFAs were continuous variables.  
Statistical Analysis for n-3 PUFA Associations with PFTs  
Linear regression models were run, separately by European or African ancestry in each 
cohort, to estimate n-3 PUFA associations with PFTs, as described in the Supplement. Models 
were extended to include interaction terms to assess effect modification by smoking status and 
sex. Fixed-effects meta-analysis was used to combine cohort- and ancestry-specific estimates of 
n-3 PUFA-PFT associations and n-3 PUFA interactions with smoking status and sex (29). 
Smoking-stratified meta-analyses were also performed, and heterogeneity at the cohort level was 
examined (Supplement). 
Statistical Analysis for Genome-Wide Interaction with N-3 PUFAs on PFTs  
Genome-wide interactions with n-3 PUFAs were studied using joint 2df meta-analyses 
(30) under a fixed-effects model, as done before in single ancestry (31) and cross-ancestry 
genome-wide meta-analyses (32). Robust standard error estimation and inverse variance 
weighting were applied (33), similar to the prior genome-wide variant×smoking study for PFTs 
in CHARGE (24). The same covariates were adjusted (Supplement) along with ancestral 
principal components. Cohort- and ancestry-specific coefficients of SNP/indel (henceforth, 
collectively referred to as SNP) additive dosage (βSNP) and SNP×n-3 PUFA interaction term 
(βSNP×n-3 PUFA interaction) in the four discovery cohorts were combined using METAL with genomic 
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control applied (N=11,962; 11,165 EA, 797 AA; Table 1). The standard a priori level of 
genome-wide significance was used (P<5×10
-8
) for the discovery meta-analysis
 
(34), as done in 
our prior study (24). CARDIA was reserved for replication (N=1,687; 1,141 EA, 546 AA, Table 
1). The threshold for declaring significance in the replication phase was 0.05 given that only one 
SNP in one model was tested. To characterize top SNP findings, we pursued three additional 
analyses across the discovery and replication cohorts: smoking-stratified and sex-stratified joint 
2df meta-analyses to examine selected SNP×n-3 PUFA interactions; and standard 1df meta-
analyses to assess evidence of SNP associations without considering n-3 PUFA interaction. 
Bioinformatics Analysis 
Follow-up analyses were conducted to assess SNP regulatory potential and gene function. 
In silico analyses used HaploReg v4.1 (35), Roadmap Epigenomics (36), Genotype-Tissue 
Expression Project (GTEx, version 7) (37), and GeneMANIA (38) (Supplement).  
 
RESULTS 
Characteristics of cohort participants and their n-3 PUFA distributions are provided in 
Table 1 (additional details in the Supplement, Table E6, and Figure E1). There was little 
correlation (|r|<0.2) between the n-3 PUFAs (ALA, EPA, DPA or DHA) with pack-years, and 
average levels were similar across smoking strata, except for DHA, which showed a relatively 
consistent pattern across cohorts with the highest levels in never smokers, followed by former 
smokers, and then current smokers (Table E7). 
Meta-Analysis of Associations of N-3 PUFAs and Interactions with Smoking and Sex on 
PFTs 
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For FEV1 and FVC, cross-ancestry meta-analyses revealed positive associations of DHA 
and DPA at P<0.05 (Figures 1, E2–E3 and Table E8). To convey the impact of differences in n-
3 PUFA levels, we estimated that one standard deviation higher DHA (~1.3% of plasma total 
FAs) was associated with 18.6 mL higher FEV1 (P=6.1×10
-6
) and 10.9 mL higher FVC (P=0.02) 
and that one standard deviation higher DPA (~0.2% of plasma total FAs) was associated with 7.9 
mL higher FEV1 (P=0.0006) and 6.5 mL higher FVC (P=0.01) (sensitivity analysis in the 
Supplement). A positive association was also indicated between ALA and FVC: one standard 
deviation higher ALA (0.07% of plasma total FAs) being associated with 8.4 mL higher FVC 
(P=0.023). This ALA finding was mainly driven by AAs (Table E8).  
Smoking status significantly modified the DHA-FEV1 association (PDHA×current smoking 
interaction=0.02; Figure E4) such that the magnitude of the association was larger in current 
smokers. To further interpret the DHA interaction with smoking status on FEV1, β coefficients 
for current, former, and never smokers were estimated (βDHA + βDHA×smoking interaction). Across all 
cohorts, a 1% higher DHA was associated with a 39 mL higher FEV1 (P=0.0001) in current 
smokers; this effect size was about three times the magnitude observed for former (13 mL; 
P=0.010) and never smokers (11 mL; P=0.012) (Figure 2). 
For FEV1/FVC, the cross-ancestry and EA-specific meta-analyses revealed associations 
with EPA and ALA (P<0.02) and with DHA among current smokers (P<0.0001) (Figure E4). 
However, because the effect sizes were small (<1% increase in FEV1/FVC with 1 standard 
deviation higher n-3 PUFA; Table E8–E9), further analyses focused on FEV1 and FVC. No 
significant interaction of smoking status with DPA was observed for any PFT outcome (P=0.06–
0.35). 
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Sex was an effect modifier in the DPA-FVC association (PDPA×sex interaction=0.035) such 
that the magnitude of the DPA association was larger in males (1 standard deviation [~0.2%] 
higher DPA had a greater association with FVC [by 10 mL] in males than in females). Sex 
modification, however, was not observed for DPA-FEV1, DHA-FEV1, or DHA-FVC 
associations (Pinteraction=0.17–0.83). 
Genome-Wide Interaction Analyses of N-3 PUFAs on PFTs  
DHA and DPA were carried forward to genome-wide interaction analyses because each 
was associated at P<0.05 in both the EA-specific and the cross-ancestry meta-analyses. Since the 
ALA association was primarily driven by AA participants, which represented a small portion of 
the total sample size used for the n-3 PUFA-PFT analysis (~16%), ALA was not carried forward. 
Genome-wide joint 2df interaction analyses with n-3 PUFAs captured 7.2 million genotyped and 
1000 Genomes-imputed SNPs with minor allele frequency >5% across 11,165 EAs and 797 AAs 
(Table 1). There was no indication of genomic inflation bias (λgc=1.02–1.03, Figures E5–E8).  
Two novel loci were identified at cross-ancestry meta-analysis P2df<5×10
-8 
(Figures E6–
E7). For FEV1, rs79992631, a downstream C8orf4 SNP on chromosome 8p11, was identified 
when accounting for DPA interaction. However, because the signal was driven by a single cohort 
with sub-optimal imputation quality at this SNP (Rsq=0.65) and was not supported by other 
cohorts in the discovery meta-analysis with better imputation quality at this SNP, rs79992631 
was not tested further as it is likely a false-positive. For FVC, rs11693320, a dipeptidyl peptidase 
like 10 (DPP10) intronic SNP on chromosome 2q14 (Figure 3), was identified when accounting 
for DHA interaction. Meta-analysis across all discovery cohorts revealed that rs11693320 was 
associated with FVC at P2df=4.5×10
-8
 (Table 2). The rs11693320-FVC association was tested for 
replication in CARDIA (1,141 EAs, 546 AAs; Table 1) and found to be associated at P2df=0.045 
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with consistent directions of association (Table 2), and an overall P2df=9.4×10
-9
 across all 
cohorts, which passed a stringent Bonferroni-corrected cutoff of 1.25×10
-8
 that takes into account 
all four genome-wide interaction models (DHA and DPA with FEV1 and FVC). The 
rs11693320-A allele, which has a similar frequency across ancestries (81% in EAs, 79% in 
AAs), was associated with reduced FVC (βSNP=-161.0 mL, PSNP=2.1×10
-9
); this association was 
attenuated by higher DHA levels (βSNP×DHA interaction=+36.2 mL per 1% DHA of total FAs, 
PSNP×DHA interaction=2.1×10
-7
). In the discovery cohorts, the rs11693320 and rs11693320×DHA 
interaction effect sizes were larger in AAs (βSNP=-186.4 and βSNP×DHA interaction=39.7 in the single 
AA cohort compared to βSNP=-155.8 and βSNP×DHA interaction=34.0 in the EA-specific meta-analysis, 
Table 2). The same pattern was observed between AAs and EAs in the replication cohort (Table 
2). Although not passing genome-wide significance, consistent directions were observed for the 
association of rs11693320 and its interaction with DHA on FEV1 (meta-analysis βSNP [SE]=-95.2 
[23.9], β SNP× DHA interaction [SE]=19.9 [6.0], and P2df=2.1×10
-4
). 
We also used our genome-wide results to look-up previous GWAS-identified SNPs 
associated with n-3 PUFA phenotypes and PFTs. Results are shown in the Supplement and 
Tables E10–E11.  
DPP10 SNP Interaction with n-3 PUFA Biomarkers by Smoking Status and Sex 
The joint 2df meta-analyses accounting for rs11693320×DHA interaction on FVC was 
further explored in models stratified by smoking status, which suggested that the interaction was 
mainly driven by former smokers (N=5,373; βSNP=-218.5mL, PSNP=8.3×10
-6
; β SNP×DHA 
interaction=+53.8mL, PSNP×DHA interaction=6.7×10
-6
). The directions of association were consistent in 
current and never smokers, but with weaker statistical evidence (current smokers: N=3,944; 
βSNP=-130.4mL, PSNP=0.15; βSNP×DHA interaction=+21.8mL, PSNP×DHA interaction=0.45; and never 
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smokers:
 
N=4,332;
 
βSNP=-93.7mL, PSNP=0.030; βSNP×DHA interaction=+16.4mL, PSNP×DHA 
interaction=0.13). 
When stratified by sex, the rs11693320×DHA interaction finding on FVC was mainly 
driven by males (N=6,231; βSNP=-223.0mL, PSNP=2.5×10
-5
; β SNP×DHA interaction=+55.8mL, 
PSNP×DHA interaction=6.1×10
-5
). The directions of association were consistent in females, but with 
weaker statistical evidence (N=7,418; βSNP=-60.3mL, PSNP=0.09; βSNP×DHA interaction=+11.6mL, 
PSNP×DHA interaction=0.20). 
Follow-up Bioinformatics Analysis  
According to HaploReg v4.1 (35), three variants in high LD (r
2
>0.8) with rs11693320 are 
located within putative enhancer elements in lung tissue. Functional annotations of rs11693320 
and variants with r
2
>0.8 (1000 Genomes EUR) are provided (Table E12). Rs11693320 is a 
putative eQTL for DPP10 in GTEx lung tissue: its A allele being associated with lower 
expression (P=0.036, N=383) (37). To better characterize DPP10 gene function, we used 
GeneMANIA to create a network of genes biologically related to DPP10 (Figures 4 and E9). 
Within this network of 20 genes, 5 genes were co-expressed (P<0.05) with DPP10 in GTEx lung 
tissue: DPP4, FMN2, FABP4, and VAT1L were positively associated with DPP10 expression, 
while ADAM20 was inversely associated. 
 
DISCUSSION 
 Our study tested the associations of n-3 PUFA biomarkers with PFTs combining data 
across multiple cohorts, which showed positive associations of DHA and DPA with FEV1 and 
FVC. The FEV1 outcome had slightly larger magnitudes of association with n-3 PUFAs, 
consistent with the pattern observed in the only previous study that investigated plasma n-3 
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PUFA associations with PFTs (22). Importantly, we found, for the first time, that the association 
of FEV1 with DHA differed by smoking status (PDHA×smoking interaction=0.02), with the magnitude of 
the association for current smokers (β=39 mL per 1% [about one standard deviation] higher 
DHA) being about 3-fold larger than the association in never (β=11mL) and former (β=13 mL) 
smokers. We also found a significant interaction of DHA with current smoking on FEV1/FVC, 
although the magnitude of the association was negligible (<1% increase per 1% higher DHA). In 
addition, we found a DPA×sex interaction such that the magnitude of the DPA association with 
FVC was larger in males than in females (larger by 10 mL per 1 standard deviation [0.2%] 
higher DPA).  
In genome-wide interaction meta-analyses, we identified the DPP10 SNP rs11693320-A 
allele for its novel association with FVC (βSNP= -161.0 mL), which was attenuated by higher 
DHA levels (βinteraction=+36.2 mL) (Table 2). To put the magnitude of the DPP10-FVC 
association into context, rs11693320-A was associated with 88.6 mL lower FVC at DHA 
level=2% of total FAs (about 1 standard deviation below the average DHA level), whereas 
rs11693320-A was associated with 16.2 mL lower FVC at DHA level=4% of total FAs (slightly 
above the average DHA level). In comparison, one year of age-related FVC decline is about 30 
mL in US adults from the general population (39). Our findings indicate that nutrient biomarker 
levels might influence genetic factors underlying pulmonary function. 
The only prior study to directly investigate n-3 PUFA biomarkers and PFTs (N=593) 
reported suggestive positive associations of DHA with percent predicted FEV1 and FVC, and a 
positive association of DPA with percent predicted FVC in men only (22). Our study included 
large numbers, tested smoking interactions for the first time, and found a larger magnitude of the 
DHA association with FEV1 in current smokers compared to former and never smokers. The 
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positive associations of DHA and DPA with PFTs are biologically plausible and may be 
mediated by metabolic derivatives such as resolvins and protectins, which regulate the resolution 
of inflammation via mechanisms including the inhibition of pro-inflammatory gene expression 
and the clearance of inflammatory cells by macrophages (17). DHA-derived Resolvin D1 was 
shown to have anti-inflammatory effects in mice and human cell lines with cigarette smoke 
exposure (40).  
The rs11693320 association with FVC was evident only by considering interaction with 
DHA. Rs11693320 did not attain genome-wide significance in standard 1df meta-analysis 
without DHA interaction in the model (P=1.7×10
-4
; Table 2). Similarly, rs11693320 was not 
identified in previous GWASs of PFTs (6-12, 41). Our top DPP10 SNPs, some of which were 
available as HapMap-imputed SNPs in a previous GWAS of FVC with a larger sample size 
(N=52,253) (10), achieved only borderline nominal significance (P=0.06–0.1) (Table E13). 
Moreover, rs11693320 had no association with DHA in our study (P=0.57 across the five 
cohorts), and nearby HapMap-imputed DPP10 SNPs also were not associated with the DHA 
phenotype in a CHARGE GWAS meta-analysis of plasma n-3 PUFAs (Table E13) (41).  
DPP10 was previously identified as a candidate gene for asthma (42-45), and a single 
study of asthma candidate genes suggested that major alleles of DPP10 SNPs were associated 
with both FEV1 and FVC decline under a recessive mode of inheritance (46). Similarly, in our 
study, we found that the major allele of rs11693320 on DPP10 was associated with lower FEV1 
and FVC, although only the finding for FVC reached genome-wide significance. Prior GWAS 
for FVC similarly identified loci that were not detected in GWAS of FEV1, suggesting that these 
correlated, but clinically different, measures have both shared and unique genetic risk factors 
(47). Previous speculation about the biological mechanism through which DPP10 affects asthma 
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relates to conduction of electric signals in the nervous system, which could affect the activity of 
airway smooth muscle (e.g. contraction) via neural regulation (44). DPP10 is highly expressed in 
brain neurons (48) and slightly expressed in lung tissues (49). It encodes one member of the S9B 
family of serine proteases, which could be released to the extracellular space (50). The DPP10-
encoded protein can bind to the voltage-gated potassium (K
+
) channel and facilitate the 
trafficking of K
+
 channel protein to the cell membrane (48). 
Using the public bioinformatics tools, GeneMANIA (38) and GTEx (37), we found five 
genes related to DPP10 function and 4 of them positively co-expressed with DPP10 in lung 
tissue. Based on previous evidence (50-54), only FABP4 and DPP4 play a role in pulmonary 
function and may potentially interact with DHA in this regard. The FABP4 gene is a putative 
biomarker for systemic inflammation in COPD patients, and FABP4 circulating level was 
associated with lower PFTs in COPD patients (51) and non-diseased individuals (52). A small 
clinical trial (N=14) reported that DHA+EPA supplementation, which increased serum DHA, led 
to a concurrent decrease in FABP4 level (53). The other DPP10-related gene, DPP4, plays a role 
in asthma pathogenesis, as DPP10 does, albeit through a different mechanism (i.e. immune-
suppression) (50). A study in diabetic patients directly linked DPP4 to the DHA biomarker; the 
efficacy of a DPP4 inhibitor on glycemic control was positively correlated with DHA nutriture 
(r=0.73) (54). Thus, DHA may play a beneficial role in pulmonary function, potentially through 
influencing DPP10, DPP4, and FABP4, but further research is needed to investigate the 
interplay between these genes and DHA.  
Given that n-3 PUFAs are postulated to mitigate inflammatory responses brought about 
by cigarette smoking, we carried out smoking-stratified analyses and found that the rs11693320 
effect size was largest in former smokers, when considering its interaction with DHA, suggesting 
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potential effect moderation by cigarette smoking. A study of human fetal lung tissue reported 
that in utero smoking exposure was associated with methylation changes in DPP10 (55). Our 
findings suggest an inverse association of DPP10 SNPs with PFTs that are mitigated by 
circulating DHA levels, and the interplay among DPP10, DHA, and smoking status needs further 
investigation. We posit that current smoking, as compared with former smoking, induces 
additional perturbations to lipid homeostasis (e.g., lipid peroxidation of cell membranes of 
vulnerable cells such as airway epithelial cells expressing DPP10) via oxidative stress and 
epigenetic changes (including DNA methylation, histone modifications and/or micro-RNA 
dysregulation), which might affect the beneficial effects of n-3 PUFAs and their attenuation of 
genetic risk factors on FVC. Moreover, the association pattern among former smokers may also 
underlie our observed sex-stratified results, whereby the largest effect sizes for rs11693320 and 
its interaction with DHA occurred in men, who are more likely to have smoked, smoked more 
heavily, and reported being more severely dependent to nicotine in their current and past 
smoking histories as compared to women (56, 57). 
Our findings are likely to have strong external validity, thus are expected to generalize 
well to adult populations in the US and Europe. Overall, average FEV1/FVC of the included 
cohorts was in the expected 70–80% range for healthy US adults (Table E6), and the prevalence 
of COPD is expected to be similar to the US prevalence (~6.1%) (58). Participant selection bias 
is expected to be minimal given that all the measurements (spirometry, n-3 PUFA biomarkers, 
and genetic data) were collected either in all cohort participants or in a random set of 
participants. Finally, only 1,343 AAs contributed data for the genome-wide interaction analysis, 
which led us to combine EAs and AAs in cross-ancestry meta-analyses (total N=13,649) to 
increase power. Even though the rs11693320 and rs11693320×DHA interaction effect sizes were 
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larger in AAs than EAs, which has been observed for other reported SNP associations with 
complex traits (e.g., CHRNA5 SNP rs16969968 with cigarettes smoked per day (59)), drawing an 
inference of ancestral differences for this SNP was limited given fewer AAs (total N=1,343) than 
EAs (total N=12,306) available for study. While the cross-sectional design prohibits direct causal 
inferences, these findings are strengthened by the internal consistency of findings across cohorts 
with different contexts. Future studies that investigate longitudinal PFTs and the complex 
interplay of fatty acid components are needed to further strengthen the causal inference of 
associations observed in our study. 
This study has several strengths. First, we used objectively measured n-3 PUFA 
biomarkers, instead of self-reported dietary intake, as the exposures. The n-3 PUFA biomarkers 
reflect intake as well as inter-individual differences in absorption and incorporation into 
phospholipids (for n-3 PUFAs from dietary sources) and metabolic efficiency (for n-3 PUFAs 
from endogenous biosynthesis). Therefore, it is a more reliable measure of n-3 PUFA nutrients 
that are available to tissues/organs, compared to self-reported dietary intake of n-3 PUFAs. 
Second, we conducted association analyses of n-3 PUFAs on PFTs across multiple cohorts that 
together had sufficient sample size to examine effect modification by smoking and by sex. Third, 
we investigated the genome-wide variant×nutrient interactions on PFTs via joint 2df meta-
analyses and discovered a novel genetic association with pulmonary function, when considering 
the interaction with n-3 PUFAs, which was not identified previously using the standard GWAS 
approach with even larger sample sizes. 
We found positive associations of DHA and DPA biomarkers with PFTs, specifically 
FEV1 and FVC, and the magnitude of the DHA-FEV1 association was ~3-fold larger in current 
smokers. This suggested a greater beneficial effect of n-3 PUFAs, especially DHA, on 
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pulmonary function in current smokers. We also identified the DPP10 locus, where the intronic 
rs11693320-A was inversely associated with FVC, and a higher DHA level attenuated this effect. 
Few genome-wide studies investigate how nutrient status and genetic predisposition can 
influence each other and affect PFTs, and the results of this study are important in contributing to 
the evidence base needed to provide targeted dietary advice for COPD prevention.
AUTHOR DISCLOSURE 
Dr. Psaty serves on the Data and Safety Monitoring Board of a clinical trial funded by the 
manufacturer (Zoll LifeCor) and on the Steering Committee of the Yale Open Data Access 
Project funded by Johnson & Johnson.  
All other authors have no competing interests. There is no commercial support or financial 
interest from the tobacco industry for the research presented.  
The study sponsors were not involved in study design, data collection, data analysis, data 
interpretation, report writing, or decisions to submit the paper for publication. PAC and DBH 
had full access to this study’s results and take complete responsibility for the integrity of the data 
and the accuracy of the data analysis. 
 
  
Page 24 of 108 AJRCCM Articles in Press. Published on 10-September-2018 as 10.1164/rccm.201802-0304OC 
 Copyright © 2018 by the American Thoracic Society 
 2 
 
REFERENCES  
1. Schunemann HJ, Dorn J, Grant BJ, Winkelstein W, Jr., Trevisan M. Pulmonary function is a long-term predictor 
of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000; 118: 
656-664. 
2. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, 
Fabbri LM, Frith P, Halpin DM, Lopez Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, 
Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Global Strategy for the Diagnosis, Management, 
and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American 
journal of respiratory and critical care medicine 2017; 195: 557-582. 
3. Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-
2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1151-1210. 
4. Zhang WZ, Gomi K, Mahjour SB, Martinez FJ, Shaykhiev R. Update in Chronic Obstructive Pulmonary Disease 
2017. American journal of respiratory and critical care medicine 2018. 
5. Ge T, Chen CY, Neale BM, Sabuncu MR, Smoller JW. Phenome-wide heritability analysis of the UK Biobank. 
PLoS genetics 2017; 13: e1006711. 
6. Wain LV, Shrine N, Artigas MS, Erzurumluoglu AM, Noyvert B, Bossini-Castillo L, Obeidat M, Henry AP, 
Portelli MA, Hall RJ, Billington CK, Rimington TL, Fenech AG, John C, Blake T, Jackson VE, Allen RJ, 
Prins BP, Understanding Society Scientific G, Campbell A, Porteous DJ, Jarvelin MR, Wielscher M, James 
AL, Hui J, Wareham NJ, Zhao JH, Wilson JF, Joshi PK, Stubbe B, Rawal R, Schulz H, Imboden M, 
Probst-Hensch NM, Karrasch S, Gieger C, Deary IJ, Harris SE, Marten J, Rudan I, Enroth S, Gyllensten U, 
Kerr SM, Polasek O, Kahonen M, Surakka I, Vitart V, Hayward C, Lehtimaki T, Raitakari OT, Evans DM, 
Henderson AJ, Pennell CE, Wang CA, Sly PD, Wan ES, Busch R, Hobbs BD, Litonjua AA, Sparrow DW, 
Gulsvik A, Bakke PS, Crapo JD, Beaty TH, Hansel NN, Mathias RA, Ruczinski I, Barnes KC, Bosse Y, 
Joubert P, van den Berge M, Brandsma CA, Pare PD, Sin DD, Nickle DC, Hao K, Gottesman O, Dewey 
FE, Bruse SE, Carey DJ, Kirchner HL, Geisinger-Regeneron Discov EHRC, Jonsson S, Thorleifsson G, 
Jonsdottir I, Gislason T, Stefansson K, Schurmann C, Nadkarni G, Bottinger EP, Loos RJ, Walters RG, 
Chen Z, Millwood IY, Vaucher J, Kurmi OP, Li L, Hansell AL, Brightling C, Zeggini E, Cho MH, 
Silverman EK, Sayers I, Trynka G, Morris AP, Strachan DP, Hall IP, Tobin MD. Genome-wide association 
analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential 
druggable targets. Nat Genet 2017; 49: 416-425. 
7. Tang W, Kowgier M, Loth DW, Soler Artigas M, Joubert BR, Hodge E, Gharib SA, Smith AV, Ruczinski I, 
Gudnason V, Mathias RA, Harris TB, Hansel NN, Launer LJ, Barnes KC, Hansen JG, Albrecht E, Aldrich 
MC, Allerhand M, Barr RG, Brusselle GG, Couper DJ, Curjuric I, Davies G, Deary IJ, Dupuis J, Fall T, 
Foy M, Franceschini N, Gao W, Glaser S, Gu X, Hancock DB, Heinrich J, Hofman A, Imboden M, 
Ingelsson E, James A, Karrasch S, Koch B, Kritchevsky SB, Kumar A, Lahousse L, Li G, Lind L, Lindgren 
C, Liu Y, Lohman K, Lumley T, McArdle WL, Meibohm B, Morris AP, Morrison AC, Musk B, North KE, 
Palmer LJ, Probst-Hensch NM, Psaty BM, Rivadeneira F, Rotter JI, Schulz H, Smith LJ, Sood A, Starr JM, 
Strachan DP, Teumer A, Uitterlinden AG, Volzke H, Voorman A, Wain LV, Wells MT, Wilk JB, Williams 
OD, Heckbert SR, Stricker BH, London SJ, Fornage M, Tobin MD, O'Connor GT, Hall IP, Cassano PA. 
Large-scale genome-wide association studies and meta-analyses of longitudinal change in adult lung 
function. PloS one 2014; 9: e100776. 
8. Soler Artigas M, Wain LV, Miller S, Kheirallah AK, Huffman JE, Ntalla I, Shrine N, Obeidat M, Trochet H, 
McArdle WL, Alves AC, Hui J, Zhao JH, Joshi PK, Teumer A, Albrecht E, Imboden M, Rawal R, Lopez 
LM, Marten J, Enroth S, Surakka I, Polasek O, Lyytikainen LP, Granell R, Hysi PG, Flexeder C, Mahajan 
A, Beilby J, Bosse Y, Brandsma CA, Campbell H, Gieger C, Glaser S, Gonzalez JR, Grallert H, Hammond 
CJ, Harris SE, Hartikainen AL, Heliovaara M, Henderson J, Hocking L, Horikoshi M, Hutri-Kahonen N, 
Ingelsson E, Johansson A, Kemp JP, Kolcic I, Kumar A, Lind L, Melen E, Musk AW, Navarro P, Nickle 
DC, Padmanabhan S, Raitakari OT, Ried JS, Ripatti S, Schulz H, Scott RA, Sin DD, Starr JM, BiLEVE 
UK, Vinuela A, Volzke H, Wild SH, Wright AF, Zemunik T, Jarvis DL, Spector TD, Evans DM, 
Lehtimaki T, Vitart V, Kahonen M, Gyllensten U, Rudan I, Deary IJ, Karrasch S, Probst-Hensch NM, 
Heinrich J, Stubbe B, Wilson JF, Wareham NJ, James AL, Morris AP, Jarvelin MR, Hayward C, Sayers I, 
Strachan DP, Hall IP, Tobin MD. Sixteen new lung function signals identified through 1000 Genomes 
Project reference panel imputation. Nat Commun 2015; 6: 8658. 
Page 25 of 108  AJRCCM Articles in Press. Published on 10-September-2018 as 10.1164/rccm.201802-0304OC 
 Copyright © 2018 by the American Thoracic Society 
 3 
 
9. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M, Zhao JH, Ramasamy A, Zhai G, Vitart V, 
Huffman JE, Igl W, Albrecht E, Deloukas P, Henderson J, Granell R, McArdle WL, Rudnicka AR, 
Wellcome Trust Case Control C, Barroso I, Loos RJ, Wareham NJ, Mustelin L, Rantanen T, Surakka I, 
Imboden M, Wichmann HE, Grkovic I, Jankovic S, Zgaga L, Hartikainen AL, Peltonen L, Gyllensten U, 
Johansson A, Zaboli G, Campbell H, Wild SH, Wilson JF, Glaser S, Homuth G, Volzke H, Mangino M, 
Soranzo N, Spector TD, Polasek O, Rudan I, Wright AF, Heliovaara M, Ripatti S, Pouta A, Naluai AT, 
Olin AC, Toren K, Cooper MN, James AL, Palmer LJ, Hingorani AD, Wannamethee SG, Whincup PH, 
Smith GD, Ebrahim S, McKeever TM, Pavord ID, MacLeod AK, Morris AD, Porteous DJ, Cooper C, 
Dennison E, Shaheen S, Karrasch S, Schnabel E, Schulz H, Grallert H, Bouatia-Naji N, Delplanque J, 
Froguel P, Blakey JD, Team NRS, Britton JR, Morris RW, Holloway JW, Lawlor DA, Hui J, Nyberg F, 
Jarvelin MR, Jackson C, Kahonen M, Kaprio J, Probst-Hensch NM, Koch B, Hayward C, Evans DM, 
Elliott P, Strachan DP, Hall IP, Tobin MD. Genome-wide association study identifies five loci associated 
with lung function. Nature genetics 2010; 42: 36-44. 
10. Loth DW, Artigas MS, Gharib SA, Wain LV, Franceschini N, Koch B, Pottinger TD, Smith AV, Duan Q, 
Oldmeadow C, Lee MK, Strachan DP, James AL, Huffman JE, Vitart V, Ramasamy A, Wareham NJ, 
Kaprio J, Wang XQ, Trochet H, Kahonen M, Flexeder C, Albrecht E, Lopez LM, de Jong K, Thyagarajan 
B, Alves AC, Enroth S, Omenaas E, Joshi PK, Fall T, Vinuela A, Launer LJ, Loehr LR, Fornage M, Li G, 
Wilk JB, Tang W, Manichaikul A, Lahousse L, Harris TB, North KE, Rudnicka AR, Hui J, Gu X, Lumley 
T, Wright AF, Hastie ND, Campbell S, Kumar R, Pin I, Scott RA, Pietilainen KH, Surakka I, Liu Y, 
Holliday EG, Schulz H, Heinrich J, Davies G, Vonk JM, Wojczynski M, Pouta A, Johansson A, Wild SH, 
Ingelsson E, Rivadeneira F, Volzke H, Hysi PG, Eiriksdottir G, Morrison AC, Rotter JI, Gao W, Postma 
DS, White WB, Rich SS, Hofman A, Aspelund T, Couper D, Smith LJ, Psaty BM, Lohman K, Burchard 
EG, Uitterlinden AG, Garcia M, Joubert BR, McArdle WL, Musk AB, Hansel N, Heckbert SR, Zgaga L, 
van Meurs JB, Navarro P, Rudan I, Oh YM, Redline S, Jarvis DL, Zhao JH, Rantanen T, O'Connor GT, 
Ripatti S, Scott RJ, Karrasch S, Grallert H, Gaddis NC, Starr JM, Wijmenga C, Minster RL, Lederer DJ, 
Pekkanen J, Gyllensten U, Campbell H, Morris AP, Glaser S, Hammond CJ, Burkart KM, Beilby J, 
Kritchevsky SB, Gudnason V, Hancock DB, Williams OD, Polasek O, Zemunik T, Kolcic I, Petrini MF, 
Wjst M, Kim WJ, Porteous DJ, Scotland G, Smith BH, Viljanen A, Heliovaara M, Attia JR, Sayers I, 
Hampel R, Gieger C, Deary IJ, Boezen HM, Newman A, Jarvelin MR, Wilson JF, Lind L, Stricker BH, 
Teumer A, Spector TD, Melen E, Peters MJ, Lange LA, Barr RG, Bracke KR, Verhamme FM, Sung J, 
Hiemstra PS, Cassano PA, Sood A, Hayward C, Dupuis J, Hall IP, Brusselle GG, Tobin MD, London SJ. 
Genome-wide association analysis identifies six new loci associated with forced vital capacity. Nature 
genetics 2014; 46: 669-677. 
11. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, Franceschini N, van Durme YM, 
Chen TH, Barr RG, Schabath MB, Couper DJ, Brusselle GG, Psaty BM, van Duijn CM, Rotter JI, 
Uitterlinden AG, Hofman A, Punjabi NM, Rivadeneira F, Morrison AC, Enright PL, North KE, Heckbert 
SR, Lumley T, Stricker BH, O'Connor GT, London SJ. Meta-analyses of genome-wide association studies 
identify multiple loci associated with pulmonary function. Nat Genet 2010; 42: 45-52. 
12. Wilk JB, Shrine NR, Loehr LR, Zhao JH, Manichaikul A, Lopez LM, Smith AV, Heckbert SR, Smolonska J, 
Tang W, Loth DW, Curjuric I, Hui J, Cho MH, Latourelle JC, Henry AP, Aldrich M, Bakke P, Beaty TH, 
Bentley AR, Borecki IB, Brusselle GG, Burkart KM, Chen TH, Couper D, Crapo JD, Davies G, Dupuis J, 
Franceschini N, Gulsvik A, Hancock DB, Harris TB, Hofman A, Imboden M, James AL, Khaw KT, 
Lahousse L, Launer LJ, Litonjua A, Liu Y, Lohman KK, Lomas DA, Lumley T, Marciante KD, McArdle 
WL, Meibohm B, Morrison AC, Musk AW, Myers RH, North KE, Postma DS, Psaty BM, Rich SS, 
Rivadeneira F, Rochat T, Rotter JI, Soler Artigas M, Starr JM, Uitterlinden AG, Wareham NJ, Wijmenga 
C, Zanen P, Province MA, Silverman EK, Deary IJ, Palmer LJ, Cassano PA, Gudnason V, Barr RG, Loos 
RJ, Strachan DP, London SJ, Boezen HM, Probst-Hensch N, Gharib SA, Hall IP, O'Connor GT, Tobin 
MD, Stricker BH. Genome-wide association studies identify CHRNA5/3 and HTR4 in the development of 
airflow obstruction. American journal of respiratory and critical care medicine 2012; 186: 622-632. 
13. Wyss AB, Sofer T, Lee MK, Terzikhan N, Nguyen JN, Lahousse L, Latourelle JC, Smith AV, Bartz TM, Feitosa 
MF, Gao W, Ahluwalia TS, Tang W, Oldmeadow C, Duan Q, de Jong K, Wojczynski MK, Wang XQ, 
Noordam R, Hartwig FP, Jackson VE, Wang T, Obeidat M, Hobbs BD, Huan T, Gui H, Parker MM, Hu D, 
Mogil LS, Kichaev G, Jin J, Graff M, Harris TB, Kalhan R, Heckbert SR, Paternoster L, Burkart KM, Liu 
Y, Holliday EG, Wilson JG, Vonk JM, Sanders JL, Barr RG, de Mutsert R, Menezes AMB, Adams HHH, 
van den Berge M, Joehanes R, Levin AM, Liberto J, Launer LJ, Morrison AC, Sitlani CM, Celedon JC, 
Kritchevsky SB, Scott RJ, Christensen K, Rotter JI, Bonten TN, Wehrmeister FC, Bosse Y, Xiao S, Oh S, 
Page 26 of 108 AJRCCM Articles in Press. Published on 10-September-2018 as 10.1164/rccm.201802-0304OC 
 Copyright © 2018 by the American Thoracic Society 
 4 
 
Franceschini N, Brody JA, Kaplan RC, Lohman K, McEvoy M, Province MA, Rosendaal FR, Taylor KD, 
Nickle DC, Williams LK, Burchard EG, Wheeler HE, Sin DD, Gudnason V, North KE, Fornage M, Psaty 
BM, Myers RH, O'Connor G, Hansen T, Laurie CC, Cassano PA, Sung J, Kim WJ, Attia JR, Lange L, 
Boezen HM, Thyagarajan B, Rich SS, Mook-Kanamori DO, Horta BL, Uitterlinden AG, Im HK, Cho MH, 
Brusselle GG, Gharib SA, Dupuis J, Manichaikul A, London SJ. Multiethnic meta-analysis identifies 
ancestry-specific and cross-ancestry loci for pulmonary function. Nature communications 2018; 9: 2976. 
14. Tamimi A, Serdarevic D, Hanania NA. The effects of cigarette smoke on airway inflammation in asthma and 
COPD: therapeutic implications. Respiratory medicine 2012; 106: 319-328. 
15. Burdge GC. Metabolism of alpha-linolenic acid in humans. Prostaglandins, leukotrienes, and essential fatty 
acids 2006; 75: 161-168. 
16. Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. 
The American journal of clinical nutrition 2006; 83: 1467S-1476S. 
17. Duvall MG, Levy BD. DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation. 
European journal of pharmacology 2016; 785: 144-155. 
18. Khaddaj-Mallat R, Hiram R, Sirois C, Sirois M, Rizcallah E, Marouan S, Morin C, Rousseau E. MAG-DPA 
curbs inflammatory biomarkers and pharmacological reactivity in cytokine-triggered hyperresponsive 
airway models. Pharmacology research & perspectives 2016; 4: e00263. 
19. Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain 
omega-3 fatty acids. Nutrition reviews 2010; 68: 280-289. 
20. Shahar E, Folsom AR, Melnick SL, Tockman MS, Comstock GW, Gennaro V, Higgins MW, Sorlie PD, Ko WJ, 
Szklo M. Dietary n-3 polyunsaturated fatty acids and smoking-related chronic obstructive pulmonary 
disease. Atherosclerosis Risk in Communities Study Investigators. The New England journal of medicine 
1994; 331: 228-233. 
21. McKeever TM, Lewis SA, Cassano PA, Ocke M, Burney P, Britton J, Smit HA. The relation between dietary 
intake of individual fatty acids, FEV1 and respiratory disease in Dutch adults. Thorax 2008; 63: 208-214. 
22. Kompauer I, Demmelmair H, Koletzko B, Bolte G, Linseisen J, Heinrich J. Association of fatty acids in serum 
phospholipids with lung function and bronchial hyperresponsiveness in adults. European journal of 
epidemiology 2008; 23: 175-190. 
23. Shahar E, Boland LL, Folsom AR, Tockman MS, McGovern PG, Eckfeldt JH. Docosahexaenoic acid and 
smoking-related chronic obstructive pulmonary disease. The Atherosclerosis Risk in Communities Study 
Investigators. American journal of respiratory and critical care medicine 1999; 159: 1780-1785. 
24. Hancock DB, Artigas MS, Gharib SA, Henry A, Manichaikul A, Ramasamy A, Loth DW, Imboden M, Koch B, 
McArdle WL, Smith AV, Smolonska J, Sood A, Tang W, Wilk JB, Zhai G, Zhao JH, Aschard H, Burkart 
KM, Curjuric I, Eijgelsheim M, Elliott P, Gu X, Harris TB, Janson C, Homuth G, Hysi PG, Liu JZ, Loehr 
LR, Lohman K, Loos RJ, Manning AK, Marciante KD, Obeidat M, Postma DS, Aldrich MC, Brusselle 
GG, Chen TH, Eiriksdottir G, Franceschini N, Heinrich J, Rotter JI, Wijmenga C, Williams OD, Bentley 
AR, Hofman A, Laurie CC, Lumley T, Morrison AC, Joubert BR, Rivadeneira F, Couper DJ, Kritchevsky 
SB, Liu Y, Wjst M, Wain LV, Vonk JM, Uitterlinden AG, Rochat T, Rich SS, Psaty BM, O'Connor GT, 
North KE, Mirel DB, Meibohm B, Launer LJ, Khaw KT, Hartikainen AL, Hammond CJ, Glaser S, 
Marchini J, Kraft P, Wareham NJ, Volzke H, Stricker BH, Spector TD, Probst-Hensch NM, Jarvis D, 
Jarvelin MR, Heckbert SR, Gudnason V, Boezen HM, Barr RG, Cassano PA, Strachan DP, Fornage M, 
Hall IP, Dupuis J, Tobin MD, London SJ. Genome-wide joint meta-analysis of SNP and SNP-by-smoking 
interaction identifies novel loci for pulmonary function. PLoS Genet 2012; 8: e1003098. 
25. Imboden M, Kumar A, Curjuric I, Adam M, Thun GA, Haun M, Tsai MY, Pons M, Bettschart R, Turk A, 
Rochat T, Kunzli N, Schindler C, Kronenberg F, Probst-Hensch NM. Modification of the association 
between PM10 and lung function decline by cadherin 13 polymorphisms in the SAPALDIA cohort: a 
genome-wide interaction analysis. Environmental health perspectives 2015; 123: 72-79. 
26. Liao SY, Lin X, Christiani DC. Gene-environment interaction effects on lung function- a genome-wide 
association study within the Framingham heart study. Environmental health : a global access science 
source 2013; 12: 101. 
27. Xu JY, Bartz TM, Eiriksdottir G, Frazier-Wood AC, Gudnason V, Lahousse L, Manichaikul A, Rohde RR, Sun 
FG, Terzikhan N, Zhou X, Barr RG, Brusselle GG, Dupuis J, Gharib SA, London SJ, North KE, Psaty BM, 
Smith AV, Steffen LM, Hancock DB, Cassano PA. Meta-Analysis of the Association of Omega-3 Fatty 
Acids Biomarkers with Pulmonary Function. Faseb Journal 2017; 31. 
Page 27 of 108  AJRCCM Articles in Press. Published on 10-September-2018 as 10.1164/rccm.201802-0304OC 
 Copyright © 2018 by the American Thoracic Society 
 5 
 
28. Tu WC, Muhlhausler BS, Yelland LN, Gibson RA. Correlations between blood and tissue omega-3 LCPUFA 
status following dietary ALA intervention in rats. Prostaglandins, leukotrienes, and essential fatty acids 
2013; 88: 53-60. 
29. Rice K, Higgins JPT, Lumley T. A re-evaluation of fixed effect(s) meta-analysis. J R Stat Soc a Stat 2018; 181: 
205-227. 
30. Manning AK, LaValley M, Liu CT, Rice K, An P, Liu Y, Miljkovic I, Rasmussen-Torvik L, Harris TB, Province 
MA, Borecki IB, Florez JC, Meigs JB, Cupples LA, Dupuis J. Meta-analysis of gene-environment 
interaction: joint estimation of SNP and SNP x environment regression coefficients. Genetic epidemiology 
2011; 35: 11-18. 
31. Gref A, Merid SK, Gruzieva O, Ballereau S, Becker A, Bellander T, Bergstrom A, Bosse Y, Bottai M, Chan-
Yeung M, Fuertes E, Ierodiakonou D, Jiang R, Joly S, Jones M, Kobor MS, Korek M, Kozyrskyj AL, 
Kumar A, Lemonnier N, MacIntyre E, Menard C, Nickle D, Obeidat M, Pellet J, Standl M, Saaf A, 
Soderhall C, Tiesler CMT, van den Berge M, Vonk JM, Vora H, Xu CJ, Anto JM, Auffray C, Brauer M, 
Bousquet J, Brunekreef B, Gauderman WJ, Heinrich J, Kere J, Koppelman GH, Postma D, Carlsten C, 
Pershagen G, Melen E. Genome-Wide Interaction Analysis of Air Pollution Exposure and Childhood 
Asthma with Functional Follow-up. American journal of respiratory and critical care medicine 2017; 195: 
1373-1383. 
32. Hancock DB, Guo Y, Reginsson GW, Gaddis NC, Lutz SM, Sherva R, Loukola A, Minica CC, Markunas CA, 
Han Y, Young KA, Gudbjartsson DF, Gu F, McNeil DW, Qaiser B, Glasheen C, Olson S, Landi MT, 
Madden PAF, Farrer LA, Vink J, Saccone NL, Neale MC, Kranzler HR, McKay J, Hung RJ, Amos CI, 
Marazita ML, Boomsma DI, Baker TB, Gelernter J, Kaprio J, Caporaso NE, Thorgeirsson TE, Hokanson 
JE, Bierut LJ, Stefansson K, Johnson EO. Genome-wide association study across European and African 
American ancestries identifies a SNP in DNMT3B contributing to nicotine dependence. Molecular 
psychiatry 2017. 
33. Tchetgen Tchetgen EJ, Kraft P. On the robustness of tests of genetic associations incorporating gene-
environment interaction when the environmental exposure is misspecified. Epidemiology 2011; 22: 257-
261. 
34. Pe'er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide association 
studies of nearly all common variants. Genetic epidemiology 2008; 32: 381-385. 
35. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif 
alterations within sets of genetically linked variants. Nucleic acids research 2012; 40: D930-934. 
36. Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren B, Milosavljevic A, Meissner A, Kellis M, Marra MA, 
Beaudet AL, Ecker JR, Farnham PJ, Hirst M, Lander ES, Mikkelsen TS, Thomson JA. The NIH Roadmap 
Epigenomics Mapping Consortium. Nature biotechnology 2010; 28: 1045-1048. 
37. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, Hasz R, Walters G, Garcia F, Young N, Foster B, 
Moser M, Karasik E, Gillard B, Ramsey K, Sullivan S, Bridge J, Magazine H, Syron J, Fleming J, Siminoff 
L, Traino H, Mosavel M, Barker L, Jewell S, Rohrer D, Maxim D, Filkins D, Harbach P, Cortadillo E, 
Berghuis B, Turner L, Hudson E, Feenstra K, Sobin L, Robb J, Branton P, Korzeniewski G, Shive C, Tabor 
D, Qi LQ, Groch K, Nampally S, Buia S, Zimmerman A, Smith A, Burges R, Robinson K, Valentino K, 
Bradbury D, Cosentino M, Diaz-Mayoral N, Kennedy M, Engel T, Williams P, Erickson K, Ardlie K, 
Winckler W, Getz G, DeLuca D, MacArthur D, Kellis M, Thomson A, Young T, Gelfand E, Donovan M, 
Meng Y, Grant G, Mash D, Marcus Y, Basile M, Liu J, Zhu J, Tu ZD, Cox NJ, Nicolae DL, Gamazon ER, 
Im HK, Konkashbaev A, Pritchard J, Stevens M, Flutre T, Wen XQ, Dermitzakis ET, Lappalainen T, 
Guigo R, Monlong J, Sammeth M, Koller D, Battle A, Mostafavi S, McCarthy M, Rivas M, Maller J, 
Rusyn I, Nobel A, Wright F, Shabalin A, Feolo M, Sharopova N, Sturcke A, Paschal J, Anderson JM, 
Wilder EL, Derr LK, Green ED, Struewing JP, Temple G, Volpi S, Boyer JT, Thomson EJ, Guyer MS, Ng 
C, Abdallah A, Colantuoni D, Insel TR, Koester SE, Little AR, Bender PK, Lehner T, Yao Y, Compton 
CC, Vaught JB, Sawyer S, Lockhart NC, Demchok J, Moore HF. The Genotype-Tissue Expression (GTEx) 
project. Nature genetics 2013; 45: 580-585. 
38. Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q. GeneMANIA: a real-time multiple association 
network integration algorithm for predicting gene function. Genome Biol 2008; 9 Suppl 1: S4. 
39. Ford ES, Mannino DM, Wheaton AG, Giles WH, Presley-Cantrell L, Croft JB. Trends in the prevalence of 
obstructive and restrictive lung function among adults in the United States: findings from the National 
Health and Nutrition Examination surveys from 1988-1994 to 2007-2010. Chest 2013; 143: 1395-1406. 
Page 28 of 108 AJRCCM Articles in Press. Published on 10-September-2018 as 10.1164/rccm.201802-0304OC 
 Copyright © 2018 by the American Thoracic Society 
 6 
 
40. Hsiao HM, Sapinoro RE, Thatcher TH, Croasdell A, Levy EP, Fulton RA, Olsen KC, Pollock SJ, Serhan CN, 
Phipps RP, Sime PJ. A novel anti-inflammatory and pro-resolving role for resolvin D1 in acute cigarette 
smoke-induced lung inflammation. PloS one 2013; 8: e58258. 
41. Lemaitre RN, Tanaka T, Tang W, Manichaikul A, Foy M, Kabagambe EK, Nettleton JA, King IB, Weng LC, 
Bhattacharya S, Bandinelli S, Bis JC, Rich SS, Jacobs DR, Jr., Cherubini A, McKnight B, Liang S, Gu X, 
Rice K, Laurie CC, Lumley T, Browning BL, Psaty BM, Chen YD, Friedlander Y, Djousse L, Wu JH, 
Siscovick DS, Uitterlinden AG, Arnett DK, Ferrucci L, Fornage M, Tsai MY, Mozaffarian D, Steffen LM. 
Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide 
association studies from the CHARGE Consortium. PLoS Genet 2011; 7: e1002193. 
42. Mathias RA, Grant AV, Rafaels N, Hand T, Gao L, Vergara C, Tsai YJ, Yang M, Campbell M, Foster C, Gao P, 
Togias A, Hansel NN, Diette G, Adkinson NF, Liu MC, Faruque M, Dunston GM, Watson HR, Bracken 
MB, Hoh J, Maul P, Maul T, Jedlicka AE, Murray T, Hetmanski JB, Ashworth R, Ongaco CM, Hetrick 
KN, Doheny KF, Pugh EW, Rotimi CN, Ford J, Eng C, Burchard EG, Sleiman PM, Hakonarson H, Forno 
E, Raby BA, Weiss ST, Scott AF, Kabesch M, Liang L, Abecasis G, Moffatt MF, Cookson WO, Ruczinski 
I, Beaty TH, Barnes KC. A genome-wide association study on African-ancestry populations for asthma. 
The Journal of allergy and clinical immunology 2010; 125: 336-346 e334. 
43. Qi SY, Riviere PJ, Trojnar J, Junien JL, Akinsanya KO. Cloning and characterization of dipeptidyl peptidase 10, 
a new member of an emerging subgroup of serine proteases. The Biochemical journal 2003; 373: 179-189. 
44. Zhou H, Hong X, Jiang S, Dong H, Xu X, Xu X. Analyses of associations between three positionally cloned 
asthma candidate genes and asthma or asthma-related phenotypes in a Chinese population. BMC medical 
genetics 2009; 10: 123. 
45. Wu H, Romieu I, Shi M, Hancock DB, Li H, Sienra-Monge JJ, Chiu GY, Xu H, del Rio-Navarro BE, London 
SJ. Evaluation of candidate genes in a genome-wide association study of childhood asthma in Mexicans. 
The Journal of allergy and clinical immunology 2010; 125: 321-327 e313. 
46. Poon AH, Houseman EA, Ryan L, Sparrow D, Vokonas PS, Litonjua AA. Variants of asthma and chronic 
obstructive pulmonary disease genes and lung function decline in aging. J Gerontol A Biol Sci Med Sci 
2014; 69: 907-913. 
47. Loth DW, Soler Artigas M, Gharib SA, Wain LV, Franceschini N, Koch B, Pottinger TD, Smith AV, Duan Q, 
Oldmeadow C, Lee MK, Strachan DP, James AL, Huffman JE, Vitart V, Ramasamy A, Wareham NJ, 
Kaprio J, Wang XQ, Trochet H, Kahonen M, Flexeder C, Albrecht E, Lopez LM, de Jong K, Thyagarajan 
B, Alves AC, Enroth S, Omenaas E, Joshi PK, Fall T, Vinuela A, Launer LJ, Loehr LR, Fornage M, Li G, 
Wilk JB, Tang W, Manichaikul A, Lahousse L, Harris TB, North KE, Rudnicka AR, Hui J, Gu X, Lumley 
T, Wright AF, Hastie ND, Campbell S, Kumar R, Pin I, Scott RA, Pietilainen KH, Surakka I, Liu Y, 
Holliday EG, Schulz H, Heinrich J, Davies G, Vonk JM, Wojczynski M, Pouta A, Johansson A, Wild SH, 
Ingelsson E, Rivadeneira F, Volzke H, Hysi PG, Eiriksdottir G, Morrison AC, Rotter JI, Gao W, Postma 
DS, White WB, Rich SS, Hofman A, Aspelund T, Couper D, Smith LJ, Psaty BM, Lohman K, Burchard 
EG, Uitterlinden AG, Garcia M, Joubert BR, McArdle WL, Musk AB, Hansel N, Heckbert SR, Zgaga L, 
van Meurs JB, Navarro P, Rudan I, Oh YM, Redline S, Jarvis DL, Zhao JH, Rantanen T, O'Connor GT, 
Ripatti S, Scott RJ, Karrasch S, Grallert H, Gaddis NC, Starr JM, Wijmenga C, Minster RL, Lederer DJ, 
Pekkanen J, Gyllensten U, Campbell H, Morris AP, Glaser S, Hammond CJ, Burkart KM, Beilby J, 
Kritchevsky SB, Gudnason V, Hancock DB, Williams OD, Polasek O, Zemunik T, Kolcic I, Petrini MF, 
Wjst M, Kim WJ, Porteous DJ, Scotland G, Smith BH, Viljanen A, Heliovaara M, Attia JR, Sayers I, 
Hampel R, Gieger C, Deary IJ, Boezen HM, Newman A, Jarvelin MR, Wilson JF, Lind L, Stricker BH, 
Teumer A, Spector TD, Melen E, Peters MJ, Lange LA, Barr RG, Bracke KR, Verhamme FM, Sung J, 
Hiemstra PS, Cassano PA, Sood A, Hayward C, Dupuis J, Hall IP, Brusselle GG, Tobin MD, London SJ. 
Genome-wide association analysis identifies six new loci associated with forced vital capacity. Nat Genet 
2014; 46: 669-677. 
48. Zagha E, Ozaita A, Chang SY, Nadal MS, Lin U, Saganich MJ, McCormack T, Akinsanya KO, Qi SY, Rudy B. 
DPP10 modulates Kv4-mediated A-type potassium channels. The Journal of biological chemistry 2005; 
280: 18853-18861. 
49. Allen M, Heinzmann A, Noguchi E, Abecasis G, Broxholme J, Ponting CP, Bhattacharyya S, Tinsley J, Zhang 
Y, Holt R, Jones EY, Lench N, Carey A, Jones H, Dickens NJ, Dimon C, Nicholls R, Baker C, Xue L, 
Townsend E, Kabesch M, Weiland SK, Carr D, von Mutius E, Adcock IM, Barnes PJ, Lathrop GM, 
Edwards M, Moffatt MF, Cookson WO. Positional cloning of a novel gene influencing asthma from 
chromosome 2q14. Nature genetics 2003; 35: 258-263. 
Page 29 of 108  AJRCCM Articles in Press. Published on 10-September-2018 as 10.1164/rccm.201802-0304OC 
 Copyright © 2018 by the American Thoracic Society 
 7 
 
50. Nieto-Fontarigo JJ, Gonzalez-Barcala FJ, San Jose E, Arias P, Nogueira M, Salgado FJ. CD26 and Asthma: a 
Comprehensive Review. Clinical reviews in allergy & immunology 2016. 
51. Zhang X, Li D, Wang H, Pang C, Wu Y, Wen F. Gender difference in plasma fatty-acid-binding protein 4 levels 
in patients with chronic obstructive pulmonary disease. Bioscience reports 2016; 36: e00302. 
52. Park HJ, Park SE, Park CY, Lim SY, Lee WY, Oh KW, Park SW, Rhee EJ. The relationship between serum 
fatty-acid binding protein 4 level and lung function in Korean subjects with normal ventilatory function. 
BMC pulmonary medicine 2016; 16: 34. 
53. Furuhashi M, Hiramitsu S, Mita T, Omori A, Fuseya T, Ishimura S, Watanabe Y, Hoshina K, Matsumoto M, 
Tanaka M, Moniwa N, Yoshida H, Ishii J, Miura T. Reduction of circulating FABP4 level by treatment 
with omega-3 fatty acid ethyl esters. Lipids in health and disease 2016; 15: 5. 
54. Iwasaki M, Hoshian F, Tsuji T, Hirose N, Matsumoto T, Kitatani N, Sugawara K, Usui R, Kuwata H, Sugizaki 
K, Kitamoto Y, Fujiwara S, Watanabe K, Hyo T, Kurose T, Seino Y, Yabe D. Predicting efficacy of 
dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin 
reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. Journal of diabetes 
investigation 2012; 3: 464-467. 
55. Chhabra D, Sharma S, Kho AT, Gaedigk R, Vyhlidal CA, Leeder JS, Morrow J, Carey VJ, Weiss ST, Tantisira 
KG, DeMeo DL. Fetal lung and placental methylation is associated with in utero nicotine exposure. 
Epigenetics 2014; 9: 1473-1484. 
56. Peters SA, Huxley RR, Woodward M. Do smoking habits differ between women and men in contemporary 
Western populations? Evidence from half a million people in the UK Biobank study. BMJ open 2014; 4: 
e005663. 
57. Johnson EO, Morgan-Lopez AA, Breslau N, Hatsukami DK, Bierut LJ. Test of measurement invariance of the 
FTND across demographic groups: assessment, effect size, and prediction of cessation. Drug and alcohol 
dependence 2008; 93: 260-270. 
58. Ward BW, Nugent CN, Blumberg SJ, Vahratian A. Measuring the Prevalence of Diagnosed Chronic Obstructive 
Pulmonary Disease in the United States Using Data From the 2012-2014 National Health Interview Survey. 
Public health reports 2017; 132: 149-156. 
59. Chen LS, Saccone NL, Culverhouse RC, Bracci PM, Chen CH, Dueker N, Han Y, Huang H, Jin G, Kohno T, 
Ma JZ, Przybeck TR, Sanders AR, Smith JA, Sung YJ, Wenzlaff AS, Wu C, Yoon D, Chen YT, Cheng 
YC, Cho YS, David SP, Duan J, Eaton CB, Furberg H, Goate AM, Gu D, Hansen HM, Hartz S, Hu Z, Kim 
YJ, Kittner SJ, Levinson DF, Mosley TH, Payne TJ, Rao DC, Rice JP, Rice TK, Schwantes-An TH, Shete 
SS, Shi J, Spitz MR, Sun YV, Tsai FJ, Wang JC, Wrensch MR, Xian H, Gejman PV, He J, Hunt SC, 
Kardia SL, Li MD, Lin D, Mitchell BD, Park T, Schwartz AG, Shen H, Wiencke JK, Wu JY, Yokota J, 
Amos CI, Bierut LJ. Smoking and genetic risk variation across populations of European, Asian, and 
African American ancestry--a meta-analysis of chromosome 15q25. Genetic epidemiology 2012; 36: 340-
351. 
 
Page 30 of 108 AJRCCM Articles in Press. Published on 10-September-2018 as 10.1164/rccm.201802-0304OC 
 Copyright © 2018 by the American Thoracic Society 
 8 
Table 1. Participant Characteristics in All Seven Cohorts (N = 16,134; 13,629 EA and 2,505 AA)
* 
 
N-3 PUFA biomarkers and genome-wide interaction on PFT measures 
  Discovery phase of genome-wide interaction analysis of n-3 PUFA 
biomarkers 
Replication phase 
Cohort/ 
Sub-Cohort 
AGES RS CHS
‡‡
 ARIC FHS MESA CARDIA 
-Offspring -Gen3 
Ancestry EA EA AA EA EA EA EA AA EA AA EA 
N for n-3 PUFA-PFT 
association
†
 
424 141 243 1,690 3,254 2,169 3,052 801 1,140 1,461 1,759 
N for genome-wide 
interaction
‡
 
NA
§§ 
NA
§§
 NA
§§
 1,684 3,143 5,198
lll
 797 1,140 546
***
 1,141
***
 
Males, % 45.0 48.9 30.9 39.1 48.5 45.0 47.2 47.7 49.6 39.3 46.5 
Age, year 76.3  
(5.5) 
74.6 
(5.7) 
72.9 
(5.2) 
74.5 
(4.8) 
53.8 
(5.6) 
66.0 (8.9) 
46.0 
(8.8) 
65.6 
(9.7) 
66.4 
(9.9) 
44.6 
(3.8) 
45.8 
(3.4) 
Height, m 1.67 
(0.09) 
1.68 
(0.09) 
1.64 
(0.08) 
1.64 
(0.09) 
1.69 
(0.09) 
1.67 (0.10) 
1.70 
(0.09) 
1.68 
(0.10) 
1.69 
(0.10) 
1.70 
(0.10) 
1.72 
(0.09) 
Weight, kg
§
 76.4 
(14.8) 
77.9 
(13.7) 
77.4 
(13.0) 
71.3 
(13.8) 
77.9 
(16.2) 
79.3 (17.6) 
81.1 
(19.3) 
84.8 
(17.2) 
79.8 
(17.5) 
90.5 
(23.0) 
81.8 
(19.5) 
Current smokers, % 11.1 14.2 12.3 8.4 22.8 8.0 9.8 15.5 8.7 24.1 14.3 
Former smokers, % 40.1 57.5 42.0 48.5 39.5 53.0 32.2 38.6 47.1 13.5 24.4 
Pack-Years
ll
 24.6 
(17.5) 
27.0 
(23.5) 
25.4 
(26.0) 
28.7 
(25.2) 
26.8 
(19.7) 
24.6 (21.7) 
13.1 
(14.3) 
24.6 
(23.5) 
29.7 
(29.1) 
10.8 
(9.2) 
12.2 
(12.5) 
FEV1, mL 2176 
(664) 
2387 
(748) 
1765 
(482) 
2036 
(614) 
3080 
(780) 
2630 (767) 
3388 
(773) 
2189 
(662) 
2555 
(761) 
2704 
(684) 
3329 
(753) 
FVC, mL 2920 
(815) 
3238 
(952) 
2440 
(694) 
2936 
(838) 
4144 
(984) 
3651 (995) 
4449 
(993) 
2920 
(862) 
3494 
(983) 
3409 
(871) 
4291 
(979) 
FEV1/FVC (%) 74.4  
(8.1) 
73.7 
(8.3) 
73.0 
(8.1) 
69.6 
(9.7) 
74.3 
(7.3) 
72.0 (7.8) 
76.3 
(6.6) 
75.4 
(9.5) 
73.3 
(8.7) 
79.7 
(7.0) 
77.9 
(6.3) 
ALA (% of total FAs) 0.23 
(0.09) 
0.17 
(0.06) 
0.14 
(0.04) 
0.15 
(0.06) 
0.14 
(0.05) 
0.18 (0.11) 
0.17 
(0.07) 
0.16 
(0.06) 
0.18 
(0.10) 
0.17 
(0.08) 
0.19 
(0.08) 
EPA (% of total FAs) 2.87 
(1.66) 
0.85 
(0.57) 
0.61 
(0.36) 
0.60 
(0.39) 
0.56 
(0.25) 
0.74 (0.48) 
0.67 
(0.42) 
0.91 
(0.72) 
0.93 
(0.73) 
0.68 
(0.42) 
0.84 
(0.61) 
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N-3 PUFA biomarkers and genome-wide interaction on PFT measures 
  Discovery phase of genome-wide interaction analysis of n-3 PUFA 
biomarkers 
Replication phase 
DPA (% of total FAs) 1.18 
(0.21) 
0.94 
(0.17) 
0.86 
(0.20) 
0.83 
(0.17) 
0.90 
(0.17) 
2.76 (0.46) 
2.55 
(0.45) 
0.95 
(0.23) 
0.93 
(0.22) 
0.93 
(0.21) 
0.94 
(0.21) 
DHA (% of total FAs) 6.33 
(1.52) 
3.52 
(0.93) 
3.55 
(0.98) 
2.98 
(0.95) 
2.81 
(0.86) 
4.87 
(1.37) 
4.19 
(1.22) 
4.28 
(1.37) 
3.53 
(1.33) 
3.29 
(0.99) 
3.10 
(1.12) 
Total n-3 PUFAs (% of 
total FA)
**
 
10.60 
(3.08) 
5.48 
(1.38) 
5.16 
(1.31) 
4.56 
(1.27) 
4.41 
(1.04) 
8.56 (2.00) 
7.59 
(1.78) 
6.29 
(2.07) 
5.57 
(2.02) 
5.07 
(1.32) 
5.08 
(1.65) 
Time Difference 
between PFT and n-3 
PUFAs, days
††
 
1 (6) 
1705 
(178) 
353 (27) 
362 
(29) 
0 (0) 3 (77) 0 (0) 
1724 
(116) 
1769 
(110) 
0 (0) 0 (0) 
Abbreviations: AA = African ancestry; AGES = Age, Gene, Environment, Susceptibility Study—Reykjavik, Iceland; ALA = Alpha-
linolenic acid; ARIC = Atherosclerosis Risk in Communities; CARDIA = Coronary Artery Risk Development in Young Adults; CHS 
= Cardiovascular Health Study; DHA = Docosahexaenoic acid; DPA = Docosapentaenoic acid; EA = European ancestry; EPA = 
Eicosapentaenoic acid; FA= Fatty acid; FEV1 = Forced expiratory volume in the first second; FHS (Offspring) = Framingham Heart 
Study—Offspring Cohort; FHS (Gen3) = Framingham Heart Study—Generation 3 Cohort; FVC = Forced vital capacity; MESA = 
Multi-Ethnic Study of Atherosclerosis; NA = Not applicable; n-3 PUFA = Omega-3 poly-unsaturated fatty acid; PFT = Pulmonary 
function test; RS = Rotterdam (Netherlands) Study. 
*
Data are presented as mean (standard deviation) unless otherwise indicated. Seven cohorts are included in total. All the cohorts 
measured n-3 PUFAs in plasma, except FHS, which measured n-3 PUFAs in red blood cells in its two sub-cohorts (the Offspring 
Cohort and the Generation 3 Cohort). The descriptive statistics presented here are based on all participants in the main n-3 PUFA-
PFT association analyses.  
†
The total sample size for the meta-analysis of omega-3 fatty acid biomarker associations with PFTs was 16,134, in which 13,629 
were European ancestry participants, and 2,505 were African ancestry participants. 
 
‡
The total sample size for the genome-wide interaction analyses of omega-3 fatty acid biomarkers (84.6% of those included in the n-3 
PUFA-PFT association analysis) was 13,649, in which 12,306 were European ancestry participants (90.3% of all EA participants), 
and 1,343 were African ancestry participants (53.6% of all AA participants). Any discrepancy in numbers of participants for the n-3 
PUFA-PFT association and discovery-phase genome-wide analyses was due to participants whose genetic data did not pass quality 
control.  
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§
Number of participants with weight data was slightly different from the number of participants shown in this table for some cohorts. 
In CHS, 242 out of 243 AAs and 1,687 out of 1,690 EAs had weight data. In CARDIA, all 1,759 EAs and 1,456 out of 1,461 AAs 
had weight data.  
ll
Descriptive statistics of pack-years was conducted among ever smokers. 
**
Total n-3 PUFA biomarkers is the sum of ALA, EPA, DPA, and DHA in plasma or red blood cells.  
††
The time difference refers to the interval between measurement of PFT and n-3 PUFA biomarkers. The difference is positive if the 
n-3 PUFA biomarkers were measured before the PFTs, while the value is negative if the n-3 PUFA biomarkers were measured after 
the PFTs. In MESA, 16 EA participants and 18 AA participants had missing data for the time difference variable.
 
‡‡
In CHS, 6 EA participants and 6 AA participants were excluded as residual outliers (studentized residual >4 for EA participants, and 
>3 for AA participants), based on the main effect model without the n-3 PUFA term. All other cohorts have descriptive statistics on 
participants before applying the exclusion of residual outliers. In addition, in CHS, 1,684 EA participants and 242 AA participants 
were used for the descriptive statistics of weight and FVC.  
 
§§
Genome-wide interaction analysis was not performed in these cohorts/sub-cohorts due to their small sample sizes (N<500). 
lll
The genome-wide interaction analysis in FHS was performed using two sub-cohorts combined, with adjustment of family 
relatedness.  
***
CARDIA was used as a replication cohort to test novel associations from the genome-wide interaction analyses. The n-3 PUFAs-
PFT association analysis did not exclude participants according to their availability of genetic data. Therefore, the sample size was 
smaller for the genetic analysis. 
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Table 2. Cohort-Specific Results for the Association of DPP10 rs11693320-A with FVC, with and without DHA Interaction 
Included in the Model
*
 
Cohort and ancestry 
(sample size) 
A allele 
frequency 
Model without 
interaction with DHA              
(total N = 13,649)
†
 Model with interaction with DHA (total N = 13,649)
‡
 
β (SE) P βSNP (SE) PSNP 
βSNP×DHA 
interaction (SE) 
PSNP×DHA 
interaction P2df 
Discovery Cohorts:         
ARIC EA (n = 3,143) 0.80 -65.9 (18.0) 2.4×10
-4
 -145.6 (60.0) 0.015 28.3 (20.4) 0.17 4.4×10
-4
 
CHS EA (n = 1,684) 0.80 -72.6 (26.4) 0.0060 -15.0 (90.6) 0.87 -19.8 (29.1) 0.50 0.011 
FHS EA (n = 5,198) 0.82 -8.6 (15.2) 0.57 -147.6 (56.9) 0.0095 34.7 (11.8) 0.0032 0.011 
MESA EA (n = 1,137) 0.81 -15.8 (29.6) 0.30 -156.1 (84.9) 0.066 38.7 (22.2) 0.081 0.15 
MESA AA (n = 797) 0.79 -16.0 (35.1) 0.20 -186.4 (116.6) 0.11 39.7 (25.1) 0.11 0.27 
Discovery cohort meta-analysis  
(EA only) 
-36.0 (10.0) 2.7×10
-4
 -155.8 (28.7) 5.8×10
-8
 34.0 (7.6) 7.4×10
-6
 1.5×10
-7
 
Discovery cohort meta-analysis 
(EA and AA) 
-34.9 (9.6) 2.9×10
-4
 -157.1 (27.7) 1.4×10
-8
 34.3 (7.2) 1.7×10
-6
 4.5×10
-8
 
Replication Cohort:         
CARDIA EA (n = 1,141) 0.81 -49.6 (63.2) 0.43 -115.5 (160.1) 0.47 36.6 (47.3) 0.44 0.76 
CARDIA AA (n = 546) 0.77 -32.4 (50.5) 0.52 -320.7 (153.1) 0.036 107.3 (43.1) 0.013 0.061 
Replication cohort meta-analysis -39.1 (39.4) 0.32 -222.6 (110.7) 0.044 75.2 (31.9) 0.018 0.045 
Overall meta-analysis -35.1 (9.3) 1.7×10
-4
 -161.0 (26.9) 2.1×10
-9
 36.2 (7.0) 2.1×10
-7
 9.4×10
-9
 
Abbreviations: AA = African ancestry; ARIC = Atherosclerosis Risk in Communities; CARDIA = Coronary Artery Risk 
Development in Young Adults; CHS = Cardiovascular Health Study; DHA = Docosahexaenoic acid; EA = European ancestry; FHS = 
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Framingham Heart Study; FVC = Forced vital capacity; MESA = Multi-Ethnic Study of Atherosclerosis; SE = Standard error; SNP = 
Single nucleotide polymorphism. 
*
Genome-wide significant (P<5×10
-8
) results are shown in bold. The imputation quality of rs11693320 ranged from 0.72–0.85 across 
discovery cohorts.
 
†
Model included SNP/indel additive dosage as the predictor and age, age
2
, sex, standing height, standing height
2
, weight, study site (if 
applicable), current/former smoking (dummy variables, never smokers as the reference group), pack-years, and principal 
components (PCs) as covariates. 
‡
Model included DHA as the exposure, SNP/indel additive dosage and SNP/indel interaction term with DHA as predictors, and age, 
age
2
, sex, standing height, standing height
2
, weight, study site (if applicable), current/former smoking (dummy variables, never 
smokers as the reference group), pack-years, and PCs as covariates. 
Page 35 of 108  AJRCCM Articles in Press. Published on 10-September-2018 as 10.1164/rccm.201802-0304OC 
 Copyright © 2018 by the American Thoracic Society 
 13 
Figure Legends 
 
Figure 1. Forest Plots of the Meta-Analysis of Omega-3 Fatty Acid Biomarkers on FEV1 
and FVC. Associations are presented for (A) DHA-FEV1, (B) DPA-FEV1, (C) DHA-FVC, and 
(D) DPA-FVC. β (unit: mL) denotes the coefficient from the fixed-effects meta-analysis for each 
omega-3 fatty acid biomarker (DHA or DPA) on the pulmonary function outcome per 1% (of 
total fatty acids) increment, with its 95% confidence interval. The linear model in each cohort 
was adjusted for smoking status (never/former/current smokers), pack-years, sex, age, age
2
, 
height, height
2
, weight (FVC outcome only), and study center (if applicable). The vertical line in 
the center indicates no association of the omega-3 fatty acid biomarker with the pulmonary 
function outcome; β value to the right of the line indicates a positive effect, while β value to the 
left of the line denotes a negative or inverse effect. The size of black square for each cohort 
represents the variance of the β coefficient, so that cohorts with smaller variances have larger 
black squares. Cohorts listed in the forest plots are in alphabetical order, with sample size of each 
cohort shown in parenthesis.
 *
FHS has omega-3 fatty acid biomarkers measured in red blood 
cells, rather than plasma. Abbreviations: AA = African ancestry; AGES = Age, Gene, 
Environment, Susceptibility Study—Reykjavik, Iceland; ARIC = Atherosclerosis Risk in 
Communities; CARDIA = Coronary Artery Risk Development in Young Adults; CHS = 
Cardiovascular Health Study; CI= Confidence interval; DHA = Docosahexaenoic acid; DPA = 
Docosapentaenoic acid; EA = European ancestry; FEV1 = Forced expiratory volume in the first 
second; FHS (Offspring) = Framingham Heart Study—Offspring Cohort; FHS (Gen3) = 
Framingham Heart Study—Generation 3 Cohort; FVC = Forced vital capacity; MESA = Multi-
Ethnic Study of Atherosclerosis; RS = Rotterdam (Netherlands) Study.
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Figure 2. Meta-Analysis of the Association of DHA Biomarker–FEV1 Outcome, by 
Smoking Status. Smoking status categories were never smoker, former smoker, and current 
smoker. The y-axis shows the coefficient β (unit: mL), which denotes that a 1% (of total fatty 
acids) higher DHA level was associated with a β mL higher FEV1, in participants stratified by 
smoking status. The error bar represents ± 1 standard error. A total of 16,106 participants was 
used for the FEV1 outcome.  
Abbreviations: DHA = Docosahexaenoic acid; FEV1 = Forced expiratory volume in the first 
second. 
 
Figure 3. Novel DPP10 Locus Identified at Genome-Wide Significance (P2df < 5×10
-8
) for 
FVC, Accounting for SNP/indel × DHA Interaction. SNP/indel associations are shown from 
the cross-ancestry joint 2df meta-analysis across DPP10 and its 100kb flanking region (NCBI 
build 37 positions presented), using the LocusZoom tool. r
2
 values between the top SNP 
rs11693320 and all other SNPs are shown in reference to the 1000 Genomes European (panel A) 
or African ancestry (panel B). Indels with missing r
2
 values are indicated in grey. 
 
Figure 4. GeneMANIA Network Built Around DPP10. 20 genes are included in this network. 
Network genes with a red star are the ones that were co-expressed with DPP10 in GTEx v7 lung 
tissue (N = 383), after adjustment of sex, age and three genotyping principal components. The 
associations (coefficient estimate, standard error, and p-value) with DPP10 expression in GTEx 
lung tissue are shown in the table portion of the figure (all P < 0.05). 
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Figure 1a. Forest Plots of the Meta-Analysis of Omega-3 Fatty Acid Biomarkers on FEV1 and FVC. 
Associations are presented for (A) DHA-FEV1, (B) DPA-FEV1, (C) DHA-FVC, and (D) DPA-FVC. β (unit: mL) 
denotes the coefficient from the fixed-effects meta-analysis for each omega-3 fatty acid biomarker (DHA or 
DPA) on the pulmonary function outcome per 1% (of total fatty acids) increment, with its 95% confidence 
interval. The linear model in each cohort was adjusted for smoking status (never/former/current smokers), 
pack-years, sex, age, age2, height, height2, weight (FVC outcome only), and study center (if applicable). The 
vertical line in the center indicates no association of the omega-3 fatty acid biomarker with the pulmonary 
function outcome; β value to the right of the line indicates a positive effect, while β value to the left of the 
line denotes a negative or inverse effect. The size of black square for each cohort represents the variance of 
the β coefficient, so that cohorts with smaller variances have larger black squares. Cohorts listed in the 
forest plots are in alphabetical order, with sample size of each cohort shown in parenthesis. *FHS has 
omega-3 fatty acid biomarkers measured in red blood cells, rather than plasma. Abbreviations: AA = African 
ancestry; AGES = Age, Gene, Environment, Susceptibility Study—Reykjavik, Iceland; ARIC = 
Atherosclerosis Risk in Communities; CARDIA = Coronary Artery Risk Development in Young Adults; CHS = 
Cardiovascular Health Study; CI= Confidence interval; DHA = Docosahexaenoic acid; DPA = 
Docosapentaenoic acid; EA = European ancestry; FEV1 = Forced expiratory volume in the first second; FHS 
(Offspring) = Framingham Heart Study—Offspring Cohort; FHS (Gen3) = Framingham Heart Study—
Generation 3 Cohort; FVC = Forced vital capacity; MESA = Multi-Ethnic Study of Atherosclerosis; RS = 
Rotterdam (Netherlands) Study.  
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Figure 1b. Forest Plots of the Meta-Analysis of Omega-3 Fatty Acid Biomarkers on FEV1 and FVC. 
Associations are presented for (A) DHA-FEV1, (B) DPA-FEV1, (C) DHA-FVC, and (D) DPA-FVC. β (unit: mL) 
denotes the coefficient from the fixed-effects meta-analysis for each omega-3 fatty acid biomarker (DHA or 
DPA) on the pulmonary function outcome per 1% (of total fatty acids) increment, with its 95% confidence 
interval. The linear model in each cohort was adjusted for smoking status (never/former/current smokers), 
pack-years, sex, age, age2, height, height2, weight (FVC outcome only), and study center (if applicable). The 
vertical line in the center indicates no association of the omega-3 fatty acid biomarker with the pulmonary 
function outcome; β value to the right of the line indicates a positive effect, while β value to the left of the 
line denotes a negative or inverse effect. The size of black square for each cohort represents the variance of 
the β coefficient, so that cohorts with smaller variances have larger black squares. Cohorts listed in the 
forest plots are in alphabetical order, with sample size of each cohort shown in parenthesis. *FHS has 
omega-3 fatty acid biomarkers measured in red blood cells, rather than plasma. Abbreviations: AA = African 
ancestry; AGES = Age, Gene, Environment, Susceptibility Study—Reykjavik, Iceland; ARIC = 
Atherosclerosis Risk in Communities; CARDIA = Coronary Artery Risk Development in Young Adults; CHS = 
Cardiovascular Health Study; CI= Confidence interval; DHA = Docosahexaenoic acid; DPA = 
Docosapentaenoic acid; EA = European ancestry; FEV1 = Forced expiratory volume in the first second; FHS 
(Offspring) = Framingham Heart Study—Offspring Cohort; FHS (Gen3) = Framingham Heart Study—
Generation 3 Cohort; FVC = Forced vital capacity; MESA = Multi-Ethnic Study of Atherosclerosis; RS = 
Rotterdam (Netherlands) Study.  
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Figure 1c. Forest Plots of the Meta-Analysis of Omega-3 Fatty Acid Biomarkers on FEV1 and FVC. 
Associations are presented for (A) DHA-FEV1, (B) DPA-FEV1, (C) DHA-FVC, and (D) DPA-FVC. β (unit: mL) 
denotes the coefficient from the fixed-effects meta-analysis for each omega-3 fatty acid biomarker (DHA or 
DPA) on the pulmonary function outcome per 1% (of total fatty acids) increment, with its 95% confidence 
interval. The linear model in each cohort was adjusted for smoking status (never/former/current smokers), 
pack-years, sex, age, age2, height, height2, weight (FVC outcome only), and study center (if applicable). The 
vertical line in the center indicates no association of the omega-3 fatty acid biomarker with the pulmonary 
function outcome; β value to the right of the line indicates a positive effect, while β value to the left of the 
line denotes a negative or inverse effect. The size of black square for each cohort represents the variance of 
the β coefficient, so that cohorts with smaller variances have larger black squares. Cohorts listed in the 
forest plots are in alphabetical order, with sample size of each cohort shown in parenthesis. *FHS has 
omega-3 fatty acid biomarkers measured in red blood cells, rather than plasma. Abbreviations: AA = African 
ancestry; AGES = Age, Gene, Environment, Susceptibility Study—Reykjavik, Iceland; ARIC = 
Atherosclerosis Risk in Communities; CARDIA = Coronary Artery Risk Development in Young Adults; CHS = 
Cardiovascular Health Study; CI= Confidence interval; DHA = Docosahexaenoic acid; DPA = 
Docosapentaenoic acid; EA = European ancestry; FEV1 = Forced expiratory volume in the first second; FHS 
(Offspring) = Framingham Heart Study—Offspring Cohort; FHS (Gen3) = Framingham Heart Study—
Generation 3 Cohort; FVC = Forced vital capacity; MESA = Multi-Ethnic Study of Atherosclerosis; RS = 
Rotterdam (Netherlands) Study.  
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Figure 1d. Forest Plots of the Meta-Analysis of Omega-3 Fatty Acid Biomarkers on FEV1 and FVC. 
Associations are presented for (A) DHA-FEV1, (B) DPA-FEV1, (C) DHA-FVC, and (D) DPA-FVC. β (unit: mL) 
denotes the coefficient from the fixed-effects meta-analysis for each omega-3 fatty acid biomarker (DHA or 
DPA) on the pulmonary function outcome per 1% (of total fatty acids) increment, with its 95% confidence 
interval. The linear model in each cohort was adjusted for smoking status (never/former/current smokers), 
pack-years, sex, age, age2, height, height2, weight (FVC outcome only), and study center (if applicable). The 
vertical line in the center indicates no association of the omega-3 fatty acid biomarker with the pulmonary 
function outcome; β value to the right of the line indicates a positive effect, while β value to the left of the 
line denotes a negative or inverse effect. The size of black square for each cohort represents the variance of 
the β coefficient, so that cohorts with smaller variances have larger black squares. Cohorts listed in the 
forest plots are in alphabetical order, with sample size of each cohort shown in parenthesis. *FHS has 
omega-3 fatty acid biomarkers measured in red blood cells, rather than plasma. Abbreviations: AA = African 
ancestry; AGES = Age, Gene, Environment, Susceptibility Study—Reykjavik, Iceland; ARIC = 
Atherosclerosis Risk in Communities; CARDIA = Coronary Artery Risk Development in Young Adults; CHS = 
Cardiovascular Health Study; CI= Confidence interval; DHA = Docosahexaenoic acid; DPA = 
Docosapentaenoic acid; EA = European ancestry; FEV1 = Forced expiratory volume in the first second; FHS 
(Offspring) = Framingham Heart Study—Offspring Cohort; FHS (Gen3) = Framingham Heart Study—
Generation 3 Cohort; FVC = Forced vital capacity; MESA = Multi-Ethnic Study of Atherosclerosis; RS = 
Rotterdam (Netherlands) Study.  
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Figure 2. Meta-Analysis of the Association of DHA Biomarker–FEV1 Outcome, by Smoking Status. Smoking 
status categories were never smoker, former smoker, and current smoker. The y-axis shows the coefficient 
β (unit: mL), which denotes that a 1% (of total fatty acids) higher DHA level was associated with a β mL 
higher FEV1, in participants stratified by smoking status. The error bar represents ± 1 standard error. A total 
of 16,106 participants was used for the FEV1 outcome.  
Abbreviations: DHA = Docosahexaenoic acid; FEV1 = Forced expiratory volume in the first second.  
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Figure 3a. Novel DPP10 Locus Identified at Genome-Wide Significance (P2df < 5×10
-8) for FVC, Accounting 
for SNP/indel × DHA Interaction. SNP/indel associations are shown from the cross-ancestry joint 2df meta-
analysis across DPP10 and its 100kb flanking region (NCBI build 37 positions presented), using the 
LocusZoom tool. r2 values between the top SNP rs11693320 and all other SNPs are shown in reference to 
the 1000 Genomes European (panel A) or African ancestry (panel B). Indels with missing r2 values are 
indicated in grey.  
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Figure 3b. Novel DPP10 Locus Identified at Genome-Wide Significance (P2df < 5×10
-8) for FVC, Accounting 
for SNP/indel × DHA Interaction. SNP/indel associations are shown from the cross-ancestry joint 2df meta-
analysis across DPP10 and its 100kb flanking region (NCBI build 37 positions presented), using the 
LocusZoom tool. r2 values between the top SNP rs11693320 and all other SNPs are shown in reference to 
the 1000 Genomes European (panel A) or African ancestry (panel B). Indels with missing r2 values are 
indicated in grey.  
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Figure 4. GeneMANIA Network Built Around DPP10. 20 genes are included in this network. Network genes 
with a red star are the ones that were co-expressed with DPP10 in GTEx v7 lung tissue (N = 383), after 
adjustment of sex, age and three genotyping principal components. The associations (coefficient estimate, 
standard error, and p-value) with DPP10 expression in GTEx lung tissue are shown in the table portion of the 
figure (all P < 0.05).  
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 1 
Online Data Supplement 
 
Omega-3 Fatty Acids and Genome-wide Interaction Analyses Reveal DPP10-Pulmonary 
Function Association  
 
Supplemental Methods 
Cohorts and Participants 
Seven cohorts in the Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) Consortium were used for the meta-analysis of omega-3 poly-unsaturated fatty acid 
(n-3 PUFA) biomarkers on pulmonary function, with a total sample size of 16,134 participants. 
Among these cohorts, the Framingham Heart Study (FHS) is sub-divided into the Offspring 
cohort and the Generation 3 cohort (Gen3). One cohort [Multi-Ethnic Study of Atherosclerosis 
(MESA)] includes Hispanic and Chinese participants, but these were not included in this meta-
analysis study given the limited sample size.  
Our genome-wide interaction analyses focused on the five largest cohorts (N>500): 
ARIC EAs, CHS EAs, FHS EAs, and MESA EAs and AAs for discovery, and CARDIA EAs 
and AAs for replication. Besides having limited statistical power, small sample sizes can produce 
inflated type-I error, especially when analyzing interactions (1, 2). We found genomic control λ 
(λgc) values ranging from 1.14 to 1.33 for the smallest cohorts; λgc=1 is optimal, whereas λgc>1.1 
is viewed as problematic in the conduct of genome-wide meta-analysis (3). All cohorts with 
N>500 had λgc values ranging from 0.98 to 1.07. Other genome-wide interaction studies 
conducted in the CHARGE consortium had similar minimum cohort-specific sample sizes (4-7). 
An analysis pipeline was developed and distributed to each cohort, in which we 
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harmonized the definitions and units of outcomes, exposures, and other covariates, as well as the 
statistical models. The exclusion criteria for the analyses of n-3 PUFA biomarkers (Table E1) 
included missing data on pulmonary function, unacceptable pulmonary function data that failed 
to meet the criteria of American Thoracic Society (ATS)/European Respiratory Society (ERS) 
guidelines (Table E4 for more details about the ATS/ERS criteria used in each cohort), and 
missing data on n-3 PUFAs and/or other covariates. 
Genotyping, quality control, and imputation 
Participants were excluded from the genome-wide interaction analyses if they had poor 
call rate, unusually high heterozygosity, outlying ancestry, and/or relatedness (for population-
based studies only) (see details in Table E2). Relatedness was not used as an exclusion criterion 
for FHS; instead, relatedness was taken into account in statistical analyses of this family-based 
study. 
Different genotyping platforms were used across the cohorts. Genotyped single 
nucleotide polymorphisms (SNPs) were excluded if they had poor call rate, Hardy Weinberg 
disequilibrium, high duplicate discordance rates, and/or monomorphism (Table E3). Imputation 
was performed using 1000 Genomes reference panels (8) to harmonize SNPs and 
insertions/deletions (indels) for the meta-analysis (Table E3). Cohort-specific genomic data are 
available on the database of Genotypes and Phenotypes (dbGaP) via accession numbers: ARIC 
(phs000280), CARDIA (phs000285), CHS (phs000287), FHS (phs000007), and MESA 
(phs000209). 
Pulmonary Function Test (PFT) Outcomes 
Spirometry testing was planned for all the participants who remained in the cohorts at the 
time of measurement (Table E4 for measurement details in each cohort), except MESA and 
Page 47 of 108  AJRCCM Articles in Press. Published on 10-September-2018 as 10.1164/rccm.201802-0304OC 
 Copyright © 2018 by the American Thoracic Society 
AGES (Age, Gene, Environment, Susceptibility Study—Reykjavik, Iceland), in which 
pulmonary function was measured in a random subset (~54% of the MESA population and ~78% 
of the AGES population, respectively) (Table E1). Cohorts adhered to strict quality control and 
American Thoracic Society/European Respiratory Society standardization guidelines once 
released. Forced expiratory volume in the first second (FEV1) and its ratio with forced vital 
capacity (FVC) are commonly used parameters to assess airway obstruction, whereas FVC is an 
indicator of restrictive lung disorders; across the PFT outcomes, lower values indicate worse 
pulmonary function. Pre-bronchodilator pulmonary function data was used, and results would 
likely have remained similar if post-bronchodilator data was used, given the expected small 
percentage of participants with evidence of asthma (9). 
N-3 PUFA Biomarkers 
Measurement of n-3 PUFA biomarkers was planned for either all the participants with 
blood samples available, or a random set of participants (Table E1). All cohorts have PFTs and 
n-3 PUFA biomarkers measured concurrently or within 1 year on average, with the exception of 
MESA and RS (Rotterdam Study), in which the PFTs were performed ~5 years after the n-3 
PUFA biomarkers were measured (see Table E5 for details of measurement time in each 
cohort). The representativeness of single n-3 PUFA measurement with long-term n-3 PUFA 
status is fairly strong, with correlations ranging from 0.5 to 0.8 for EPA, DPA, and DHA 
between measurements separated by 6 years in a subset of CHS participants (10) and modest 
correlations over a 15-year period (ranged from 0.2–0.5 for ALA, EPA, DPA, and DHA) (11). 
Therefore, a single measurement of the n-3 PUFA biomarker and a corresponding PFT 
measurement within 5 years is not likely to lead to severe bias in the estimated cross-sectional 
association of n-3 PUFA biomarkers with pulmonary function. In addition, the n-3 PUFAs have 
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been reported to be stable for about 4 years in red blood cells (12), and over 10 years in plasma, 
if stored at -80℃ (13). 
Statistical Analysis in Individual Cohorts 
Using linear regression models, covariates measured concurrently with PFTs—smoking 
status (indicator variables for current and former smoking, with never smoking as the reference), 
pack-years (defined as number of packs of cigarettes smoked per day, multiplied by number of 
years the participant has smoked), sex, age (unit: year), age
2
, standing height (unit: meter), 
standing height
2
, weight (unit: kilogram, for FVC outcome only), and study center (if applicable 
for studies with more than one site)—were adjusted to reduce potential confounding. Age
2
 and 
height
2
 were included to more fully adjust for the non-linear relationship of age and height to 
PFTs (14), as done in prior GWAS (9, 15, 16). CHS used covariates measured concurrently with 
n-3 PUFA biomarkers, and they were within 1 year of the PFT measures (Table E5). The FHS 
models added a random effect to account for familial relatedness. Weight was included in the 
FVC analyses only because it could affect the expiratory reserve volume included in FVC, which 
is not relevant for FEV1. In preliminary models without the n-3 PUFA predictor term included, 
participants who had studentized residuals greater than ±3 (or ±4), depending on each cohort, 
were excluded from further analyses. The number of participants excluded could vary across the 
three PFT outcomes (FEV1, FVC, and FEV1/FVC) (Table E1). After exclusion of outliers, 
ancestry-specific association testing of each n-3 PUFA with each PFT measure was conducted. 
Interactions of select n-3 PUFAs with smoking status and with sex on PFTs were also tested. 
For the genome-wide testing of SNP/indel (henceforth, collectively referred to as SNP) 
and SNP × n-3 PUFA biomarker interaction, each cohort ran four genome-wide linear regression 
models that included FEV1 or FVC as the outcome, DPA or DHA as the n-3 PUFA exposure, 
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and SNP additive dosage and SNP × n-3 PUFA (DPA or DHA) interaction term as the predictors 
(linear regression model: FEV1 or FVC ~ DHA [or DPA] + SNP + DHA [or DPA] × SNP + 
other covariates). The covariates are the same as the ones included for the associations of n-3 
PUFA biomarkers on PFTs, with ancestral principal components (PCs) added to minimize 
confounding by population stratification. Models were run separately by cohort and ancestry 
using ProbAbel (17), R (18) or SUGEN (19) (Table E3). Genomic control (gc) was applied to 
results by correcting the p-values via a genomic inflation factor (λgc). λgc was defined as the ratio 
of observed median chi-square statistics with 2 degree-of-freedom (2df) over the expected 
median, to quantify the extent of inflation, which could lead to false positive findings. 
Meta-Analysis of the Associations of N-3 PUFAs and Interactions with Smoking on PFTs 
Both ancestry-specific and cross-ancestry meta-analyses were performed. The interaction 
term of the n-3 PUFA (ALA, EPA, DPA, DHA) and smoking status (current smokers and former 
smokers, with never smokers as the reference) was meta-analyzed. If the interaction term was 
significant, additional meta-analysis was conducted stratified by smoking status. The cohort-
specific n-3 PUFA-PFT associations by smoking status were calculated from the requested 
coefficients, standard errors, and covariance, with equations shown below. 
βn-3 PUFA in current smokers = βn-3 PUFA in never smokers/reference group + βinteraction of n-3 PUFA and current smokers (1) 
Varn-3 PUFA in current smokers = Varn-3 PUFA in never smokers [a] + Varinteraction of n-3 PUFA and current smokers [b]  
+ 2 × Cov([a],[b])   (2) 
Fixed-effects meta-analysis was used to evaluate the magnitude and significance of the 
association of each n-3 PUFA biomarker with each PFT measure, while random-effects meta-
analysis was used to assess the between-study heterogeneity. The metafor package (version 1.9-
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9) in R (version 3.3.1, R Foundation for Statistical Computing, Vienna, Austria) was used for the 
meta-analyses and follow-up meta-regression analyses of the n-3 PUFA-PFT associations, and 
the interaction meta-analyses of n-3 PUFA with smoking on PFT measures.  
Joint 2df Meta-Analysis to Test Genome-Wide Interactions with N-3 PUFAs 
Joint 2df testing is constrained on a joint null hypothesis for the variant main effect and 
interaction; the regression framework means that it can accommodate other covariates and is 
amenable to various coding schemes for predictors and outcomes. Joint 2df testing has been 
shown repeatedly in theoretical (1, 20-22) and empirical (4, 23, 24) studies to offer more 
statistical power over a range of variant main and interactive effects, as compared to 1df tests of 
variant main or interactive effects only. In this study, ancestry-specific coefficients of the SNP 
additive dosage (βSNP) and the SNP × n-3 PUFA interaction term (βinteraction) in each cohort were 
combined via joint 2df meta-analysis using METAL (25), with genomic control applied for 
variants with minor allele frequency (MAF) > 5% and imputation quality > 0.3. Meta-analysis 
results are presented for SNP variants tested in two or more cohorts.  
Bioinformatics Analysis 
HaploReg v4.1 (26) and Roadmap Epigenomics data [chromHMM (for chromatin state 
discovery and characterization)] (27) were used to functionally characterize the novel locus and 
any variants in high linkage disequilibrium (LD) (r
2
≥0.8 in 1000 Genomes Phase 1 EUR 
reference panel), focusing on predicted functional elements in lung tissue. The predicted fetal 
lung chromatin state based on Roadmap Epigenomics chromatin immunoprecipitation 
sequencing data (27) was viewed in the UCSC Genome Browser using the GRCh37/hg19 human 
assembly. Presence of certain chromatin marks could indicate the presence of an enhancer 
element. If a variant of interest is located nearby a region with predicted enhancer activity, it may 
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be more likely to influence the expression of nearby (or even distant) genes. The Genotype-
Tissue Expression Project (GTEx, version 7) cis-expression quantitative trait locus (cis-eQTL) 
results were used to look up whether the novel intronic variant is an eQTL for its host gene in 
lung tissue (28). GeneMANIA, a gene function prediction tool, was used to construct a network 
of genes biologically related to the gene of interest (29). R v3.2.4 was used to run linear 
regression models to test for association between network genes identified from GeneMANIA 
and the gene of interest in lung tissue (linear regression model: normalized expression of gene of 
interest in GTEx ~ normalized expression of GeneMANIA network gene in GTEx + sex + age + 
genotyping principal components), using GTEx v7 RNA-Seq data (fully processed, filtered and 
normalized expression data, as previously described) (28). Nominal p-value of 0.05 was used as 
a significance threshold for co-expressions of genes in lung tissues. 
 
Supplemental Results 
N-3 PUFA Distributions 
Of the n-3 PUFAs, DHA had the highest level (average of 3.7% of total FAs); ALA had 
the lowest level (average of 0.2% of total FAs; Table E6). ALA, EPA, and DHA levels were 
similar in plasma phospholipids and red blood cells. DPA measured in red blood cells was nearly 
three times more concentrated than in plasma (~2.6% vs ~0.9%, Table E6). Whether the 
differences between red blood cell and plasma measurements reflect true differences between 
cohorts or differences that derive mainly from compartment of measurement cannot be fully 
addressed by these data. Average n-3 PUFAs ranged from 4.4% of total FAs to 10.6% of total 
FAs across cohorts (Figure E1). 
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Meta-Analysis of N-3 PUFA Associations with PFTs 
Cross-ancestry meta-analyses revealed positive associations of DHA and DPA with FEV1 
and FVC at P<0.05. These associations were largely driven by EA participants, which comprise 
most of the total sample size (Table E8 for ancestry-specific results). To explore the linearity of 
the n-3 PUFA-PFT associations across cohorts, a meta-regression analysis tested whether the β 
coefficients varied by mean of each n-3 PUFA; the cohort-specific β and mean n-3 PUFA level 
had little to no association (results not shown), supporting a linear n-3 PUFA-PFT association 
across the range of each n-3 PUFA. Also, sensitivity analyses demonstrated that DHA and DPA 
were robustly associated with FEV1 and FVC, when limited to cohorts with n-3 PUFAs 
measured in plasma only (Figure E2) or cohorts with n-3 PUFA measurements within one year 
of PFTs (Figure E3).  
Targeted Look-up of Established N-3 PUFA and PFT-Related Variants 
We used our 2df meta-analysis results to look-up previous GWAS-identified SNPs 
associated with n-3 PUFA phenotypes (Table E10). Using Bonferroni correction for 14 variants 
(P<3.6×10
-3
), one previously identified DPA-related SNP, rs174468 (upstream of FADS3 on 
chromosome 11), was associated with FEV1 when considering its interaction with DPA 
(P2df=1.8×10
-3
).  
Similarly, we used our 2df meta-analysis results to look-up SNPs identified in previous 
GWAS of PFTs (Table E11). Using Bonferroni correction for 199 variants (P<2.5×10
-4
), ten 
previously identified FEV1-related SNPs were associated with FEV1 in this study when 
considering interaction with either DHA or DPA. However, signals were primarily driven by 
main effects, not interactive effects with n-3 PUFAs (PSNP×n-3 PUFA interaction=0.11–1.00).
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Table E1. Flowchart of Sample Size Dynamics in Each Cohort for the Meta-Analysis of Omega-3 Fatty Acid Biomarker Associations with Pulmonary 
Function Tests, Stratified by Ancestry
*
 
European Ancestry Cohort CARDIA§ CHSll MESA** AGES†† ARIC§§ FHSlll RS
***
 
Original sample size 2,478 4,346 2,501 5,519 11,478 6,158 9,895 
Excluded for the following reasons:        
  Missing PFT (outcome of interest) -632 -980 -1,119 -2,672 -47 -354 -2,542 
  Unacceptable PFT (outcome of interest) 0 -415 0 -16 -9 NA -2,774 
  Missing height  0 -43 0 0 0 0 -1 
  Missing gender  0 0 0 0 0 0 0 
  Missing age  0 0 0 0 0 0 0 
  Missing smoking status  -15 -63 -12 -63 -7 -123 -6 
  Missing pack-years  0 -71 -51 -27 -130 -116 -172 
  Missing site (if applicable) 0 0 0 0 0 0 0 
  Missing genetic data
†
 0
†††
 -786 0 -1,056 -1,947 -344 -590 
  Missing n-3 PUFA biomarkers data (exposure of interest) -72 -292 -170 -1,261 -6,084 0 -3,669 
  Missing weight (for the FVC analysis only)
 
0 -3 0 0 0 0 0 
Sample size for the FEV1 analysis
‡ 1,754 1,690 1,137 424 3,244 5,216 141 
Sample size for the FVC analysis
‡ 1,758 1,687 1,140 424 3,252 5,217 140 
Sample size for the FEV1/FVC analysis
‡ 1,753 1,690 1,134 424‡‡ 3,233 5,205 141 
African Ancestry Cohort CARDIA§ CHSll MESA**     
Original sample size 2,637 885 2,575     
Excluded for the following reasons:        
  Missing PFT (outcome of interest) -1,053 -262 -1,646     
  Unacceptable PFT (outcome of interest) 0 -122 0     
  Missing height  -5 -3 0     
  Missing gender  0 0 0     
  Missing age  0 0 0     
  Missing smoking status  -12 -5 -17     
  Missing pack-years  0 -22 -37     
  Missing site (if applicable) 0 0 0     
  Missing genetic data
†
 0††† -49 0     
  Missing n-3 PUFA biomarkers data (exposure of interest) -106 -173 -65     
  Missing weight (for the FVC analysis only)
 
-5 -1 0     
Sample size for the FEV1 analysis
‡ 1,460 243 797     
Sample size for the FVC analysis
‡ 1,454 242 797     
Sample size for the FEV1/FVC analysis
‡ 1,440 243 797     
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Abbreviations: AGES = Age, Gene, Environment, Susceptibility Study – Reykjavik; ARIC = Atherosclerosis Risk in Communities; CARDIA = Coronary Artery 
Risk Development in Young Adults; CHS = Cardiovascular Health Study; FEV1 = Forced expiratory volume in the first second; FHS = Framingham Heart 
Study; FVC = Forced vital capacity; MESA = Multi-Ethnic Study of Atherosclerosis; n-3 PUFA = Omega-3 poly-unsaturated fatty acid; PFT = Pulmonary 
function test; RS = Rotterdam Study. 
*
The final sample size of each cohort for each outcome variable is shown in the last three rows, stratified by ancestry.  
†
Participants who did not have genetic data were excluded for consistency and comparison with the genome-wide analyses.
 
‡
For each outcome, participants whose studentized residual absolute value is greater than 3 (or 4), depending on each cohort, were excluded.
 
§
PFTs were measured in year 20, therefore some CARDIA participants might have dropped out at that time point. 
ll
In CHS, PFTs were measured in year 6, therefore some participants might have dropped out at that time point. In addition, only those who did not have 
cardiovascular diseases at baseline, had available DNA, and consented to genetic testing had genetic data available (N= 3,865 out of 5,231). In terms of n-3 
PUFA biomarker data, they were measured in all available blood samples in year 5 (N= 3,941). 
**
PFTs were measured in 3,965 participants who were enrolled in the MESA Lung Study (30, 31). The MESA Lung Study enrolled 3,965 participants out of 
4,484 selected who were randomly sampled among those who consented to genetic analyses, underwent baseline endothelial function measures, and attended 
an examination in the MESA-Lung recruitment period in 2004-2006 (99%, 89%, and 91% of the MESA cohort, respectively) (31). In addition, the final sample 
size for each outcome additionally excluded participants who were related genetically (NEuropean Ancestry=9, NAfrican Ancestry=9). 
††
In AGES, only a random set of participants had PFTs (N= 3,000 out of 5,519) (32), and n-3 PUFA biomarkers (N = 1,012 out of 5,519) measured (33). In 
addition, only 3,219 out of 5,519 participants had genetic data (34).  
‡‡
In AGES, for FEV1/FVC, two participants had residuals around 4.3 but were not filtered out. We would not expect this to influence the results much given that 
this was such a small number, and the residual values were close to 4. 
§§
In ARIC, genotyping was planned for the whole cohort (34). N-3 PUFA biomarkers were measured only in the Minneapolis study center, out of the 4 study 
centers across U.S (N=4,009) (35).  
lll
The flowchart of sample size in FHS has combined participants in the Offspring cohort and the Generation 3 cohort. FHS only has participants with acceptable 
PFT measures, therefore the exclusion criteria of unacceptable PFTs are not applicable here. N-3 PUFA biomarkers were measured at Exam 8 of the Offspring 
cohort, and at Exam 2 of the 3
rd
 Generation cohort. The starting sample size for Exam 8 of the Offspring cohort and Exam 2 of the 3
rd
 Generation cohort was 
6,158. 
***
In RS, spirometry was not carried out in the cohort until 2002. At that time point, the total sample size of participants who still visited the research center was 
9,895. Plasma n-3 PUFAs were measured for a nested case-control study of depression in the RS-I cohort during Exam 3 and only the participants in the 
control group were included in this meta-analysis. They were randomly selected from the RS-I cohort among those who had negative results for the depression 
screening (N = 461) (36). 
†††
In CARDIA, which was used for replication of top findings from the genome-wide interaction analyses, the analysis of omega-3 fatty acid biomarkers with 
pulmonary function did not exclude participants according to the availability of genetic data.  
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Table E2. Genotyping QC for Participants and Genetic Analysis Sample Size in Each Cohort
*
  
Study (ancestry) QC filters for excluding participants 
N, genotyped 
participants 
passing QC 
N, genotyped 
participants 
passing QC with PFT, 
n-3 FA biomarkers and 
complete covariate data 
ARIC (EA) call rate<95%, sex mismatch, discordances with prior genotyping, >8 
SD for any of the first 10 principal components, outlying average 
identity-by-state estimates, or first-degree relatives 
9,338 3,143 
CHS (EA) call rate<95%, non-European ancestry, sex mismatch, or discordance 
with prior genotyping 
3,268 1,684 
FHS – Offspring (EA) call rate<97%, non-European ancestry heterozygosity>5 SD from the 
mean, or >1000 Mendelian errors 
3,753 2,158 
FHS – Gen3 (EA)  call rate<97%, non-European ancestry heterozygosity>5 SD from the 
mean, or >1000 Mendelian errors 
3,893 3,040 
MESA (EA) call rate < 95%, unexpected first-degree relatives, or first three PCs of 
ancestry > 3.5 SD from the mean 
2,685 1,137 for FEV1 and 1,140 
for FVC 
MESA (AA) call rate < 95%, unexpected first-degree relatives, or first three PCs of 
ancestry > 3.5 SD from the mean   
2,588 797 
CARDIA (EA)  call rate < 98%, non-European ancestry, sex mismatch, sample 
duplicates, or first- or second-degree relatives 
1,663 1,141 
CARDIA (AA)  call rate < 98%, low heterozygosity (inbreeding coefficient F < -0.15), 
sex mismatch, sample duplicates, or first- or second-degree relatives 
955 546 
Abbreviations: AA = African ancestry; ARIC = Atherosclerosis Risk in Communities; CARDIA = Coronary Artery Risk Development in Young 
Adults; CHS = Cardiovascular Health Study; EA = European ancestry; FHS (Offspring) = Framingham Heart Study—Offspring Cohort; FHS 
(Gen3) = Framingham Heart Study—Generation 3 Cohort; MESA = Multi-Ethnic Study of Atherosclerosis; n-3 FA = Omega-3 fatty acid; PFT = 
Pulmonary function test; QC = Quality control; SD = Standard deviation. 
*
ARIC, CHS, FHS, and MESA were used for discovery, and CARDIA was used for replication.  
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Table E3. Genotyping, QC, and Analysis Details for Genotyped SNPs
* 
 
Study 
(ancestry) 
Genotyping 
platform 
QC filters for 
excluding 
genotyped SNPs 
N, genotyped 
autosomal 
SNPs passing 
QC 
Imputation 
software 
1000 Genomes 
imputation 
reference 
panel, using 
all available 
individuals 
N, imputed 
autosomal 
SNPs used for 
analysis 
Statistical 
analysis 
software 
ARIC (EA) Affymetrix 6.0 
chip freeze 3 
call rate < 95%, 
HWE P < 10
-6
, 
MAF < 0.001, or 
no chromosomal 
location 
719,415 Michigan 
Imputation Server, 
using minimac 
phase 3 
(version 5) 
15,482,662 SUGEN (19)  
CHS (EA) Illumina 
370CNV 
merged with 
ITMAT-Broad-
CARe Illumina 
iSELECT 
call rate < 97%, 
no heterozygotes, 
HWE P < 10
-5
,    
> 2 duplicate 
errors or, 
Mendelian 
inconsistency (for 
HapMap CEU 
trios), or SNPs 
not found in 
HapMap 
359,592 MaCH to pre-phase, 
minimac 
phase 1  
(version 3)  
6,375,477 (for 
FEV1) 
6,375,546 (for 
FVC) 
R (18) 
FHS - 
Offspring 
(EA)
†
 
Affymetrix 
500K + 50K 
Human Gene 
Focused Panel 
call rate < 96.9%,  
HWE P < 10
-6
, 
MAF < 1%, 
Mendelian  errors 
> 1000, not being 
on chromosomes 
1–22 or X, 
duplicates 
412,053 MACH/minimac 
(37) 
phase 1  
(version 3) 
6,194,157 R (18) 
FHS – Gen3 
(EA)
†
 
MESA (EA) Affymetrix 6.0 call rate < 95%, 
heterozygosity > 
53%, or 
monomorphic 
SNPs  
897,981 Minimac3 phase 3 
(version 5) 
6,779,137 ProbAbel (17) 
MESA (AA) 9,020,042 
CARDIA 
(EA)  
Affymetrix 6.0 call rate < 95%,  
HWE P < 10
-5
, 
duplicates, 
610,015 BEAGLE (38) phase 1  
(version 3) 
NA
‡
 ProbAbel (17)  
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monomorphic 
SNPs 
CARDIA 
(AA)  
Affymetrix 6.0 call rate < 95%, 
HWE P < 10
-5
, 
duplicates, MAF 
< 1% 
682,448 Minimac (39) phase 1  
(version 3) 
NA
‡
 ProbAbel (17) 
Abbreviations: AA = African ancestry; ARIC = Atherosclerosis Risk in Communities; CARDIA = Coronary Artery Risk Development in Young Adults; CHS = 
Cardiovascular Health Study; EA = European ancestry; FHS (Offspring) = Framingham Heart Study—Offspring Cohort; FHS (Gen3) = Framingham Heart 
Study—Generation 3 Cohort; HWE = Hardy Weinberg equilibrium; MAF = Minor allele frequency; MESA = Multi-Ethnic Study of Atherosclerosis; QC = 
Quality control; SNP = Single nucleotide polymorphism. 
*
ARIC, CHS, FHS, and MESA were used for discovery, and CARDIA was used for replication.
 
†
To account for family relatedness, FHS used the linear regression models with a robust variance method via generalized estimating equations, in which each 
extended pedigree is one cluster and an independent working correlation structure is implemented. 
‡
Not
 
applicable (NA) because although genome-wide imputed genotype data are available in CARDIA, this cohort was used for replication testing of the top 
finding in the current study.  
Table E4. Details of Spirometry and Omega-3 Fatty Acid Biomarkers in Each Cohort 
Cohort Cohort description Spirometry Omega-3 fatty acids biomarkers 
AGES The Age, Gene/Environment 
Susceptibility – Reykjavik Study 
(AGES) came from the Reykjavik study, 
a cohort initiated in 1967 and included a 
random sample of 30,795 men and 
women who were born in 1907-1935 and 
lived in the greater Reykjavik area of 
Iceland in 1967, and they were divided 
into 6 groups (40). The AGES 
examinations started in 2002 and 11,549 
participants in the Reykjavik Study were 
still alive at that time. Recruitment into 
the AGES study was randomly selected 
within the 6 groups of participants. The 
AGES exams ended in 2006 with a 
sample size of 5,764 survivors (32, 41). 
A Vitalograph Gold Standard Plus (Vitalograph 
Ltd., Buckingham, UK) was used to carry out 
spirometry through a disposable mouthpiece on 
participants who were in a sitting position. The 
spirometer was routinely calibrated with 1L 
syringe. The spirometry procedure was detailed 
by a technician before testing. The pulmonary 
function testing was deemed successful if there 
were at least two acceptable maneuvers, defined 
as no more than 300mL difference between the 
two attempts for at least 6 seconds in each blow. 
Pre-bronchodilation spirometry testing was 
conducted in only the first 2 years (41). 
Fasting blood was collected and plasma was 
stored at -80℃. Fatty acids (FAs) in the 
phospholipid fraction (PL) were measured, which 
reflects the short-term dietary intake of FAs 
(weeks to months) and the pool of FAs available 
to tissues. The analyses of FAs were conducted at 
the Fred Hutchinson Cancer Research Center 
(Seattle, WA). PLs was separated from other 
lipids using thin layer chromatography (TLC). 
Fatty acid methyl esters were generated by 
transesterification and isolated by Agilent 7890 
gas chromatograph (GC) with a flame ionization 
detector and a Supelco-fused silica 100-m 
capillary column SP-2560. FAs were expressed as 
a weight percentage %. The coefficients of 
variation (CV) of pooled quality-control samples 
for EPA and DHA were 2.05% and 1.44% (33).  
ARIC The Atherosclerosis Risk in 
Communities (ARIC) Study is a 
A Collins Survey II water-sealed spirometer 
(Warren E. Collins Inc., Braintree, MA) was used 
Fasting blood was collected. Plasma was stored at 
-70℃. One technician analyzed fatty acid 
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population-based cohort of about 16,000 
middle-aged men and women recruited 
from 4 communities in U.S. in 1987-
1989. They went through a 3 to 4-hour 
examination in clinics at baseline. For 
this study, only participants from the 
suburban Minneapolis area were 
included given the n-3 PUFA biomarker 
measures were only conducted in this 
population (35, 42).  
to carry out spirometry at visits 1 and 2. 
SensorMedics model 1022 dry rolling seal 
spirometers (OMI, Houston, TX) were used to 
carry out spirometry at visit 5. The spirometer 
was calibrated daily, and a single pulmonary 
function reading center was used to standardize 
the spirometry testing across the four study sites 
in ARIC. The test was deemed successful if there 
were three acceptable attempts (43).  
composition about 2 years later. The cholesterol 
ester (CE) and PL were extracted with 
chloroform/methanol, and separated using TLC. 
The methyl esters of fatty acids in CE and PL 
were measured separately by a Model 5890 GC 
(Hewlett-Packard, Avondale, PA). A total of 28 
fatty acids were identified using GC. The short-
term (usually several weeks) reliability 
coefficients were 0.31 for EPA in phospholipids 
and 0.58 for DHA in phospholipids. The long-
term (within 3 years) reliability coefficient was 
0.51 for EPA in phospholipids. Overall the 
reliability coefficient for DHA was greater than 
the one for EPA (42). The concentration was 
expressed as % of total fatty acids. The 
correlations between plasma and dietary 
polyunsaturated fatty acids were 0.25 for PL and 
0.31 for CE (44).  
CARDIA The Coronary Artery Risk Development 
in Young Adults (CARDIA) study is a 
longitudinal cohort that recruited 
participants from 4 U.S. metropolitan 
areas, including Birmingham, AL, 
Chicago, IL, Minneapolis, MN, and 
Oakland, CA. CARDIA began in 1985-
1986 and comprised 5,115 white and 
black young adults aged 18-30 yrs (45).  
A dry rolling-sealed SensorMedics model 1022 
OMI spirometer (Viasys, Yorba Linda, CA) was 
used at year 20, and the 2005 American Thoracic 
Society (ATS)/ European Respiratory Society 
(ERS) criteria was followed (46). The Pulmonary 
Waveform Generator (MH Custom Design and 
Manufacturing, Midvale, UT) validated the 
accuracy of the spirometer. The OMI spirometers 
performed better than the ATS criteria for 
accuracy and precision (47). 
Fasting plasma samples were collected at Year 20 
and EDTA plasma was frozen at -70℃. Lipids 
were extracted from plasma through 
chloroform/methanol. CE, PL, triglyceride, and 
free FAs were separated using TLC. The fatty 
acid methyl esters were generated from 
transesterification from the PL fraction and were 
measured by GC with a flame ionization detector. 
28 fatty acids were identified and were expressed 
as % of total fatty acids (48). 
CHS The Cardiovascular Health Study (CHS) 
comprised 5,201 men and women aged ≥ 
65 yrs who were recruited from 4 U.S. 
communities, including Forsyth County, 
NC, Sacramento County, CA, 
Washington County, MD, and Allegheny 
County, Pittsburgh, PA, in 1989. An 
additional 687 African Americans were 
recruited in 1992 and later on. The 
participants recruited were a random 
sample from the eligibility lists of 
Medicare from the Health Care 
A water-sealed spirometer (Collins Survey, 
Collins Medical, Inc., Braintree, MA) and 
software from S&M instruments (50) were used 
to carry out pulmonary function testing at years 2, 
6, and 9, with accuracy validated, according to 
contemporary ATS criteria (51). Due to the 
timing of omega-3 fatty acid measurements, the 
spirometry values from year 6 were used for the 
current analysis. 
Fasting blood samples were collected and stored 
at -80℃. Fatty acids in plasma PL were measured 
at the Fred Hutchinson Cancer Research Center. 
A total of 45 fatty acids were identified with the 
unit of % of total fatty acids. PLs were separated 
from other lipids via 1-dimensional TLC. The 
fatty acids in PLs were trans-methylated and 
separated by 5890 GC (Agilent Technologies, 
Palo Alto, CA), with a SP-2560 fused-silica 100-
m capillary column and a flame ionization 
detector. CVs of EPA, DPA, and DHA were all 
<3%. Measurement of plasma fatty acids across 
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Financing Administration (49).  different time points showed that 6-year 
correlations with baseline EPA, DPA and DHA 
were 0.55, 0.67, and 0.82, respectively (10).  
FHS 
(Offspring) 
Two Framingham Heart Study (FHS) 
generation cohorts were included in our 
study, the Offspring cohort and the Third 
Generation (Gen3) cohort. FHS is a U.S. 
family-based cohort in Framingham, 
MA, established in 1948. The Offspring 
cohort began in 1971 and is comprised 
of children of the original cohort and 
spouses of these children (52). Overall, 
99.7% participants across all three 
generations were self-reported 
Caucasians (53, 54). 
Spirometry testing was conducted at each exam, 
and 1994 ATS criteria was followed (55). In the 
7
th
 examination of the Offspring cohort, a 6-L 
water-filled Collins survey spirometer was used 
(Warren E. Collins Inc., Braintree, MA), 
connected to an S&M Instruments software 
(Doylestown, PA), and the spirometer was 
calibrated daily (56). Since Exam 8 of the 
Offspring Cohort, some participants in each 
cohort underwent post-bronchodilator spirometry 
testing, besides the regular spirometry testing that 
all participants performed, so as to differentiate 
participants with asthma (reversible disease) from 
those with COPD (fixed disease). 
Red blood cells (RBCs) were separated from the 
whole blood after about a 12-hour fast and was 
stored at -80℃. Fatty acid composition in RBC 
was measured using the HS-Omega-3 index® 
methodology (57). Fatty acid methyl esters were 
first generated from RBCs and then separated by 
a CG2010 GC (Shimadzu Corporation, Columbia, 
MD), with a SP2560 100-m column. The 
concentration was expressed as % of total 
identified fatty acids. The inter-assay CV for both 
EPA and DHA was 4.9%. Omega-3 index (RBC 
EPA+DHA, expressed as weight % of total fatty 
acids) was also derived in FHS (58). 
FHS 
(Gen3) 
Two Framingham Heart Study (FHS) 
generation cohorts were included in our 
study, the Offspring cohort and the Third 
Generation (Gen3) cohort. Starting in 
2002, 4,095 adults were enrolled in the 
Gen3 cohort given at least one of their 
parents were in the Offspring cohort. In 
addition, 103 parents of the Gen3 cohort 
participants were enrolled even though 
they were not in the Offspring cohort. 
Overall, 99.7% participants across all 
three generations were self-reported 
Caucasians (53, 54).  
Spirometry testing was conducted at each exam, 
and 1994 ATS criteria was followed (55). In 
Exam 2 of the Generation 3 cohort, a dry rolling-
sealed spirometer, connect to the CPL System 
(Warren E. Collins Inc., Braintree, MA), was 
used to measure pulmonary function, and the 
spirometer was calibrated daily (56).  
Same as above.  
MESA The Multi-Ethnic Study of 
Atherosclerosis (MESA) is a population-
based cohort consisting of 6,814 white, 
black, Hispanic and Asian men and 
women aged 45-84 yrs who were 
recruited from 6 sites in U.S., including 
St Paul, MN, Los Angeles, CA, northern 
Manhattan, NY, Forsyth County, NC, 
Chicago, IL, and Baltimore City and 
County, MD, from July 2000 to August 
A dry rolling-sealed spirometer, connected to an 
automated quality control software (Occupational 
Marketing, Inc., Houston, TX) was used to carry 
out pulmonary function testing, in accordance 
with the 2005 ATS/ERS criteria (46). Each 
participant was required to have 3 or more 
acceptable maneuvers. A quality score lower than 
C, from a 5-point was based on a version of the 
National Lung Health Education Program, was 
viewed as low. All results were centrally 
Fasting blood samples were stored at -70℃ (62), 
and fatty acids in the blood samples were 
analyzed at the Collaborative Studies Clinical 
Laboratory at Fairview-University Medical 
Center (Minneapolis, MN, USA). First, plasma 
PLs were extracted using chloroform/methanol, 
and then different lipids were separated by TLC 
(63). The fatty acids in PLs were trans-methylated 
and measured via a Hewlett Packard 5890 GC, 
configured for a single capillary Varian CP7420 
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2002 (59, 60). For this study, only 
whites and blacks were included.  
reviewed. (61) 100-m column with a flame ionization detector 
(64). The concentration was expressed as % of 
total fatty acids (63). 
RS The Rotterdam Study (RS) is a 
population-based cohort which sent out 
invitation to all residents aged ≥ 55 yrs 
who lived at a Rotterdam suburb in the 
Netherlands in 1990-1993 for study 
participation (65). A total of 7,983 men 
and women were eventually enrolled in 
the study (~78% of those eligible) (36). 
A SpiroPro® portable spirometer (Erich Jaeger 
GmbH, Hoechberg, Germany) was used to carry 
out spirometry from 2002 to 2009. The testing 
was performed by trained technicians, in 
accordance with ATS/ERS criteria (66). All 
measures, as collected from pre-bronchodilator 
testing, were centrally assessed and validated by 
researchers. (67) 
Fasting blood samples were collected. The 
plasma was stored at -80℃. Fatty acids in the PL 
fraction were measured. Lipid extraction was 
conducted based on a standard method (68). First, 
plasma lipids were extracted using 
chloroform/methanol. Second, the PL fraction 
was separated from other lipid fractions using the 
solid-phase extraction by NH2 columns. Third, 
the PL were methylated and fatty acid methyl 
esters were measured using high-resolution 
capillary gas-liquid chromatography (Shimadzu 
GC17A chromatograph; Shimadzu Benelux, ’s-
Hertogenbosch, NL), equipped with a 50-m fused 
silica column and a flame ionization detector. The 
fatty acids were quantified against the recovered 
amount of fatty acid methyl ester internal 
standard (19:0). Fatty acids were expressed as 
both mg/L plasma and % of total fatty acids. A 
difference between the values in % of total fatty 
acids also indicates a difference in absolute 
values (36).  
Abbreviations: AGES = Age, Gene, Environment, Susceptibility Study – Reykjavik; ARIC = Atherosclerosis Risk in Communities; ATS = American Thoracic 
Society; CARDIA = Coronary Artery Risk Development in Young Adults; CE = Cholesterol ester; CHS = Cardiovascular Health Study; CV = Coefficient of 
variation; DHA = Docosahexaenoic acid; DPA = Docosapentaenoic acid; EPA = Eicosapentaenoic acid; ERS = European Respiratory Society; FA = Fatty acid; 
FHS (Offspring) = Framingham Heart Study – the Offspring Cohort; FHS (Gen3) = Framingham Heart Study – the Generation 3 Cohort; GC = Gas 
chromatograph; MESA = Multi-Ethnic Study of Atherosclerosis; PL = Phospholipid; RBC = Red blood cell; RS = Rotterdam Study, TLC = Thin layer 
chromatography.  
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Table E5. Time of Measurement for Primary Study Variables in Each Cohort 
Cohort 
PFTs 
Collection 
Years 
n-3 PUFA 
Biomarkers 
Collection 
Years 
Smoking 
Status 
Pack-
Years 
Height Weight Age 
AGES 2002-2004 Concurrent 
with PFTs
*
 
All the covariates are concurrent with PFTs. 
ARIC 1987-1989 
(Baseline) 
Concurrent 
with PFTs 
All the covariates are concurrent with PFTs. 
CARDIA 2005-2006 
(Year 20) 
Concurrent 
with PFTs 
All the covariates are concurrent with PFTs. 
CHS
†
 1993-1994 
(Year 6) 
1992-1993 
(Year 5) 
All the covariates are concurrent with n-3 PUFAs.
‡
  
FHS 
(Offspring) 
1998-2001 
(Exam 7)
§
/ 
2005-2008 
(Exam 8) 
2005-2008 
(Exam 8) 
All the covariates are concurrent with PFTs. 
FHS  
(Gen 3) 
2008-2011 
(Exam 2) 
Concurrent 
with PFTs 
All the covariates are concurrent with PFTs. 
MESA 2004-2006 
(Exam 4) 
2000-2002 
(Exam 1) 
All the covariates are concurrent with PFTs. 
RSI 2002-2004 
(Exam 4) 
1997-1999 
(Exam 3) 
All the covariates are concurrent with PFTs. 
Abbreviations: AGES = Age, Gene, Environment, Susceptibility Study – Reykjavik; ARIC = Atherosclerosis Risk 
in Communities; CARDIA = Coronary Artery Risk Development in Young Adults; CHS = Cardiovascular Health 
Study; FHS (Offspring) = Framingham Heart Study – the Offspring Cohort; FHS (Gen3) = Framingham Heart Study 
– the Generation 3 Cohort; MESA = Multi-Ethnic Study of Atherosclerosis; n-3 PUFA = Omega-3 poly-unsaturated 
fatty acid; PFT = Pulmonary function test; RS = Rotterdam Study. 
*
In AGES, the blood samples were drawn at the time concurrent with PFTs (2002-2004). However, the n-3 PUFA 
biomarkers were measured from blood samples in 2013. 
†
In CHS, covariates from year 5 (concurrent with n-3 PUFA biomarkers) were used, but results were similar using 
covariates from either year 5 or year 6 (concurrent with PFT).  
‡
In CHS, the initial cohort (European and African ancestry participants) was enrolled in 1989-1990 and an additional 
cohort (African ancestry participants only) was recruited in 1992 and 1993. For the original cohort, pack-years in 
year 5 was extrapolated from that at baseline; for the additional cohort, pack-years in year 5 was calculated based 
on years and amount smoked. In addition, in CHS, height was only measured in year 5, but not in year 6. 
§
For the Offspring cohort, 2,165 participants had their PFT and other covariates measured at exam 8. However, 4 
participants with PFT and other covariates measured at exam 7 were included in this study due to their missing 
data at exam 8. 
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Table E6. Participant Characteristics Averaged across Cohorts
*
  
Characteristics 
Mean (SD) or 
Percent (%)
ll
 
Range of 
Mean or Percent
**
 
No. of Participants 16,134 141 – 3,254 
Males, % 45.4 30.9 – 49.6 
African ancestry, % 15.5 12.6 – 45.4
††
 
Current Smoker, % 14.1 8.0 – 24.1 
Former Smoker, % 37.6 13.5 – 57.5 
Pack-Years
†
 21 (21) 11 – 30 
Age, year 57 (13) 45 – 76 
Height, m 1.69 (0.10) 1.64 – 1.72 
Weight, kg
‡
 80.0 (18.5) 71.3 – 90.5 
FEV1, mL 2,831 (876) 1,765 – 3,388 
FVC, mL 3,786 (1,104) 2,440 – 4,449 
FEV1/FVC (%) 74.7 (8.2) 69.6 – 79.7 
ALA (% of total FAs) 0.17 (0.08) 0.14 – 0.23 
EPA (% of total FAs) 0.76 (0.65) 0.56 – 2.87 
DPA (% of total FAs)   
- Plasma Phospholipids 0.92 (0.20) 0.83 – 1.18 
- RBC‡‡ 2.64 (0.47) 2.55 – 2.76 
DHA (% of total FAs) 3.67 (1.41) 2.81 – 6.33 
Total n-3 PUFAs (% of total FAs) 6.08 (2.37) 4.41 – 10.60 
Time Difference between PFT and n-3 
PUFAs, days
§
 
266 (580) 0 – 1,769 
Abbreviations: AA = African ancestry; AGES = Age, Gene, Environment, Susceptibility Study—Reykjavik, 
Iceland; ALA = Alpha-linolenic acid; ARIC = Atherosclerosis Risk in Communities; CARDIA = Coronary Artery 
Risk Development in Young Adults; CHS = Cardiovascular Health Study; DHA = Docosahexaenoic acid; DPA = 
Docosapentaenoic acid; EA = European ancestry; EPA = Eicosapentaenoic acid; FA = Fatty acid; FEV1 = Forced 
expiratory volume in the first second; FHS (Offspring) = Framingham Heart Study—Offspring Cohort; FHS (Gen3) 
= Framingham Heart Study—Generation 3 Cohort; FVC = Forced vital capacity; MESA = Multi-Ethnic Study of 
Atherosclerosis; n-3 PUFA = Omega-3 poly-unsaturated fatty acid; PFT = Pulmonary function test; RBC = Red 
blood cell; RS = Rotterdam (Netherlands) Study; SD = Standard Deviation. 
 
*
Data are presented as mean (SD) unless otherwise indicated. This table corresponds to the n-3 PUFA-PFT 
association analyses and thus includes all seven cohorts. The total sample size was 16,134 for the meta-analysis of 
omega-3 fatty acid biomarkers, in which 13,629 are European ancestry participants, and 2,505 are African 
ancestry participants. All the cohorts measured n-3 PUFAs in plasma phospholipids, except FHS, which measured 
n-3 PUFAs in red blood cells. 
†
Descriptive statistics of pack-years among ever smokers. 
‡
Number of participants with weight data was slightly different from the number of participants shown in this table 
for some cohorts. In CHS, 242 out of 243 AAs and 1,687 out of 1,690 EAs had weight data. In CARDIA, all 
1,759 EAs and 1,456 out of 1,461 AAs had weight data. 
§
The time difference refers to the interval between measurement of PFT and n-3 PUFAs. If the difference is positive, 
n-3 PUFAs were measured before PFTs; if it is negative, n-3 PUFAs were measured after PFTs. 
ll
The mean (SD) or percentage was weighted by the sample size of each cohort.   
**
Range is presented for
 
each ancestry-specific cohort, therefore 11 cohorts/sub-cohorts are included here (AGES-
EA, ARIC-EA, CARDIA-EA, CARDIA-AA, CHS-EA, CHS-AA, MESA-EA, MESA-AA, RS-EA, FHS-
Offspring-EA, and FHS-Gen3-EA).   
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††
Only CARDIA, CHS, and MESA contributed to the statistical analysis for AA participants and thus contributed to 
the percentages of AA participants here. 
‡‡
Only FHS-Offspring and FHS-Gen3 have DPA measured in RBCs. 
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Table E7. Omega-3 Fatty Acid Biomarker Levels by Smoking Status in Each Cohort 
 
Cohorts 
Mean ALA biomarker level 
(% of total fatty acids) 
Mean EPA biomarker level 
(% of total fatty acids) 
Mean DPA biomarker level 
(% of total fatty acids) 
Mean DHA biomarker level 
(% of total fatty acids) 
Never 
smoker 
Former 
smoker 
Current 
smoker 
Never 
smoker 
Former 
smoker 
Current 
smoker 
Never 
smoker 
Former 
smoker 
Current 
smoker 
Never 
smoker 
Former 
smoker 
Current 
smoker 
AGES-EA 
(N=424)  
0.22 0.23 0.24 2.98 2.84 2.53 1.18 1.18 1.13 6.45 6.34 5.85 
ARIC-EA 
(N=3,143) 
0.15 0.14 0.14 0.57 0.58 0.53 0.92 0.90 0.88 2.94 2.85 2.54 
CARDIA-EA 
(N=1,759) 
0.19 0.20 0.19 0.87 0.86 0.73 0.95 0.93 0.93 3.18 3.19 2.59 
CARIDA-AA 
(N=1,461) 
0.17 0.17 0.17 0.70 0.71 0.63 0.93 0.91 0.93 3.39 3.48 2.94 
CHS-EA                 
(N = 1690) 
0.15 0.15 0.14 0.58 0.62 0.58 0.84 0.84 0.79 2.94 3.05 2.76 
CHS-AA             
(N = 243) 
0.13 0.14 0.13 0.59 0.65 0.56 0.86 0.86 0.87 3.57 3.53 3.58 
MESA-EA           
(N = 1140) 
0.18 0.18 0.18 0.93 0.97 0.71 0.95 0.93 0.88 3.63 3.56 2.86 
MESA-AA          
(N = 801) 
0.16 0.15 0.16 0.96 0.90 0.76 0.97 0.94 0.91 4.46 4.30 3.67 
RS-EA (N = 141) 0.18 0.16 0.15 0.81 0.87 0.85 0.94 0.94 0.94 3.63 3.52 3.32 
FHS-Offspring-
EA
*
 (N = 2,169) 
0.18 0.18 0.18 0.75 0.76 0.66 2.78 2.77 2.62 4.99 4.90 4.09 
FHS-Gen3-EA
*
        
(N = 3,052) 
0.17 0.17 0.16 0.66 0.71 0.57 2.56 2.57 2.49 4.29 4.24 3.43 
Page 65 of 108  AJRCCM Articles in Press. Published on 10-September-2018 as 10.1164/rccm.201802-0304OC 
 Copyright © 2018 by the American Thoracic Society 
Abbreviations: AA = African ancestry; AGES = Age, Gene, Environment, Susceptibility Study—Reykjavik, Iceland; ALA = Alpha-linolenic acid; ARIC = 
Atherosclerosis Risk in Communities; CARDIA = Coronary Artery Risk Development in Young Adults; CHS = Cardiovascular Health Study; DHA = 
Docosahexaenoic acid; DPA = Docosapentaenoic acid; EA = European ancestry; EPA = Eicosapentaenoic acid; FHS (Offspring) = Framingham Heart Study—
Offspring Cohort; FHS (Gen3) = Framingham Heart Study—Generation 3 Cohort; MESA = Multi-Ethnic Study of Atherosclerosis; RS = Rotterdam 
(Netherlands) Study. 
*
Omega-3 fatty acid biomarkers were measured in plasma in all cohorts, except those in FHS (measured in red blood cells). 
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Table E8. Meta-Analysis Results for the Primary Analyses of Each Omega-3 Fatty Acid Biomarker on Each Pulmonary Function Test Measure
*
 
 FEV1 FVC FEV1/FVC (in percent) 
n-3 
PUFA 
(Ances
try) 
β (mL) SE 
P-
value 
Effect per 
1 SD 
increment
§
 
β (mL) SE 
P-
value 
Effect per 
1 SD 
increment
§
 
β
 
(%) SE P-value 
Effect per 
1 SD 
increment
§
 
DHA 
(All) 
14.3
†
 3.2 <0.001 20.3 8.4 3.7 0.023 11.9 0.03
†
 0.05 0.478 0.05 
DHA 
(EA) 
15.4 3.4 <0.001 21.8 9.7 4.0 0.016 13.7 0.01
†
 0.05 0.816 0.02 
DHA 
(AA) 
8.4
‡
 8.1 0.300 11.8 1.3
†
 9.5 0.890 1.9 0.16
†
 0.12 0.192 0.23 
DPA 
(All) 
39.3
†
 11.5 <0.001 8.1 32.4
‡
 13.3 0.015 6.7 -0.2 0.2 0.238 -0.04 
DPA 
(EA) 
39.6
‡
 11.9 <0.001 8.1 35.7
‡
 13.8 0.010 7.3 -0.2 0.2 0.244 -0.04 
DPA 
(AA) 
35.6 41.0 0.384 7.3 -6.3 48.0 0.895 -1.3 -0.1 0.6 0.825 -0.03 
EPA 
(All) 
2.9 6.6 0.658 1.9 2.8 7.7 0.711 1.9 -0.2 0.1 0.016 -0.16 
EPA 
(EA) 
3.4 7.2 0.638 2.2 4.7 8.3 0.573 3.1 -0.3 0.1 0.007 -0.19 
EPA 
(AA) 
0.41 16.8 0.981 0.3 -7.5 19.7 0.703 -4.9 0.04 0.27 0.868 0.03 
ALA 
(All) 
81.9 45.6 0.072 6.5 120.5 53.1 0.023 9.5 -2.9
†
 0.7 <0.001 -0.23 
ALA 
(EA) 
54.3 49.1 0.270 4.3 95.4 57.3 0.096 7.5 -2.6
‡
 0.7 <0.001 -0.20 
ALA 
(AA) 
250.7 121.5 0.039 19.8 272.2
†
 140.8 0.053 21.5 -4.3 1.7 0.010 -0.34 
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Abbreviations: AA = African ancestry; ALA = Alpha-linolenic acid; DHA = Docosahexaenoic acid; DPA = Docosapentaenoic acid; EPA = Eicosapentaenoic 
acid; FEV1 = Forced expiratory volume in the first second; FVC = Forced vital capacity; n-3 PUFA = Omega-3 poly-unsaturated fatty acid; SD = Standard 
deviation; SE = Standard error. 
*
The β coefficient corresponds to the association of each n-3 PUFA biomarker on the specific pulmonary function outcome from a meta-analysis across cohorts 
[individual cohort analyses adjusted for current and former smoking, with never smoking as the reference, pack-years, sex, age, age
2
, height, height
2
, weight 
(for the FVC outcome only), and study site (cohorts with >1 site)]. P-values that are ≤0.05 are bolded. 
†
Moderate heterogeneity with I
2 
ranging from 33% to 60%. 
‡
Substantial heterogeneity with I
2 
ranging from 62% to 82%. 
§
One standard deviation increments of DHA (all cohorts), DPA (all except FHS), EPA (all cohorts), and ALA (all cohorts) biomarkers are 1.41%, 0.20%, 0.65%, 
and 0.08% of total fatty acids, respectively.
Table E9. Meta-Analysis Results of the Interaction of Each Omega-3 Fatty Acid Biomarker and Smoking Status on Each Pulmonary Function Test 
Measure
* 
 
n-3 
PUFA 
Smoking 
status (vs. 
never 
smoking as 
reference) 
FEV1 FVC FEV1/FVC (in percent) 
β (mL) SE 
P-
value 
Effect per  
1 SD 
increment
§
 
β  
(mL) 
SE 
P-
value 
Effect per  
1 SD 
increment
§
 
β
 
(%) SE 
P-
value 
Effect per  
1 SD 
increment
§
 
DHA Current  
 
26.1 11.1 0.019 36.8 9.5 12.9 0.463 13.4 0.9 0.2 <0.001 1.2 
Former 
 
3.5
†
 6.7 0.596 5.0 -0.6 7.7 0.937 -0.9 0.1 0.1 0.158 0.2 
DPA Current  
 
44.8 40.4 0.268 9.0 43.3 46.6 0.353 8.7 1.1 0.6 0.060 0.2 
Former  
 
39.3 24.1 0.104 7.9 30.0 27.9 0.282 6.0 0.4 0.4 0.208 0.1 
EPA Current  
 
34.4 25.1 0.171 22.4 19.1 29.1 0.513 12.4 0.6 0.4 0.110 0.4 
Former  
 
2.8
†
 14.1 0.841 1.8 -1.8
†
 16.4 0.912 -1.2 -0.0004 0.2222 0.999 -0.0003 
ALA Current  
 
-109.1 144.1 0.449 -8.7 -151.0 167.6 0.367 -12.1 -0.09 2.06 0.965 -0.01 
Former  
 
-147.2 106.4 0.167 -11.8 -68.2 123.5 0.581 -5.5 -2.2 1.6 0.169 -0.2 
Abbreviations: ALA = Alpha-linolenic acid; DHA = Docosahexaenoic acid; DPA = Docosapentaenoic acid; EPA = Eicosapentaenoic acid; FEV1 = Forced 
expiratory volume in the first second; FVC = Forced vital capacity; n-3 PUFA = Omega-3 poly-unsaturated fatty acid; SD = Standard deviation; SE = Standard 
error. 
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*
Fixed effect models were used. β (mL) and β (%) were the coefficients of the interaction terms only (the interaction of current smoking status with the n-3 
PUFA biomarkers, and the interaction of former smoking status with the n-3 PUFA biomarkers), with never smokers as the reference group. P-values that are 
≤0.05 are bolded. Coefficients were meta-analyzed across cohorts, and each cohort’s analysis was adjusted for the following covariates: current and former 
smoking, with never smoking as the reference, pack-years, sex, age, age
2
, height, height
2
, weight (for the FVC outcome only), and study site (cohorts with >1 
site).  
†
Moderate heterogeneity with I
2 
ranging from 30% to 60%. 
§
One standard deviation increments of DHA (all cohorts), DPA (all except FHS), EPA (all cohorts), and ALA (all cohorts) biomarkers are 1.41%, 0.20%, 0.65%, 
and 0.08% of total fatty acids, respectively. 
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Table E10. Previously Reported Lead SNPs at Genome-Wide Significant Loci for Either of the Omega-3 Fatty Acid Biomarkers (DHA or DPA) and 
Their Associations with FEV1 and FVC in the Current Genome-Wide Joint 2df Meta-Analyses that Included Interaction with the N-3 Fatty Acid 
Biomarkers (DHA or DPA)  
 
Chr Position SNP 
Gene / 
nearby 
genes 
Prior 
GWAS 
phenotype 
Prior 
GWAS P 
DHA interaction 
model for FEV1 
DPA interaction model 
for FEV1 
DHA interaction 
model for FVC 
DPA interaction 
model for FVC 
Pmain Pint P2df Pmain Pint P2df Pmain Pint P2df Pmain Pint P2df 
6 10994782 rs2236212 ELOVL2 DHA 1.0×10
-15
 0.95 0.92 0.99 0.51 0.89 0.54 0.30 0.21 0.42 0.11 0.22 0.26 
6 10968908 rs4713103 SYCP2L DHA/ 
DPA 
8.0×10
-14
 / 
3.0×10
-36
 
0.80 0.92 0.90 0.76 0.51 0.70 0.67 0.44 0.54 0.54 0.62 0.83 
6 11074114 rs4711171 ELOVL2-
AS1 
DHA 5.0×10
-13
 0.68 0.62 0.87 0.36 0.58 0.59 0.11 0.062 0.16 0.093 0.15 0.24 
2 27518370 rs780094 GCKR DPA 9.0×10
-9
 0.48 0.47 0.76 0.74 0.74 0.94 0.45 0.50 0.75 0.67 0.75 0.91 
6 10982740 rs3734398 ELOVL2 DPA 1.0×10
-43
 0.68 0.67 0.91 0.59 0.98 0.58 0.56 0.47 0.74 0.12 0.25 0.29 
6 11075793 rs1321535 ELOVL2-
AS1 
DPA 1.0×10
-38
 0.62 0.54 0.81 0.43 0.65 0.65 0.15 0.080 0.20 0.10 0.17 0.27 
11 61723014 rs198426 DAGLA DPA 3.0×10
-9
 0.39 0.73 0.31 0.040 0.18 0.080 0.52 0.99 0.21 0.063 0.33 0.079 
11 61783884 rs174535 MYRF DPA 1.0× 
10
-151
 
0.84 0.56 0.57 0.24 0.96 0.095 0.59 0.35 0.44 0.12 0.67 0.063 
11 61790331 rs102275 TMEM25
8 
DPA 8.0× 
10
-153
 
0.94 0.57 0.23 0.030 0.49 8.7× 
10
-3
 
0.81 0.44 0.36 0.040 0.45 0.018 
11 61796827 rs4246215 FEN1 DPA 1.0× 
10
-139
 
0.95 0.57 0.26 0.064 0.69 0.016 0.96 0.46 0.21 0.026 0.43 7.6× 
10
-3
 
11 61803311 rs174547 FADS1 DPA 4.0× 
10
-154
 
0.70 0.37 0.34 0.086 0.65 0.037 0.55 0.27 0.31 0.066 0.53 0.033 
11 61830500 rs1535 FADS2 DPA 3.0× 
10
-152
 
0.98 0.61 0.45 0.055 0.49 0.034 0.83 0.48 0.41 0.036 0.38 0.024 
11 61872101 rs174448 FADS2/ 
FADS3 
DPA 3.0×10
-60
 0.83 0.43 0.29 0.052 0.37 0.059 0.48 0.25 0.35 0.12 0.49 0.14 
11 61896219 rs174468 FADS3/ 
RAB3IL1 
DPA 3.0×10
-35
 0.10 0.37 0.054 2.2× 
10
-3
 
0.091 1.8× 
10
-3
 
0.16 0.52 0.083 0.010 0.27 3.9× 
10
-3
 
11 61944003 rs2521572 RAB3IL1 DPA 2.0×10
-9
 0.052 0.033 0.10 0.79 0.67 0.89 0.033 0.053 0.10 0.90 0.75 0.71 
Abbreviations: chr = Chromosome; DHA = Docosahexaenoic acid; DPA = Docosapentaenoic acid; FEV1 = Forced expiratory volume in the first second; FVC = 
Forced vital capacity; GWAS = Genome-wide association study; int = Interaction; NA = Not available; SNP = Single nucleotide polymorphism. 
*
SNPs with the smallest P values from each locus reported in the prior GWAS analysis (69) are shown and are sorted by DHA or DPA phenotype and then by 
chromosomal position (NCBI build 37). The SNP that passed the multiple testing correction (n of tests = 14, Bonferroni-corrected P<3.6×10
-3
) is bolded. 
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Table E11. Previously Reported Lead SNPs at Genome-Wide Significant Loci for any of the Pulmonary Function Test Measures (FEV1, FVC, or 
FEV1/FVC) and Their Associations in the Current Genome-Wide Joint 2df Meta-Analyses that Included Interaction with the N-3 Fatty Acid 
Biomarkers (DHA or DPA)
*
  
chr Position SNP 
Gene / 
nearby genes 
Prior 
GWAS 
phenotype 
Prior 
GWAS 
best P 
DHA interaction 
model for FEV1 
DPA interaction model 
for FEV1 
DHA interaction 
model for FVC 
DPA interaction 
model for FVC 
Pmain Pint P2df Pmain Pint P2df Pmain Pint P2df Pmain Pint P2df 
1 150586971 rs6681426 MCL1/ENSA FEV1 4.4×10
-9
 
(70) 
0.25 0.80 0.054 0.13 0.71 0.062 0.020 0.15 0.013 0.049 0.52 0.019 
1 204434927 rs12092943 PIK3C2B FEV1 4.8×10
-8
 
(71) 
0.057 0.22 0.055 0.060 0.34 0.071 0.15 0.51 0.064 0.073 0.44 0.060 
1 221765779 1:221765779:
C_CA 
C1orf140/ 
DUSP10 
FEV1 3.4×10
-8
 
(71) 
0.56 0.69 0.69 0.76 0.58 0.54 0.69 0.68 0.92 0.45 0.41 0.71 
1 237941781 rs3766889 RYR2 FEV1 4.1×10
-8
 
(71) 
6.3× 
10
-4
 
5.6× 
10
-3
 
6.4× 
10
-4
 
0.24 0.56 0.022 0.021 0.099 9.9× 
10
-3
 
0.13 0.33 0.025 
2 42355947 rs963406 PKDCC/ 
EML4 
FEV1 3.2×10
-8
 
(71) 
0.56 0.95 0.20 0.28 0.86 0.15 0.27 0.55 0.24 0.11 0.37 0.16 
2 218683154 rs2571445 TNS1 FEV1 1.1×10
-12
 
(72) 
0.081 0.99 6.0× 
10
-6
 
2.4× 
10
-3
 
0.52 5.5× 
10
-6
 
0.57 0.20 1.3× 
10
-5
 
0.021 1.00 3.5× 
10
-5
 
3 57494433 rs79294353 DNAH12 FEV1 4.8×10
-9
 
(71) 
0.41 0.65 0.50 0.84 0.66 0.46 0.59 0.61 0.86 0.70 0.72 0.93 
3 98815640 rs6778584 DCBLD2/ 
MIR548G 
FEV1 4.5×10
-8
 
(71) 
0.27 0.35 0.52 0.046 0.037 0.11 0.074 0.16 0.15 0.010 0.020 0.036 
3 169300219 rs1344555 MECOM FEV1 2.7×10
-8
 
(73) 
0.57 0.76 0.69 0.52 0.82 0.65 0.31 0.22 0.43 0.31 0.16 0.35 
4 106137033 rs2047409 TET2 FEV1 1.3×10
-8
 
(74) 
0.21 0.51 0.14 0.17 0.66 0.15 0.49 0.80 0.44 0.21 0.49 0.34 
4 106531846 rs17035960 FLJ20184 FEV1 9.4×10
-14
 
(9) 
0.11 0.83 3.3× 
10
-6
 
0.14 0.28 6.9× 
10
-6
 
0.10 0.81 4.2× 
10
-4
 
0.17 0.48 2.8× 
10
-4
 
4 106563379 rs17036052 FLJ20184 FEV1 1.8×10
-15
 
(9) 
0.13 0.85 1.1× 
10
-5
 
0.19 0.29 1.4× 
10
-5
 
0.17 0.93 1.9× 
10
-3
 
0.29 0.42 9.0× 
10
-4
 
4 106593574 rs17036090 FLJ20184 FEV1 5.6×10
-15
 
(9) 
0.23 0.57 9.8× 
10
-6
 
0.34 0.12 9.7× 
10
-6
 
0.17 0.89 2.2× 
10
-3
 
0.22 0.50 1.2× 
10
-3
 
4 106619140 rs11727189 INTS12 FEV1 4.7×10
-17
 
(9) 
0.17 0.74 2.1× 
10
-5
 
0.19 0.33 3.5× 
10
-5
 
0.18 0.95 2.3× 
10
-3
 
0.14 0.71 1.8× 
10
-3
 
4 106688904 rs10516526 GSTCD FEV1 2.2×10
-23
 
(72) 
0.13 0.80 9.6× 
10
-6
 
0.14 0.38 2.1× 
10
-5
 
0.15 0.91 1.7× 
10
-3
 
0.12 0.76 1.3× 
10
-3
 
4 106729933 rs11097901 GSTCD FEV1 3.3×10
-18
 
(9) 
0.083 0.97 1.4× 
10
-5
 
0.18 0.30 2.0× 
10
-5
 
0.075 0.59 2.1× 
10
-3
 
0.15 0.66 1.5× 
10
-3
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4 106755996 rs11728716 GSTCD FEV1 7.2×10
-18
 
(9) 
0.18 0.69 1.1× 
10
-5
 
0.11 0.49 3.1× 
10
-5
 
0.18 0.90 4.0× 
10
-3
 
0.17 0.73 3.5× 
10
-3
 
4 106796829 rs17036341 GSTCD/ 
NPNT 
FEV1 2.2×10
-15
  
(9) 
0.023 0.38 1.5× 
10
-4
 
0.57 0.11 1.8× 
10
-4
 
0.056 0.33 0.012 0.45 0.43 0.015 
4 106808107 rs17331332 GSTCD/ 
NPNT 
FEV1 5.7×10
-15
 
(9, 72) 
0.10 0.93 1.3× 
10
-5
 
0.11 0.51 3.1× 
10
-5
 
0.17 0.85 4.6× 
10
-3
 
0.19 0.68 3.9× 
10
-3
 
4 106819053 rs34712979 NPNT FEV1 9.6×10
-16
 
(74) 
0.061 0.34 0.022 0.012 0.16 0.014 0.28 0.57 0.32 0.037 0.13 0.093 
4 146174040 rs111898810 OTUD4/ 
SMAD1 
FEV1 2.1×10
-8
 
(71) 
0.22 0.054 0.050 0.79 0.32 0.33 0.18 0.051 0.072 0.95 0.54 0.56 
5 55922145 rs11748173 ANKRD55/ 
MAP3K1 
FEV1 3.9×10
-10
 
(71) 
0.50 0.73 0.57 0.43 0.76 0.56 0.61 0.86 0.66 0.88 0.43 0.45 
5 77392117 
rs252746 
AP3B1 FEV1 6.2×10
-9
 
(71) 
0.80 0.66 0.83 0.12 0.081 0.22 0.80 0.74 0.94 0.43 0.49 0.73 
5 147845815 rs3995090 HTR4 FEV1 4.3×10
-9
 
(72) 
8.5× 
10
-4
 
6.4× 
10
-3
 
2.2× 
10
-3
 
0.068 0.61 0.023 0.025 7.8× 
10
-3
 
0.024 0.75 0.58 0.82 
5 147846707 rs6889822 HTR4 FEV1 8.2×10
-9
 
(72) 
6.2× 
10
-4
 
6.5× 
10
-3
 
1.3× 
10
-3
 
0.015 0.29 7.6× 
10
-3
 
0.042 0.025 0.081 0.40 0.39 0.68 
5 148596693 rs3839234 ABLIM3 FEV1 4.5×10
-11
 
(75) 
0.54 0.35 0.53 0.50 0.64 0.77 1.00 0.79 0.78 0.62 0.83 0.81 
6 28322296 rs6903823 ZKSCAN3/ 
ZNF323 
FEV1 2.2×10
-10
 
(73) 
0.91 0.42 0.15 0.84 0.28 0.18 0.94 0.71 0.72 0.61 0.38 0.58 
6 32635592 rs9274600 HLA-DQB1/ 
HLA-DQA3 
FEV1 1.3×10
-10
 
(74) 
0.40 0.28 0.50 0.44 0.42 0.71 0.42 0.42 0.72 0.24 0.24 0.50 
6 32648418 rs114229351
†
 HLA-DQB1/ 
HLA-DQA2 
FEV1 2.1×10
-10
 
(75) 
0.065 0.10 0.18 0.082 0.16 0.22 0.088 0.070 0.19 0.14 0.090 0.24 
7 156127246 rs12698403 LOC389602/
LOC285889 
FEV1 1.1×10
-13
 
(75) 
0.84 0.39 0.16 0.85 0.54 0.30 0.67 0.21 0.050 0.75 0.40 0.093 
9 4124377 rs7872188 GLIS3 FEV1 1.6×10
-10
 
(75) 
0.24 0.62 0.16 0.057 0.29 0.091 0.13 0.43 0.080 0.013 0.12 0.026 
10 65087468 rs7899503 JMJD1C FEV1 8.7×10
-14
 
(71) 
0.037 0.24 8.9× 
10
-3
 
0.028 0.47 5.4× 
10
-3
 
0.30 0.89 0.035 0.080 0.66 0.026 
10 78315224 rs11001819 C10orf11 FEV1 3.0×10
-12
 
(73) 
0.46 0.13 0.053 0.97 0.22 0.070 0.99 0.48 0.14 0.93 0.29 0.083 
11 62310909 rs2509961 AHNAK FEV1 1.5×10
-13
 
(75) 
0.16 0.21 0.37 0.30 0.41 0.58 0.14 0.17 0.34 0.49 0.66 0.75 
11 86442733 rs145729347 ME3/PRSS23 FEV1 8.6×10
-9
 
(75) 
0.24 0.66 0.13 0.67 0.63 0.21 0.85 0.70 0.85 0.99 0.95 0.99 
11 126008910 rs567508 CDON/ FEV1 4.8×10
-10
 0.63 0.28 0.20 0.85 0.28 0.21 0.63 0.96 0.47 0.93 0.36 0.25 
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RPUSD4 (75) 
12 56390364 rs772920 RAB5B FEV1 2.5×10
-8
 
(71) 
0.87 0.80 0.95 0.44 0.30 0.57 0.48 0.67 0.63 0.92 0.65 0.57 
12 65824670 rs1494502 MSRB3 FEV1 9.8×10
-10
 
(75) 
0.044 0.069 0.13 0.48 0.80 0.59 0.31 0.39 0.58 0.68 0.93 0.80 
12 114743533 chr12: 
114743533 
RBM19/ 
TBX5 
FEV1 1.2×10
-8
 
(74) 
NA NA NA NA NA NA NA NA NA NA NA NA 
12 115201436 rs10850377 TBX3 FEV1 2.5×10
-12
 
(70) 
0.60 0.96 0.28 0.88 0.24 0.12 0.58 0.86 0.12 0.36 0.82 0.084 
12 125230287 rs11057793 NCOR2\ 
SCARB1 
FEV1 4.8×10
-8
 
(71) 
0.57 0.87 0.53 0.20 0.47 0.34 0.77 0.86 0.46 0.26 0.61 0.36 
14 92485881 rs7155279 TRIP11 FEV1 1.4×10
-9
 
(70) 
0.75 0.46 0.46 0.17 0.28 0.38 0.46 0.25 0.35 0.086 0.14 0.23 
14 93118229 rs117068593 RIN3 FEV1 2.3×10
-8
 
(70) 
0.21 0.76 0.029 0.31 0.65 0.020 0.44 0.80 0.33 0.75 0.63 0.33 
17 29087285 rs62070631 SUZ12P1 FEV1 2.6×10
-8
 
(71) 
0.070 0.38 0.021 0.11 0.80 0.029 0.30 0.74 0.16 0.25 0.78 0.20 
17 43682323 rs186806998 LOC644172/
CRHR1 
FEV1 3.5×10
-10
 
(71) 
0.19 0.95 4.2× 
10
-3
 
0.10 0.93 3.4× 
10
-3
 
0.21 0.88 9.7× 
10
-3
 
0.020 0.40 5.2× 
10
-3
 
17 43685698 rs143246821 FEV1 9.1×10
-10
 
(71) 
0.082 0.61 3.1× 
10
-3
 
0.046 0.72 2.2× 
10
-3
 
0.11 0.59 9.8× 
10
-3
 
8.6× 
10
-3
 
0.20 3.7× 
10
-3
 
17 44339473 rs2532349 KANSL1 FEV1 1.7×10
-10
 
(70) 
0.13 0.81 3.2× 
10
-3
 
0.056 0.80 2.4× 
10
-3
 
0.15 0.77 7.6× 
10
-3
 
0.012 0.28 3.8× 
10
-3
 
17 44847834 rs199525 WNT3 FVC, FEV1 9.6×10
-10
 
(71) 
0.50 0.58 6.0× 
10
-3
 
0.098 0.93 6.1× 
10
-3
 
0.49 0.78 0.039 0.026 0.28 0.020 
17 44863133 rs916888 FEV1 3.8×10
-9
 
(71) 
0.81 0.39 0.014 0.32 0.67 0.024 0.96 0.31 0.033 0.096 0.54 0.070 
17 69125606 rs11654749 KCNJ2/ 
SOX9 
FEV1 1.3×10
-8
 
(4) 
0.53 0.65 0.016 0.21 0.88 0.031 0.83 0.32 0.10 0.67 0.29 0.12 
17 73513185 rs7218675 TSEN54 FEV1 1.2×10
-8 
(74) 
0.20 0.34 0.34 0.11 0.25 0.26 0.064 0.23 0.061 3.0× 
10
-3
 
0.022 0.010 
18 8801351 rs513953 SOGA2 FEV1 2.0×10
-8
 
(71) 
0.012 0.084 0.011 0.30 0.80 0.039 0.063 0.12 0.16 0.16 0.35 0.34 
18 20148531 rs7243351 CTAGE1/ 
RBBP8 
FEV1 4.7×10
-8
 
(71) 
0.72 0.48 0.017 0.011 0.15 0.011 0.66 0.26 0.13 0.077 0.27 0.14 
20 25669052 rs6138639 ZNF337 FEV1 3.2×10
-10
 
(71) 
9.5× 
10
-3
 
0.20 3.0× 
10
-4
 
0.10 0.79 1.1× 
10
-3
 
0.014 0.15 2.0× 
10
-3
 
0.039 0.58 5.7× 
10
-3
 
20 31042176 rs1737889 C20orf112 FEV1 4.2×10
-8
 
(71) 
0.16 0.31 0.25 0.64 0.80 0.39 0.39 0.72 0.33 0.15 0.43 0.24 
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20 62363640 rs72448466 ZGPAT FEV1 4.3×10
-13
  
(75) 
0.66 0.86 0.22 0.62 0.69 0.19 0.55 0.91 0.40 0.89 0.58 0.39 
22 18450287 rs11704827 MICAL3 FEV1 8.3×10
-13
 
(75) 
0.29 0.48 0.44 0.74 0.82 0.58 0.71 0.90 0.79 0.48 0.66 0.75 
22 28056338 rs134041 MN1 FEV1 3.0×10
-9
 
(70) 
0.28 0.39 0.52 0.86 0.77 0.65 0.65 0.86 0.72 0.76 0.88 0.68 
22 28181399 rs2283847 MN1 FEV1 3.4×10
-11
 
(75) 
0.87 0.80 0.48 0.38 0.27 0.34 0.65 0.89 0.62 0.59 0.44 0.45 
11 86376739 rs507211 ME3 longitu- 
dinal FEV1 
2.2×10
-8
 
(76) 
1.00 0.58 0.33 0.20 0.58 0.23 0.54 0.98 0.31 0.56 0.77 0.24 
1 118862070 rs200154334 SPAG17/ 
TBX15 
FVC 8.2×10
-14
 
(75) 
NA NA NA NA NA NA NA NA NA NA NA NA 
1 146494027 rs12724426 LOC728989 FVC 3.0×10
-8
 
(71) 
NA NA NA NA NA NA NA NA NA NA NA NA 
1 200085714 rs2821332 NR5A2 FVC 7.7×10
-9
 
(71) 
0.91 0.86 0.73 0.97 0.65 0.68 0.99 0.83 0.83 0.57 0.76 0.80 
1 215095003 rs512597 CENPF/ 
KCNK2 
FVC 3.9×10
-9
 
(71) 
0.61 0.80 0.72 0.22 0.31 0.47 0.35 0.77 0.18 0.15 0.49 0.20 
1 221630555 rs6657854 C1orf140/ 
DUSP10 
FVC 1.2×10
-8
  
(71)  
0.26 0.77 0.069 0.10 0.56 0.067 0.13 0.47 0.053 0.15 0.75 0.056 
1 221635207 rs12046746 FVC 1.4×10
-9
 
(71) 
0.26 0.78 0.069 0.10 0.56 0.068 0.13 0.47 0.052 0.15 0.76 0.055 
1 237929787 1:237929787:
T_TCA 
RYR2 FVC 4.5×10
-8
 
(71) 
0.59 0.36 0.43 0.14 0.23 0.33 0.59 0.37 0.46 0.16 0.24 0.38 
2 56120853 rs1430193 EFEMP1 FVC 1.9×10
-12
 
(77) 
0.12 0.35 0.14 0.096 0.37 0.14 0.074 0.46 0.010 0.053 0.55 0.014 
2 109571508 rs17034666 EDAR FVC 1.8×10
-8
 
(71) 
0.34 0.24 0.48 0.54 0.52 0.81 0.082 0.065 0.18 0.94 0.99 0.99 
2 119660943 rs114962105 EN1/ 
MARCO 
FVC 3.8×10
-8
 
(71) 
NA NA NA NA NA NA NA NA NA NA NA NA 
2 147046592 rs6746679 DKFZp686O
1327/ 
PABPC1P2 
FVC 2.2×10
-8
 
(71) 
0.18 0.15 0.36 0.96 0.89 0.98 0.13 0.16 0.32 0.59 0.77 0.82 
3 67452043 rs1490265 SUCLG2 FVC 1.6×10
-9
 
(75) 
0.15 0.17 0.36 0.68 0.85 0.86 0.70 0.78 0.90 0.67 0.50 0.76 
3 98806782 rs1404098 DCBLD2/ 
MIR548G 
FVC 5.5×10
-9
 
(71) 
0.38 0.50 0.63 0.044 0.037 0.10 0.10 0.24 0.17 7.5× 
10
-3
 
0.017 0.028 
3 158282459 rs6441207 RSRC1/ 
MLF1 
FVC 1.3×10
-13
 
(70) 
0.27 0.79 0.066 0.36 0.86 0.11 0.089 0.18 0.20 0.75 0.73 0.49 
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5 33334312 rs91731 LOC340113/
TARS 
FVC 4.3×10
-13
 
(75) 
0.84 0.75 0.36 0.70 0.79 0.47 0.63 0.95 0.30 0.26 0.58 0.39 
5 53444498 rs2441026 ARL15 FVC 2.8×10
-12
 
(75) 
0.27 0.43 0.44 0.49 0.84 0.60 0.34 0.46 0.57 0.88 0.57 0.67 
5 77450828 rs12513481 AP3B1 FVC 2.2×10
-11
 
(71) 
0.44 0.38 0.67 0.16 0.14 0.32 0.96 0.93 0.93 0.43 0.54 0.72 
5 77440196 rs72776440 FVC 3.2×10
-11
 
(71) 
0.62 0.50 0.75 0.18 0.13 0.32 0.97 1.00 1.00 0.55 0.58 0.83 
6 7801112 rs6923462 BMP6 FVC 5.9×10
-13
 
(77) 
0.13 0.29 0.21 0.58 0.76 0.28 0.18 0.57 0.074 0.89 0.13 0.025 
6 126792095 rs11759026 CENPW/ 
RSPO3 
FVC 4.3×10
-9
 
(71) 
0.69 0.31 0.22 0.68 0.19 0.15 0.45 0.99 0.13 0.81 0.33 0.067 
7 15506529 rs55905169 AGMO FVC 1.3×10
-8
 
(71) 
0.39 0.074 0.011 0.96 0.14 0.019 0.94 0.54 0.13 0.82 0.40 0.11 
9 1555835 rs771924 DMRT2/ 
SMARCA2 
FVC 7.2×10
-9
 
(71) 
0.080 0.47 9.1× 
10
-3
 
0.19 0.87 0.012 0.046 0.36 7.6× 
10
-3
 
0.22 0.77 0.016 
9 1574877 rs9407640 FVC, FEV1 2.9×10
-8
 
(71) 
0.21 0.72 0.033 0.55 0.43 0.027 0.24 0.68 0.092 0.76 0.39 0.080 
9 139094805 rs2274116 LHX3 FVC 5.5×10
-14
 
(70) 
0.42 0.70 3.5× 
10
-3
 
0.31 0.42 3.0× 
10
-3
 
0.59 0.46 2.9× 
10
-3
 
0.27 0.47 3.2× 
10
-3
 
9 139257411 rs10870202 DNLZ  FVC 9.3×10
-10
 
(75) 
0.78 0.83 0.95 0.83 0.88 0.98 0.32 0.20 0.36 1.00 0.72 0.78 
10 69957350 rs7095607 MYPN  FVC 8.7×10
-15
 
(75) 
0.77 0.54 0.58 0.83 0.36 0.31 0.71 0.56 0.75 0.67 0.35 0.47 
10 77002679 10:77002679:
TC_T 
COMTD1/ 
ZNF503-AS1 
FVC 4.9×10
-8
 
(71) 
0.011 0.050 0.023 0.014 0.079 0.039 0.29 0.61 0.26 0.13 0.40 0.22 
11 43648368 rs4237643 HSD17B12 FVC 3.5×10
-8
 
(77) 
0.33 0.66 0.28 0.80 0.64 0.36 0.11 0.53 0.021 0.66 0.34 0.028 
11 45250732 rs2863171 PRDM11/ 
SYT13 
FVC 9.0×10
-10
 
(77) 
0.34 0.92 0.051 0.064 0.43 0.057 0.014 0.14 3.1× 
10
-3
 
2.5× 
10
-3
 
0.092 2.2× 
10
-3
 
11 127995904 rs73025192 KIRREL3-
AS3/ETS1 
FVC 1.6×10
-8
 
(71) 
0.47 0.35 0.58 0.73 0.58 0.83 0.54 0.64 0.79 0.66 0.86 0.85 
12 28283187 rs11383346 CCDC91 FVC 9.5×10
-18
 
(70) 
0.62 0.91 0.23 0.93 0.42 0.16 0.18 0.55 0.069 0.34 0.98 0.10 
12 85724305 rs7971039 ALX1/ 
RASSF9 
FVC, FEV1 1.4×10
-8
 
(71) 
0.79 0.70 0.23 0.95 0.41 0.23 0.15 0.63 0.034 0.71 0.25 0.021 
12 85724096 rs10779158 FVC 1.5×10
-8
 
(71) 
0.48 0.96 0.18 0.90 0.35 0.13 0.31 0.95 0.019 0.84 0.16 0.011 
12 94184082 rs11107184 CRADD FVC 3.9×10
-8
 0.14 0.075 0.18 0.27 0.12 0.26 0.29 0.14 0.24 0.30 0.082 0.14 
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(71) 
12 94852628 rs10859698 CCDC41 FVC 3.5×10
-8
 
(71) 
0.67 0.34 0.27 0.34 0.75 0.37 0.92 0.49 0.29 0.41 0.91 0.32 
12 115500691 rs35506 TBX3/ 
MED13L 
FVC 9.9×10
-10
 
(75) 
0.16 0.32 0.27 0.38 0.83 0.40 0.058 0.17 0.092 0.27 0.80 0.22 
15 46722435 rs4775429 SQRDL/ 
SEMA6D 
FVC 2.5×10
-8
 
(71) 
0.14 0.039 0.027 0.86 0.58 0.26 0.16 0.078 0.12 0.41 0.29 0.40 
15 67483276 rs8025774 SMAD3 FVC 9.3×10
-13
 
(71) 
0.45 0.88 0.24 0.56 0.72 0.19 0.47 0.85 0.047 0.29 0.79 0.035 
16 70040398 rs3973397 PDXDC2P FVC 3.3×10
-8
 
(71) 
0.031 0.074 0.078 0.60 0.83 0.32 1.9× 
10
-3
 
0.011 4.3× 
10
-3
 
0.40 0.68 0.088 
16 72252097 rs55771535 PMFBP1/ 
ZFHX3 
FVC 6.4×10
-10
 
(71) 
0.031 0.049 0.096 9.0× 
10
-3
 
8.7× 
10
-3
 
0.25 0.020 0.15 7.3× 
10
-3
 
1.5× 
10
-3
 
0.034 3.3× 
10
-3
 
16 78187138 rs1079572 WWOX FVC 1.0×10
-8
 
(77) 
0.49 0.68 9.9× 
10
-3
 
0.17 0.94 0.015 0.11 0.48 0.028 0.16 0.95 0.031 
17 37611352 rs8067511 MED1/ 
CDK12 
FVC 1.1×10
-8
 
(71) 
0.11 0.29 0.14 0.063 0.31 0.090 0.055 0.15 0.10 0.023 0.13 0.050 
17 43682405 rs150741403 LOC644172/
CRHR1 
FVC 1.9×10
-9
 
(71) 
NA NA NA NA NA NA NA NA NA NA NA NA 
17 68976415 rs6501431 KCNJ2 FVC 2.9×10
-9
 
(77) 
1.00 0.82 0.82 0.15 0.19 0.36 0.41 0.16 0.17 0.17 0.47 0.27 
18 20728158 rs7238093 CABLES1 FVC 6.8×10
-9
 
(71) 
0.31 0.78 2.0× 
10
-3
 
0.031 0.58 3.4× 
10
-3
 
0.14 0.74 4.9× 
10
-3
 
4.0× 
10
-3
 
0.15 2.2× 
10
-3
 
18 50957922 rs8089865 DCC FVC 2.0×10
-10
 
(71) 
0.86 0.96 0.94 0.85 0.99 0.92 0.42 0.83 0.24 0.89 0.42 0.18 
20 6632901 rs6140050 CASC20/ 
BMP2 
FVC 6.4×10
-14
 
(75) 
7.0× 
10
-3
 
0.016 0.025 5.6× 
10
-3
 
0.018 0.021 0.010 0.064 0.013 6.2× 
10
-3
 
0.086 0.011 
20 45529571 rs2236519 EYA2 FVC 3.5×10
-8
 
(71) 
0.87 0.47 0.28 0.57 0.92 0.42 0.84 0.35 0.13 0.42 0.92 0.22 
1 17306675 rs2284746 MFAP2 FEV1/FVC 7.5×10
-16
 
(73) 
0.32 0.61 0.34 0.099 0.33 0.19 0.10 0.34 0.085 0.061 0.43 0.058 
1 40035686 rs17513135 LOC 
101929516  
FEV1/FVC 2.3×10
-16
 
(75) 
0.18 0.61 0.057 9.0× 
10
-3
 
0.11 0.014 0.38 0.54 0.59 0.094 0.17 0.24 
1 92068967 rs1192404 CDC7/ 
TGFBR3 
FEV1/FVC 6.1×10
-20
 
(75) 
0.60 0.26 0.20 0.79 0.29 0.26 0.91 0.38 0.041 0.62 0.43 0.053 
1 92374517 rs12140637 TGFBR3/ 
BRDT2 
FEV1/FVC 1.2×10
-9
 
(75) 
0.45 0.58 0.68 0.61 0.94 0.68 0.69 0.38 0.35 0.76 0.30 0.30 
1 160206067 rs11591179 DCAF8 FEV1/FVC 3.5×10
-8
 
(71) 
0.51 0.85 0.41 1.00 0.45 0.31 0.87 0.68 0.28 0.76 0.54 0.22 
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1 218860068 rs993925 TGFB2 FEV1/FVC 1.2×10
-8
 
(73) 
0.56 0.53 5.4× 
10
-3
 
0.89 0.046 1.1× 
10
-3
 
0.29 0.93 0.024 0.60 0.35 0.021 
1 219963090 rs201204531 LYPLAL1/ 
RNUSF-1 
FEV1/FVC 2.7×10
-10
 
(70) 
0.40 0.52 0.66 0.65 0.79 0.88 0.96 0.91 0.92 0.44 0.52 0.75 
1 239850588 rs6688537 CHRM3  FEV1/FVC 6.7×10
-22
 
(75) 
0.52 0.52 0.81 0.26 0.19 0.43 0.20 0.13 0.30 0.12 0.05 0.14 
2 10418806 rs139215025 C2orf48/ 
HPCAL1 
FEV1/FVC 9.0×10
-11
 
(71) 
NA NA NA NA NA NA NA NA NA NA NA NA 
2 18292452 rs61067109 KCNS3/ 
RDH14 
FEV1/FVC 1.4×10
-15
 
(70) 
0.32 0.53 0.45 0.50 0.99 0.45 0.34 0.49 0.55 0.59 0.97 0.63 
2 157046432 rs72904209 KCNJ3/ 
NR4A2 
FEV1/FVC 3.1×10
-8
 
(71) 
0.78 0.82 0.39 0.84 0.32 0.25 0.33 0.12 0.13 0.72 0.30 0.33 
2 229502503 rs10498230 PID1 FEV1/FVC 3.9×10
-8
 
(9) 
0.43 1.00 0.097 0.26 0.88 0.048 0.41 0.47 0.71 0.48 0.66 0.74 
2 229510929 rs1435867 PID1 FEV1/FVC 3.7×10
-8
 
(9) 
0.45 0.95 0.085 0.27 0.84 0.042 0.42 0.48 0.72 0.52 0.71 0.77 
2 230224031 rs7594321 DNER FEV1/FVC 2.6×10
-9
 
(4) 
0.15 0.67 0.022 0.61 0.31 0.012 0.44 0.57 0.69 0.70 0.89 0.87 
2 239316560 rs61332075 TRAF3IP1/ 
ASB1 
FEV1/FVC 2.6×10
-10
 
(75) 
0.83 0.63 0.73 0.24 0.32 0.51 0.27 0.31 0.54 0.54 0.35 0.60 
2 239877148 rs12477314 FLJ43879/ 
HDAC4 
FEV1/FVC 1.7×10
-12
 
(73) 
0.35 0.94 0.020 0.56 0.28 5.8× 
10
-3
 
0.24 0.60 0.14 0.31 0.96 0.15 
3 25520582 rs1529672 RARB FEV1/FVC 4.0×10
-14
 
(73) 
0.26 0.75 2.9× 
10
-4
 
0.017 0.53 5.5× 
10
-4
 
0.73 0.26 0.090 0.046 0.19 0.097 
3 29431565 rs28723417 RBMS3 FEV1/FVC 1.8×10
-8
 
(71) 
0.76 0.78 0.24 0.38 0.99 0.22 0.59 0.54 0.82 0.71 0.62 0.88 
3 29469675 rs17666332 FEV1/FVC 4.8×10
-8
 
(71) 
0.43 0.76 0.32 0.22 0.63 0.23 0.98 0.99 0.99 0.90 0.95 0.98 
3 55150677 rs1458979 CACNA2D3/
WNT5A 
FEV1/FVC 4.4×10
-10
 
(75) 
0.11 0.19 0.26 0.17 0.28 0.37 0.44 0.30 0.50 0.43 0.16 0.27 
3 62386350 rs111793843 CADPS FEV1/FVC 2.0×10
-8
 
(71) 
NA NA NA NA NA NA NA NA NA NA NA NA 
3 99359368 rs80217917 DCBLD2/ 
MIR548G 
FEV1/FVC 2.6×10
-8
 
(71) 
0.81 0.50 0.43 0.27 0.50 0.46 0.32 0.19 0.35 0.55 0.77 0.77 
3 127991527 rs2811415 EEFSEC FEV1/FVC 5.5×10
-11
 
(75) 
0.73 0.50 0.56 0.58 0.85 0.71 0.87 0.74 0.86 0.68 0.84 0.88 
3 168715808 rs56341938 LOC1005076
61/MECOM 
FEV1/FVC 4.5×10
-14
 
(75) 
0.49 0.51 0.79 0.13 0.13 0.29 0.17 0.12 0.28 0.47 0.38 0.67 
4 7846240 rs28520091 AFAP1 FEV1/FVC 2.2×10
-9
 0.33 0.33 0.61 0.15 0.82 0.22 0.49 0.44 0.74 0.40 0.26 0.51 
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(71) 
4 89777081 rs6830970 FAM13A FEV1/FVC 1.9×10
-8
 
(9) 
0.59 0.92 0.19 0.056 0.24 0.10 0.26 0.41 0.44 0.88 0.48 0.52 
4 89815695 rs13110699 FAM13A FEV1/FVC 7.9×10
-15
 
(75) 
0.79 0.64 0.82 0.92 0.86 0.88 0.30 0.66 0.22 0.26 0.79 0.21 
4 89869332 rs2869967 FAM13A FEV1/FVC 1.6×10
-8
 
(9) 
0.44 0.71 0.44 0.049 0.15 0.13 0.35 0.65 0.32 0.72 0.24 0.23 
4 106841962 rs6856422 NPNT FEV1/FVC 1.5×10
-23
 
(70) 
0.33 0.96 0.050 0.093 0.51 0.065 0.87 0.65 0.25 0.17 0.53 0.22 
4 145434584 rs1032295 HHIP FEV1/FVC 4.4×10
-15
 
(9) 
0.68 0.71 0.11 0.47 0.73 0.12 0.92 0.90 0.99 0.73 0.71 0.93 
4 145436324 rs12504628 HHIP FEV1/FVC 6.5×10
-13
 
(72) 
0.64 0.53 0.018 0.35 0.63 0.023 0.58 0.62 0.86 0.85 0.93 0.97 
4 145485738 rs1980057 HHIP FEV1/FVC 3.2×10
-20
 
(9) 
0.34 0.87 0.013 0.29 0.64 0.014 0.92 0.92 0.99 0.97 0.93 1.00 
5 52195033 rs1551943 ITGA1 FEV1/FVC 1.9×10
-18
 
(75) 
0.12 0.40 0.075 0.27 0.93 0.13 0.95 0.98 0.99 1.00 0.99 1.00 
5 95036700 rs153916 SPATA9 FEV1/FVC 2.1×10
-8
 
(73) 
0.19 0.24 0.042 0.12 0.15 0.29 0.52 0.35 0.54 0.96 0.77 0.80 
5 131788334 rs7713065 C5orf56 FEV1/FVC 2.8×10
-11
 
(75) 
0.34 0.86 0.085 0.012 0.086 0.028 0.66 0.55 0.79 0.19 0.18 0.38 
5 147842353 rs11168048 HTR4 FEV1/FVC 1.1×10
-11
 
(9) 
1.1× 
10
-3
 
9.9× 
10
-3
 
2.2× 
10
-3
 
0.062 0.64 0.016 0.035 0.016 0.052 0.63 0.55 0.84 
5 147844392 rs7735184 HTR4 FEV1/FVC 6.2×10
-11
 
(9) 
7.8× 
10
-4
 
6.4× 
10
-3
 
1.7× 
10
-3
 
0.051 0.57 0.015 0.026 0.011 0.039 0.56 0.50 0.79 
5 156810072 rs10515750 CYFIP2 FEV1/FVC 5.3×10
-13
 
(75) 
0.98 0.48 0.15 0.32 0.94 0.20 0.61 0.77 0.13 0.15 0.60 0.15 
5 156932376 rs2277027 ADAM19 FEV1/FVC 9.9×10
-11
 
(9) 
0.87 0.29 4.2× 
10
-3
 
0.51 0.30 5.0× 
10
-3
 
0.59 0.56 0.85 0.56 0.53 0.82 
5 156936364 rs1422795 ADAM19 FEV1/FVC 2.6×10
-10
 
(9) 
0.90 0.26 3.3× 
10
-3
 
0.51 0.29 4.1× 
10
-3
 
0.56 0.52 0.81 0.54 0.51 0.80 
6 22017738 rs1928168 LINC00340 FEV1/FVC 6.7×10
-14
 
(71) 
0.063 0.24 0.058 0.11 0.54 0.091 0.42 0.53 0.69 0.064 0.070 0.16 
6 22021373 rs9350408 FEV1/FVC 7.5×10
-14
 
(71) 
0.25 0.46 0.37 0.52 0.99 0.48 0.42 0.34 0.63 0.20 0.11 0.27 
6 31556155 rs28986170 LST1 FEV1/FVC 1.6×10
-10
 
(75) 
NA NA NA NA NA NA NA NA NA NA NA NA 
6 31568469 rs2857595 NCR3 FEV1/FVC 2.3×10
-10
 
(73) 
0.067 0.049 0.14 0.21 0.14 0.34 0.25 0.090 0.14 0.54 0.78 0.74 
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6 32124424 rs10947233 PPT2 FEV1/FVC 6.7×10
-12
 
(9) 
0.99 0.86 0.93 0.34 0.18 0.39 0.18 0.74 0.047 0.18 0.82 0.093 
6 32151443 rs2070600 AGER FEV1/FVC 3.1×10
-15
 
(9, 72) 
0.56 0.65 0.83 0.34 0.14 0.29 0.38 0.89 0.052 0.14 0.73 0.074 
6 32680576 rs7764819 HLA-DQB1/ 
HLA-DQA2 
FEV1/FVC 4.4×10
-9
 
(4) 
0.68 0.28 0.15 0.27 0.71 0.26 0.85 0.92 0.97 0.28 0.22 0.48 
6 67863782 rs9351637 SLC25A51P1
/BAI3 
FEV1/FVC 2.9×10
-8
 
(71) 
0.54 0.78 0.59 0.90 0.74 0.67 0.20 0.76 0.027 0.23 0.90 0.036 
6 73670095 rs141651520 KCNQ5 FEV1/FVC 9.9×10
-18
 
(75) 
0.89 0.86 0.67 0.76 0.85 0.81 0.45 0.40 0.70 0.89 0.92 0.97 
6 109268050 rs2798641 ARMC2 FEV1/FVC 8.4×10
-9
 
(73) 
0.22 0.44 0.28 0.19 0.41 0.34 0.97 0.58 0.39 0.55 0.97 0.54 
6 142691549 rs11155242 GPR126 FEV1/FVC 9.1×10
-9
 
(9) 
0.061 0.10 0.17 0.10 0.18 0.26 0.26 0.21 0.45 0.34 0.26 0.53 
6 142707133 rs6937121 GPR126 FEV1/FVC 2.5×10
-9
 
(9) 
0.37 0.75 0.27 0.30 0.69 0.35 0.49 0.50 0.78 0.95 0.81 0.93 
6 142750516 rs3817928 GPR126 FEV1/FVC 2.6×10
-10
 
(9) 
0.13 0.23 0.27 0.088 0.18 0.23 0.37 0.32 0.61 0.24 0.16 0.38 
6 142777064 rs7776375 GPR126/ 
HIVEP2 
FEV1/FVC 1.3×10
-9
 
(9) 
0.40 0.69 0.42 0.41 0.74 0.55 0.36 0.39 0.66 0.99 0.78 0.88 
6 142838173 rs148274477 GPR126 FEV1/FVC 9.6×10
-26
 
(70) 
0.30 0.29 0.56 0.81 0.84 0.96 0.091 0.17 0.20 0.16 0.25 0.22 
7 7286445 rs10246303 C1GALT1 FEV1/FVC 2.4×10
-8
 
(75) 
0.055 0.075 0.16 0.67 0.95 0.65 0.027 0.022 0.071 0.24 0.23 0.47 
7 99635967 rs72615157 ZKSCAN1 FEV1/FVC 2.0×10
-9
 
(75) 
0.72 0.81 0.90 0.45 0.24 0.43 0.86 0.76 0.90 0.42 0.42 0.71 
7 146651409 rs1404154 CNTNAP2 FEV1/FVC 2.8×10
-8
 
(71) 
NA NA NA NA NA NA NA NA NA NA NA NA 
9 23588583 rs10965947 FLJ35282/ 
ELAVL2 
FEV1/FVC 2.7×10
-9
 
(71) 
0.18 0.51 0.13 0.080 0.44 0.078 0.78 0.75 0.28 0.23 0.67 0.23 
9 98231008 rs16909898 PTCH1 FEV1/FVC 1.8×10
-8
 
(9) 
0.32 0.12 0.15 0.87 0.42 0.43 0.96 0.39 0.059 0.79 0.092 0.022 
9 98256309 rs10512249 PTCH1 FEV1/FVC 2.8×10
-8
 
(9) 
0.35 0.19 0.32 0.51 0.26 0.45 0.71 0.66 0.11 0.73 0.096 0.033 
9 109496630 rs2451951 TMEM38B/ 
ZNF462 
FEV1/FVC 2.4×10
-8
 
(71) 
0.30 0.40 0.56 0.34 0.49 0.61 0.30 0.17 0.31 0.38 0.16 0.30 
9 119359372 rs34886460 ASTN2 FEV1/FVC 4.7×10
-11
 
(70) 
0.17 0.29 0.30 0.92 0.61 0.43 0.88 0.66 0.68 0.67 0.94 0.70 
10 12277992 rs7068966 CDC123 FEV1/FVC 6.1×10
-13
 0.13 0.68 6.6× 0.10 0.96 6.0× 0.72 1.00 0.62 0.95 0.64 0.59 
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(73) 10
-3
 10
-3
 
10 30267810 rs3847402 SVIL/ 
KIAA1462 
FEV1/FVC 7.7×10
-11
 
(75) 
0.39 0.43 0.69 0.33 0.41 0.62 0.47 0.73 0.51 0.26 0.53 0.43 
10 64916064 rs75159994 JMJD1C FEV1/FVC 6.1×10
-9
 
(71) 
0.067 0.35 0.015 0.059 0.62 0.011 0.17 0.70 0.019 0.050 0.54 0.016 
10 124273671 rs2293871 HTRA1 FEV1/FVC 1.5×10
-8
 
(71) 
0.54 0.32 0.44 0.51 0.19 0.28 0.36 0.34 0.63 0.37 0.31 0.59 
11 73280955 11:73280955:
GA_G 
FAM168A FEV1/FVC 2.7×10
-8
 
(71) 
0.10 0.11 0.26 0.84 0.45 0.52 0.12 0.19 0.28 0.98 0.58 0.53 
12 57527283 rs11172113 LRP1 FEV1/FVC 1.2×10
-8
 
(73) 
4.1× 
10
-3
 
0.030 6.7× 
10
-3
 
0.60 0.39 0.033 0.047 0.18 0.054 0.40 0.86 0.15 
12 95554771 rs113745635 FGD6 FEV1/FVC 8.5×10
-18
 
(75) 
0.91 0.62 0.25 0.25 0.70 0.25 0.82 0.96 0.77 0.11 0.15 0.27 
12 96271428 rs1036429 CCDC38 FEV1/FVC 2.3×10
-11
 
(73) 
0.44 0.35 0.62 0.57 0.42 0.70 0.65 0.71 0.099 0.92 0.26 0.067 
14 54410919 rs4444235 DDHD1\ 
MIR5580 
FEV1/FVC 4.0×10
-8
 
(71) 
0.18 0.61 0.065 0.042 0.32 0.050 0.52 0.85 0.47 0.068 0.14 0.19 
14 84309664 rs1698268 LINC01467/L
INC00911 
FEV1/FVC 3.2×10
-8
 
(75) 
0.80 0.85 0.96 0.44 0.24 0.44 0.73 0.80 0.92 0.62 0.35 0.54 
15 41977690 rs72724130 MGA FEV1/FVC 9.6×10
-10
 
(75) 
0.45 0.36 0.63 0.30 0.14 0.30 0.81 0.81 0.44 0.54 0.15 0.16 
15 50555681 rs180930492 HDC FEV1/FVC 2.6×10
-9
 
(71) 
NA NA NA NA NA NA NA NA NA NA NA NA 
15 71645120 rs12899618 THSD4 FEV1/FVC 7.2×10
-15
 
(72) 
0.20 0.53 0.14 0.52 0.76 0.19 0.73 0.87 0.86 0.99 0.87 0.95 
15 71788387 rs12591467 THSD4 FEV1/FVC 5.7×10
-10
 
(75) 
0.97 0.87 0.87 0.24 0.28 0.49 0.32 0.17 0.31 0.15 0.034 0.079 
15 84261689 rs66650179 SH3GL3 FEV1/FVC 3.7×10
-12
 
(75) 
0.22 0.27 0.46 0.46 0.56 0.65 0.26 0.27 0.52 0.049 0.050 0.14 
16 10706328 rs12149828 EMP2/ 
TEKT5 
FEV1/FVC 7.7×10
-10
 
(70) 
9.6× 
10
-3
 
0.023 0.031 0.16 0.44 0.26 0.058 0.038 0.12 0.37 0.30 0.59 
16 58075282 rs12447804 MMP15 FEV1/FVC 3.6×10
-8
 
(73) 
0.052 0.17 0.078 0.13 0.48 0.16 0.99 0.73 0.66 0.37 0.17 0.35 
16 66060569 rs144296676 LOC283867/
CDH5 
FEV1/FVC 5.4×10
-9
 
(71) 
NA NA NA NA NA NA NA NA NA NA NA NA 
16 75390316 rs2865531 CFDP1 FEV1/FVC 1.8×10
-11
 
(73) 
0.34 0.98 0.025 0.30 0.78 0.039 0.53 0.80 0.56 0.56 0.91 0.62 
17 28263980 rs62070270 EFCAB5 FEV1/FVC 7.3×10
-18
 
(75) 
0.28 0.34 0.56 0.90 0.65 0.78 0.58 0.80 0.69 0.99 0.61 0.60 
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17 36886828 rs11658500 CISD3 FEV1/FVC 7.2×10
-11
 
(75) 
0.034 0.12 0.054 0.01 0.04 0.02 0.13 0.20 0.31 0.084 0.12 0.22 
19 31829613 rs9636166 TSHZ3 FEV1/FVC 3.3×10
-9
 
(71) 
0.58 0.74 0.78 0.099 0.13 0.25 0.60 0.51 0.79 0.25 0.17 0.39 
19 31846907 rs1353531 FEV1/FVC 4.5×10
-8
 
(71) 
0.48 0.87 0.34 0.029 0.10 0.079 0.47 0.71 0.55 0.029 0.057 0.091 
19 41124155 rs113473882 LTBP4 FEV1/FVC 1.0×10
-12
 
(70) 
0.72 0.59 0.79 0.80 0.77 0.96 0.85 0.49 0.24 0.70 0.92 0.61 
19 50213396 rs147472287 CPT1C FEV1/FVC 3.3×10
-8
 
(71) 
NA NA NA NA NA NA NA NA NA NA NA NA 
21 35652239 rs9978142 MRPS6/ 
KCNE2 
FEV1/FVC 2.7×10
-8
 
(73) 
0.56 0.32 0.39 0.83 0.51 0.61 0.082 0.10 0.22 0.46 0.70 0.67 
22 20854161 rs4820216 KLHL22/ 
MED15 
FEV1/FVC 2.6×10
-8
 
(71) 
4.1× 
10
-3
 
0.015 0.013 0.019 0.071 0.060 0.048 0.057 0.14 0.11 0.12 0.27 
X 15964845 rs7050036 APIS2/GRPR FEV1/FVC 4.1×10
-8
 
(70) 
NA NA NA NA NA NA NA NA NA NA NA NA 
Abbreviations: chr = Chromosome; DHA = Docosahexaenoic acid; DPA = Docosapentaenoic acid; FEV1 = Forced expiratory volume in the first second; FVC = 
Forced vital capacity; GWAS = Genome-wide association study; int = Interaction; NA = Not available; SNP = Single nucleotide polymorphism. 
*
SNPs with the smallest P values from each locus reported in the prior GWAS analysis are shown and are sorted by the originally indicated PFT measure and 
then by chromosomal position (NCBI build 37). SNPs that passed the multiple testing correction (n of tests = 199, Bonferroni-corrected P<2.5×10
-4
) are 
bolded.
 
†
Originally reported SNP rs114229351 has merged into rs9275068. 
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Table E12. HaploReg v4.1 Functional Annotation of rs11693320 and Variants with r
2
 > 0.8 in the 1000 Genomes European (EUR) Reference Panel
*
  
Chr. 2 
position 
(hg38) 
LD 
(r²) 
LD 
(D') 
Variant 
Reference 
allele 
Alternative 
allele 
AFR 
freq 
EUR 
freq 
Enhancer 
histone marks 
Motifs changed 
dbSNP 
functional 
annotation 
114547473 0.8 0.93 rs7581096 C G 0.59 0.18 GI HDAC2, Ik-2, NF-AT1, NF-
I, Pou2f2, Pou3f3, TATA 
intronic 
114547629 0.8 0.93 rs7606971 G T 0.6 0.18 GI Foxf1, Foxi1, Foxp1 intronic 
114548134 0.85 0.98 rs1430112 A G 0.49 0.19 GI, PANC ATF2, CEBPA, CEBPB, 
E4BP4, Evi-1, Rad21 
intronic 
114548855 0.85 0.98 rs6738538 C T 0.54 0.19 ESC, GI, PANC  intronic 
114549091 0.85 0.98 rs2033305 G A 0.45 0.81 ESC, IPSC, GI, 
PANC, LNG, LIV 
BDP1, GR, Ik-1, Ik-2, Ik-3, 
Pax-4 
intronic 
114549684 0.85 0.98 rs201802986 A AG 0.17 0.19 BLD, GI, LNG, 
LIV 
 intronic 
114549695 0.83 0.98 rs66601344 GAAAT G 0.45 0.81 BLD, GI, LNG, 
LIV 
Dbx1, Evi-1, Foxd3, Foxi1, 
Foxj2, Foxk1, Foxl1, Foxo, 
Foxp1, HDAC2, Hoxb9, Irf, 
Nkx6-2, Pou1f1, TATA, 
Zfp105, p300 
intronic 
114550803 0.83 0.95 rs13008052 G A 0.16 0.18 GI FXR, GR intronic 
114552197 0.84 0.96 rs4289198 G A 0.15 0.18 LIV Irf intronic 
114552344 0.84 0.96 rs5833551 GT G 0.45 0.82  DBP, Smad3 intronic 
114552481 0.84 0.96 rs2082131 C T 0.35 0.18  Cdc5 intronic 
114553326 0.84 0.96 rs11886546 A G 0.15 0.18  HNF1, Ncx intronic 
114557050 0.86 0.98 rs12711799 G A 0.45 0.81  HMG-IY intronic 
114562002 0.86 0.98 rs1864437 A G 0.58 0.19   intronic 
114562416 0.86 0.98 rs1367183 G A 0.54 0.19  Arid3a, Dbx1, HP1-site-
factor, Lhx3, Ncx, Pou2f2, 
Pou3f4, Pou5f1, Sox, TATA 
intronic 
114563156 0.86 0.98 rs1835330 A G 0.59 0.19  FXR, HDAC2, HNF4, 
NR4A, RAR, RXRA 
intronic 
114566124 0.86 0.98 rs35463802 G C 0.21 0.19 GI HDAC2, Pou6f1, Spz1 intronic 
114567030 0.86 0.98 rs11683255 T C 0.28 0.19 ESDR ZBTB33 intronic 
114568698 0.85 0.97 rs6746835 G A 0.58 0.19 BRN Foxa, Foxd1, Foxf2, Foxi1, 
HDAC2, Homez, TCF12, 
p300 
intronic 
114573143 1 1 rs6735899 C T 0.39 0.83  ERalpha-a, NRSF intronic 
114574293 1 1 rs11693320 A G 0.21 0.17  Glis2 intronic 
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114574534 1 1 rs11694667 T G 0.18 0.17  HNF1, PLZF intronic 
114576974 0.98 1 rs1835329 C T 0.59 0.17  Isl2 intronic 
114579673 0.96 0.99 rs10496466 G A 0.14 0.17   intronic 
Abbreviations: AFR = African populations from 1000 Genomes; BLD = Blood tissue; BRN = Brain tissue; chr = Chromosome; dbSNP = Single Nucleotide 
Polymorphism database; ESC = Embryonic stem cells; ESDR = ESC-derived cells; EUR = European populations from 1000 Genomes; freq = Frequency; 
GENCODE = Reference human genome annotation for the ENCODE project; GI = Gastrointestinal tissue; IPSC = Induced pluripotent stem cells; LD = Linkage 
disequilibrium; LIV = Liver tissue; LNG = Lung tissue; PANC = Pancreas tissue. 
*
All variants are annotated to the DPP10 gene. 
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Table E13. DPP10 SNPs Implicated at P2df < 5×10
-6
 in Our Cross-Ancestry Genome-Wide Joint 2df Meta-Analysis of FVC with DHA Interaction 
(Discovery N=11,962) and Tested for Association in Prior HapMap-Imputed GWAS Analyses of FVC or DHA in Cohorts of European Ancestry from 
the CHARGE Consortium
*
  
SNP and 
coded allele 
Effect 
allele 
freq
†
 
r
2
 / D’ with 
rs11693320
‡
 in 
1000 Genomes 
European 
(EUR) panel 
r
2
 / D’ with 
rs11693320
‡
 in 
1000 Genomes 
African (AFR) 
panel 
Joint 2df meta-analysis of 
FVC, accounting for DHA 
interaction (N=11,962) 
GWAS meta-analysis 
of FVC (N=52,253) 
(77) 
GWAS meta-
analysis of DHA 
(N=8,866) (69) 
β2df direction P2df β direction P β direction P 
rs1835329-C 0.78 0.99 / 1 0.17 / 0.99 - 5.0×10
-8
 - 0.087 + 0.57 
rs6746835-G 0.77 0.85 / 0.96 0.15 / 0.90 - 1.2×10
-7
 - 0.060 + 0.55 
rs1864437-A 0.77 0.85 / 0.97 0.14 / 0.88 - 1.2×10
-7
 - 0.085 + 0.64 
rs2082131-C 0.79 0.85 / 0.96 0.09 / 0.44 - 1.3×10
-7
 - 0.100 + 0.63 
rs6738538-C 0.77 0.87 / 0.99 0.04 / 0.42 - 1.4×10
-7
 - 0.083 + 0.66 
rs1367183-G 0.77 0.85 / 0.96 0.05 / 0.46 - 1.6×10
-7
 - 0.091 + 0.55 
rs11683255-T 0.80 0.88 / 0.99 0.39 / 0.82 - 1.7×10
-7
 - 0.085 + 0.55 
rs2033305-A 0.77 0.87 / 0.99 0.03 / 0.36 - 1.7×10
-7
 - 0.080 + 0.64 
rs1430112-A 0.77 0.88 / 0.99 0.01 / 0.23 - 4.9×10
-7
 - 0.083 + 0.71 
rs10496466-G 0.83 0.98 / 0.99 0.46 / 0.80 - 1.2×10
-6
 - 0.082 + 0.71 
rs7581096-C 0.76 NA
§
 NA
§
 - 1.3×10
-6
 - 0.075 + 0.68 
Abbreviations: DHA = Docosahexaenoic acid; freq = Frequency; FVC = Forced vital capacity; GWAS = Genome-wide association study; NA = Not available; 
SNP = Single nucleotide polymorphism. 
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*
The SNPs, which are all located in the same intron as the 1000 Genomes-imputed SNP rs11693320, are sorted by P2df values. Linkage disequilibrium is 
presented with the top DPP10 SNP rs11693320. Linkage disequilibrium estimates with rs11693320 correspond to 1000 Genomes phase 3 panels of European 
(EUR) or African (AFR) ancestry, as computed in LDlink (78).  
†
Coded allele frequency weighted by sample size of cohorts in the joint 2df meta-analysis.  
‡
As a 1000 Genomes-imputed SNP, rs11693320 was not tested in the prior HapMap-based GWAS of FVC or DHA.  
§
NA, not available. Linkage disequilibrium estimates were not computed due to rs7581096 being a multi-allelic SNP. 
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 Figure E1. Distribution of Omega-3 Fatty Acid Biomarkers in Each Cohort. The middle bar is the median of 
each n-3 PUFA biomarker; the lower and upper bars of the box represent the 25th and 75th percentile values, 
respectively, of each n-3 PUFA biomarker; the minimum and maximum of the whisker were calculated as mean - 
SD, and mean + SD, respectively. Each cohort represents the European ancestry participants in that cohort, unless 
otherwise indicated. 
*
FHS has omega-3 fatty acid biomarkers measured in red blood cells, rather than plasma 
phospholipids. 
Abbreviations: AGES = Age, Gene, Environment, Susceptibility Study – Reykjavik; ALA = Alpha-linolenic acid; 
ARIC = Atherosclerosis Risk in Communities; CARDIA = Coronary Artery Risk Development in Young Adults; 
CHS = Cardiovascular Health Study; DHA = Docosahexaenoic acid; DPA = Docosapentaenoic acid; EPA = 
Eicosapentaenoic acid; FHS (Offspring) = Framingham Heart Study – the Offspring Cohort; FHS (Gen3) = 
Framingham Heart Study – the Generation 3 Cohort; MESA= Multi-Ethnic Study of Atherosclerosis; n-3 PUFA = 
Omega-3 poly-unsaturated fatty acid; RS = Rotterdam Study; SD = Standard deviation. 
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 Figure E2. Forest Plots of Meta-Analysis of the DPA Plasma Biomarker on Pulmonary Function (Sensitivity 
Analysis). Associations are presented for the DPA plasma biomarker on (A) FVC and (B) FEV1. β (unit: mL) 
denotes the coefficient from the fixed-effects meta-analysis for DPA plasma biomarker on the pulmonary function 
test measure per 1% (of total fatty acids) increment, with its 95% confidence interval. The vertical line in the center 
means no effect of the DPA plasma biomarker on pulmonary function; β value to the right of the line means positive 
effect, while β value to the left of the line means negative effect. The size of black square for each cohort represents 
the variance of the β coefficient, so that cohorts with smaller variances have larger black squares. Cohorts listed in 
the forest plots are ordered based on alphabetical order, with sample size of each cohort shown in the parenthesis. 
Abbreviations: AA = African ancestry; AGES = Age, Gene, Environment, Susceptibility Study—Reykjavik, 
Iceland; ARIC = Atherosclerosis Risk in Communities; CARDIA = Coronary Artery Risk Development in Young 
Adults; CHS = Cardiovascular Health Study; CI = Confidence interval; DPA = Docosapentaenoic acid; EA = 
European ancestry; FEV1 = Forced expiratory volume in the first second; FVC = Forced vital capacity; MESA = 
Multi-Ethnic Study of Atherosclerosis; RS = Rotterdam (Netherlands) Study. 
A 
B 
DPA-FVC 
DPA-FEV1 β  [    95% CI    ] 
β  [    95% CI    ] 
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Figure E3. Forest Plots of Meta-Analysis of the DHA Biomarker on Pulmonary Function (Sensitivity Analysis 
of Measurement Time). Associations are presented for the DHA biomarker on (A) FVC and (B) FEV1, only for the 
cohorts in which the spirometry test and omega-3 fatty acid biomarkers were measured within an average of one 
year. β (unit: mL) denotes the coefficient from the fixed-effects meta-analysis for DHA biomarker on the pulmonary 
function outcome per 1% (of total fatty acids) increment, with its 95% confidence interval. The vertical line in the 
center means no effect of the DHA biomarker on pulmonary function; β value to the right of the line means positive 
effect, while β value to the left of the line means negative effect. The size of black square for each cohort represents 
the variance of the β coefficient, so that cohorts with smaller variances have larger black squares. Cohorts listed in 
the forest plots are ordered based on alphabetical order, with sample size of each cohort shown in the parenthesis.
 
*
FHS has omega-3 fatty acid biomarkers measured in red blood cells, rather than plasma phospholipids. 
Abbreviations: AA = African ancestry; AGES = Age, Gene, Environment, Susceptibility Study—Reykjavik, 
Iceland; ARIC = Atherosclerosis Risk in Communities; CARDIA = Coronary Artery Risk Development in Young 
Adults; CHS = Cardiovascular Health Study; CI = Confidence interval; DHA = Docosahexaenoic acid; EA = 
European ancestry; FEV1 = Forced expiratory volume in the first second; FVC = Forced vital capacity. 
A 
B 
DHA-FVC outcome 
DHA-FEV1 outcome 
β  [  95% CI ] 
β  [  95% CI ] 
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 Figure E4. Forest Plots of the Interaction Meta-Analysis of DHA Biomarker with Current Smoking Status on 
Pulmonary Function. β denotes the interaction term coefficient of DHA biomarker with current smoking status on 
(A) FEV1, and (B) FEV1/FVC, compared to never smoking, from the fixed-effects meta-analysis, per 1% (of total 
fatty acids) increment of DHA biomarker, with its 95% confidence interval. The vertical line in the center means no 
effect of DHA on the pulmonary function outcome; β value to the right of the line means positive effect, while β 
value to the left of the line means negative effect. The size of black square for each cohort represents the variance of 
the β coefficient, so that cohorts with smaller variances have larger black squares. Cohorts listed in the forest plots 
are ordered based on alphabetical order, with sample size of each cohort shown in the parenthesis. 
*
FHS has omega-
3 fatty acid biomarkers measured in red blood cells, rather than plasma phospholipids.   
 
Abbreviations: AA = African Ancestry; AGES = Age, Gene, Environment, Susceptibility Study—Reykjavik, 
Iceland; ARIC = Atherosclerosis Risk in Communities; CARDIA = Coronary Artery Risk Development in Young 
A 
B
c 
Interaction coefficient of DHA biomarker and current smoking on FEV1 
β [95% CI] 
β [   95% CI   ] 
Interaction coefficient of DHA biomarker and current smoking on FEV1/FVC 
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Adults; CHS = Cardiovascular Health Study; CI = Confidence interval; DHA = Docosahexaenoic acid; EA = 
European ancestry; FEV1 = Forced expiratory volume in the first second; FHS (Offspring) = Framingham Heart 
Study—Offspring Cohort; FHS (Gen3) = Framingham Heart Study—Generation 3 Cohort; FVC = Forced vital 
capacity; MESA = Multi-Ethnic Study of Atherosclerosis; RS = Rotterdam (Netherlands) Study.  
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(A) 
 
(B) 
 
Figure E5. Genome-Wide SNP/Indel Associations with FEV1, Accounting for Interaction with DHA, in Cross-
Ancestry Meta-Analysis. The -log10 (meta-analysis P2df) for 7.2 million SNPs/indels with minor allele frequency > 
5% and imputation quality > 0.3 are plotted against (A) expected P values where the red line depicts the null 
hypothesis of no association and (B) chromosomal position where the solid black line depicts the genome-wide 
statistical significance threshold (P < 5×10
-8
). SNPs/indels failing to achieve minimal frequency and imputation 
quality in all but one cohort were excluded from results. 
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Figure E6. Genome-Wide SNP/Indel Associations with FVC, Accounting for Interaction with DHA, in Cross-
Ancestry Meta-Analysis. The -log10 (meta-analysis P2df) for 7.2 million SNPs/indels with minor allele frequency > 
5% and imputation quality > 0.3 are plotted against (A) expected P values where the red line depicts the null 
hypothesis of no association and (B) chromosomal position where the solid black line depicts the genome-wide 
statistical significance threshold (P < 5×10
-8
). SNPs/indels failing to achieve minimal frequency and imputation 
quality in all but one cohort were excluded from results. 
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Figure E7. Genome-Wide SNP/Indel Associations with FEV1, Accounting for Interaction with DPA, in Cross-
Ancestry Meta-Analysis. The -log10 (meta-analysis P2df) for 7.2 million SNPs/indels with minor allele frequency > 
5% and imputation quality > 0.3 are plotted against (A) expected P values where the red line depicts the null 
hypothesis of no association and (B) chromosomal position where the solid black line depicts the genome-wide 
statistical significance threshold (P < 5×10
-8
). SNPs/indels failing to achieve minimal frequency and imputation 
quality in all but one cohort were excluded from results. 
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(A) 
 
(B) 
 
Figure E8. Genome-Wide SNP/Indel Associations with FVC, Accounting for Interaction with DPA, in Cross-
Ancestry Meta-Analysis. The -log10 (meta-analysis P2df) for 7.2 million SNPs/indels with minor allele frequency > 
5% and imputation quality > 0.3 are plotted against (A) expected P values where the red line depicts the null 
hypothesis of no association and (B) chromosomal position where the solid black line depicts the genome-wide 
statistical significance threshold (P < 5×10
-8
). SNPs/indels failing to achieve minimal frequency and imputation 
quality in all but one cohort were excluded from results. 
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(B) 
 
Figure E9. Co-Expressed Genes with DPP10 in Lung Tissue. Scatterplots show the correlation between 
expression levels of DPP10 and (A) FABP4, as well as (B) DPP4. Data are based on GTEx v7 RNA-Seq data (fully 
processed, filtered and normalized expression data, as previous described (28)). Pearson correlation coefficient, r, is 
shown. 
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